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Abstract 
Background 
Fatigue is a common and distressing symptom in patients with advanced 
cancer. Although the use of a range of pharmacologic and non-pharmacologic 
strategies has resulted in advances in managing cancer-related fatigue, this symptom 
is not well-managed in patients with advanced cancer. Recognition regarding the 
benefits of self-management in managing a range of chronic conditions has 
increased. Therefore, understanding self-management behaviours from the 
perspective of patients has the potential to improve the efficacy of current 
interventions for managing fatigue in patients with advanced cancer. 
 
Objectives 
This study focused on expanding understanding of self-management 
behaviours in patients with advanced cancer over a two month period in terms of 
frequency of use, perceived effectiveness of these behaviours, and the factors 
influencing these behaviours by examining: 
i. self-management behaviours associated with fatigue (i.e. what these 
behaviours are and how frequently they are used);  
ii. the perceived effectiveness of these behaviours; and  
iii. the socio-demographic and clinical factors influencing use of these 
self-management behaviours.  
 
Methods 
The “Self-efficacy in Managing Symptoms Scale - Fatigue Subscale for 
Patients with Advanced Cancer” (SMSFS-A) was developed for the purpose of this 
study. This was achieved by modifying the “Self-efficacy in Managing Symptoms 
Scale - Fatigue” (SMS-F). Item generation was informed by the conduct of a 
comprehensive literature review and semi-structured interviews (n=10). Content 
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validity and reproducibility evaluations were conducted using two expert panel 
reviews (n=4) and a pilot test (n=10). 
A prospective longitudinal design, involving interviewer-administered surveys 
was subsequently used. Patients with breast, lung, colorectal and prostate cancer, 
diagnosed with at least one distant metastasis and experiencing fatigue (>3/10) were 
eligible for inclusion in the study. Participants were surveyed at baseline, time 2 (4 
weeks) and time 3 (8 weeks). Self-management behaviours associated with fatigue, 
socio-demographic/clinical characteristics, social support, depression, anxiety, self-
efficacy and other symptoms were also assessed. The selection of these potential 
influencing variables is based on the Self and Family Management Framework, and a 
literature review of major health behaviour models and empirical studies. 
 
Results 
One hundred and fifty two patients with advanced cancer were recruited to the 
longitudinal study. The participants commenced with moderate to severe levels of 
fatigue at baseline (M=5.85, SD 1.44, 95%CI 5.62 to 6.08), and maintained moderate 
to severe levels throughout at time 2 and time 3. On average, participants used nine 
fatigue self-management behaviours at each time point, with a range from zero to 16 
behaviours reported. The five self-management behaviours rated by participants as 
being most effective were: pacing their activities during the day, planning activities 
to make the most of energy, taking short sleeps, doing things that distract them from 
their fatigue, and doing things to improve sleep at night. The five most commonly 
used self-management behaviours were: doing relaxing things, drinking beverages 
with caffeine, rest during the day, take short sleeps during the day, and eating a 
balanced diet. To identify the predictors associated with the increased effectiveness 
and frequency of use of fatigue self-management behaviours, separate generalised 
estimating equations were used. The independent predictors of increased 
effectiveness included higher self-efficacy (p<.001), higher education level (p=.02), 
and lower levels of depressive symptoms (p=.04). The independent predictors of 
increased frequency included older age (p<.001), higher performance status (p<.01) 
and higher total self-efficacy (p<.001). 
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Conclusion and Implications 
This exploratory study is the first to examine fatigue self-management 
behaviours and the factors that predict fatigue self-management outcomes 
specifically in patients with advanced cancer. Findings suggest that enhancing self-
efficacy and improving depressive symptoms are particularly important for 
improving fatigue self-management outcomes for this population. Future research 
should investigate the effectiveness of fatigue self-management support intervention 
incorporating self-efficacy enhancement and depressive symptom management for 
improving fatigue in this population.  
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Chapter 1: Introduction 
1.1 BACKGROUND AND THE SCOPE OF THE PROBLEM 
As the number of people living with cancer increases, there is a greater need 
for innovative and effective measures to manage cancer and its consequent impacts 
on patients in order to reduce personal and health service burdens. An increase in the 
incidence of some cancers, improved treatment outcomes, advances in early 
detection, diagnosis and treatment of cancer, and longer life expectancies have 
contributed to an increasing prevalence of people living with cancer, both globally 
and in Australia1, 2. The number of cases of cancer is estimated to increase by 45% 
from 2007 to 2030 (11.3 million in 2007 to 15.5 million in 2030)2. In Australia, 
cancer diagnosis numbers are projected to rise for both males and females and are 
expected to reach about 150,000 in 2020 (an increase of almost 40% from 2006)1.  
Although the overall survival rate for a number of cancers has improved over 
the past two decades3, 4, cancer remains one of the largest causes of death in 
Australia, and the survival rates for some cancers remains poor3. The five-year 
relative survival rates for patients who have developed at least one distant metastasis 
is; 28% for people with prostate cancer, 24% for those with breast cancer, 12% for 
those with colorectal cancer, and 4% for those with lung cancer3. The goal in caring 
for these patients includes life prolongation, while maintaining optimal quality of 
life5. This includes the prevention of and relief from distressing symptoms that 
patients might experience as a result of their illness5. This thesis investigates the 
problem of fatigue, one of the most common symptoms experienced by people with 
advanced cancer that substantially impacts individuals’ quality of life.  
Fatigue is debilitating, can reduce quality of life and is one of the most 
distressing6, 7 and frequently experienced symptoms for people with advanced 
cancer, (approximately 74% of patients with advanced cancer and 88% of those who 
are at the last weeks of life)8-10. The high prevalence of fatigue associated with a 
diagnosis of cancer suggests that symptom management is challenging. Over the past 
few decades, the understanding of the aetiology and pathophysiology of fatigue, as 
well as the patient experience, and management interventions has improved. 
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However, fatigue is still not well managed in a notable proportion of patients with 
advanced cancer8-11.  
The management of fatigue is complex and can involve a combination of 
pharmacological and non-pharmacological strategies12, 13. For example, maintaining 
sleep hygiene, taking medications, energy conservation and exercise are commonly 
used strategies in the management of cancer-related fatigue (CRF). The aim of such 
strategies is to reduce the severity of fatigue by modifying aetiologic factors known 
to contribute to CRF. Ongoing research efforts aim to provide an evidence base to 
support the use of these strategies both individually (e.g. exercise interventions 
alone) or in combination (e.g. behavioural interventions involving a number of 
strategies). Regardless of which strategies are used, most of these management 
strategies require behavioural responses on the part of the patient14-16. The 
behaviours required to manage fatigue often involve a collaborative effort between 
patients and health professionals (e.g. through taking prescribed medications). They 
can also be self-initiated without any prompting by health professionals (e.g. through 
engaging in behavioural strategies such as modifying their diet). While patient self-
management is thus likely to be an important component of CRF management, there 
is limited research to date to understand its role, especially for patients whose disease 
is advanced.  
Over recent years there has been increasing recognition regarding the 
importance of self-management in care for people with chronic conditions17. The 
National Cancer Research Institute in the United Kingdom (UK) proposed self-
management research as a key area requiring innovative approaches to address 
complex symptoms, especially in relation to use of non-pharmacological approaches 
in symptom management12. In order to optimise individual’s ability to self-manage 
CRF, this study seeks to understand behaviours that patients initiate in response to 
fatigue. Given the complex range of environmental, psychological and social factors 
that can influence individuals’ engagement in health behaviours, such as fatigue self-
management, this study also seeks to understand those factors that contribute to use 
of such behaviours. Questions addressed in this study include:  
 What are the strategies that patients choose to use to manage fatigue?  
 What are their preferences for these strategies?  
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 How effective are these strategies from the perspective of the patient?  
 What enables them to use these strategies effectively?  
Although some research has been undertaken to explore self-management 
behaviours for managing fatigue in patients with cancer undergoing active treatment 
with curative intent18-20, there is a lack of information concerning such issues in 
patients with advanced disease21. Fatigue in patients with advanced cancer can 
potentially have quite different aetiologies compared to patients at earlier stages of 
their disease. As their disease progresses, they can also experience reduced cognition 
and functional status that impedes their ability to self-manage. To date, there has 
been limited evidence regarding the behaviours patients with advanced cancer 
perform in managing fatigue and the effectiveness of those behaviours. Gaining a 
deeper understanding of such behaviours in this patient group will assist with the 
design of appropriate patient-centred interventions for this population22. 
 
1.2 RESEARCH PLAN  
1.2.1 Aim  
For patients with advanced cancer, the aims of the study are to examine:  
i. self-management behaviours associated with fatigue (i.e. what these 
behaviours are and how frequently they are used);  
ii. the perceived effectiveness of these behaviours; and  
iii. the factors influencing use of these behaviours.  
The study focuses on expanding understanding of how self-management 
behaviours might change for patients in terms of frequency of use, and perceived 
effectiveness of these behaviours and the factors influencing use of these behaviours 
over a period of two months (baseline, time 2: 4 weeks, time 3: 8 weeks.)  
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1.2.2 Research questions 
For patients with advanced cancer: 
Level 1 - Descriptive 
1. What are the patterns of fatigue severity over a two month period? 
2. What are the patterns of self-management behaviours undertaken by 
patients to manage fatigue over a two month period? 
3. What are the levels of perceived effectiveness of self-management 
behaviours in relieving fatigue over a two month period?   
Level 2 - Bivariate 
1. What are the relationships between the perceived effectiveness of self-
management behaviours and symptom severity at baseline? 
2. What are the relationships between demographic factors, symptom 
severity, level of social support, level of depression, level of anxiety, 
levels of self-efficacy and  
a. The frequency of self-management behaviours that patients 
undertake at baseline? 
b. The number of self-management behaviours that patients 
undertake at baseline? 
c. The perceived effectiveness of self-management behaviours at 
baseline? 
Level 3 - Multivariable 
1. Can the frequency of self-management behaviours over a two month 
period be explained by demographics, clinical characteristics and levels 
of symptom severity, social support, depression and self-efficacy?  
2. Can the levels of perceived effectiveness of self-management 
behaviours over a two month period be explained by demographic 
factors, clinical characteristics and levels of symptom severity, social 
support, depression, and self-efficacy? 
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1.2.3 Research design and methods 
To explore the research questions, the study is divided into two stages.  
 
Stage One 
The first stage focuses on modifying the “Self-efficacy in Managing Symptoms 
Scale - Fatigue subscale” (SMS-F)23. The SMS-F was originally designed by Yates 
and her research team to assess self-management of treatment-related symptoms and 
side effects in patients with cancer undergoing anti-cancer therapy23. Therefore, the 
items in this scale might not be appropriate for use in patients with advanced cancer. 
Firstly, a comprehensive literature review and semi-structured interviews were 
conducted to modify the content of the SMS-F to ensure it was relevant to patients 
with advanced cancer. Secondly, an expert panel was consulted and a pilot test was 
undertaken to evaluate the content and face validity of the instrument.  
 
Stage Two 
Stage two involved a prospective longitudinal interviewer-administered survey 
to describe fatigue severity, fatigue interference and self-management behaviours 
associated with fatigue in patients with advanced cancer. In addition, relationships 
between self-management behaviours and demographic characteristics, diagnosis, 
self-efficacy associated with patients’ self-management behaviours, emotional state 
and social support were assessed. Patients were interviewed on three occasions over 
a two month period (baseline, 4 weeks and 8 weeks). 
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1.3 DEFINITION OF TERMS 
 
Advanced Cancer 
Conceptual definition:  
Advanced cancer refers to “a cancer that has spread to other places in the body 
and usually cannot be cured or controlled with treatment”24.  
Operational definition: 
In this study, patients with advanced cancer are those with a distant metastasis. 
Distant metastasis refers to cancer that has spread from the original (primary) tumour 
to distant organs or distant lymph nodes. It is also known as distant cancer24. 
 
Cancer-related fatigue 
Conceptual definition:  
Cancer-related fatigue is a distressing, persistent, subjective sense of physical, 
emotional and/or cognitive tiredness or exhaustion related to cancer or cancer 
treatment that is not proportional to recent activity and interferes with usual 
functioning25. 
Operational definition:  
In this study, the levels of fatigue were measured by the Brief Fatigue 
Inventory (BFI)26 and the Edmonton Symptom Assessment System (ESAS)27. 
 
Fatigue Distress 
Conceptual definition: 
Fatigue distress can be defined as the degree of discomfort28; or physical or 
mental anguish or suffering that results from the experience of fatigue29. This 
concept is differentiated from the intensity and frequency of fatigue30-34. 
Operational definition:  
In this study, fatigue distress was measured by the fatigue distress numerical 
analogue scale.  
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Metastasis 
Conceptual definition:  
Metastasis refers to the spread of cancer from one part of the body to another. 
A tumour formed by cells that have spread is called a metastatic tumour or a 
metastasis. The metastatic tumour contains cells that are like those in the original 
(primary) tumour. The plural form of metastasis is metastases24. 
 
Self-efficacy 
Conceptual definition:  
Self-efficacy refers to people’s judgement of their capabilities to organise and 
execute a course of action which requires designated types of performance35. 
Operational definition:  
In this study, the level of self-efficacy was measured by the Self-efficacy in 
Managing Symptoms Scale - Fatigue subscale for Patients with Advanced Cancer 
(SMSFS-A). 
 
Self-management 
Conceptual definition:  
Self-management is a health model that not only concerns actions and 
behaviours, but also concerns the individual’s ability to manage the symptoms, 
treatment, physical and psychosocial consequences and life style changes inherent in 
living with a chronic condition36. 
 
Self-management behaviours  
Conceptual definition:  
Self-management behaviours are behaviours that individuals perform to 
manage a health condition (e.g. advanced cancer) or its impact (e.g. CRF)17.  
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Operational definition:  
In this study, self-management behaviours associated with fatigue were 
measured using the Self-efficacy in Managing Symptoms Scale - Fatigue subscale 
for Patients with Advanced Cancer (SMSFS-A). This tool was used to assess the 
frequency of use of self-management behaviours associated with fatigue and the 
perceived effectiveness of these behaviours. 
 
Self-management support 
Conceptual definition:  
Self-management support is what health professionals, carers, and the health 
system do to assist patients to manage their condition17.  
  
1.4 OVERVIEW OF THE DISSERTATION 
This thesis consists of seven chapters. Chapter One describes the background 
and scope of the problem, research questions, design and methods, and definition of 
terms. Chapter Two provides a review of the literature on fatigue in patients with 
advanced cancer. This chapter discusses the prevalence of fatigue, the patterns of 
fatigue over time, the aetiologic factors associated with fatigue, the impact of fatigue 
and the management of fatigue. Chapter Three presents definitions of self-
management and the Self and Family Management Framework used as the 
conceptual model for this study. This chapter also discusses the factors influencing 
self-management in people with chronic conditions and its potential relevance to 
patients with advanced cancer. Chapter Four presents a comprehensive research plan 
for the study, including the research design and methods, analytical plans and ethical 
considerations. Chapter Five presents the findings of the interviews conducted with 
patients with advanced cancer to identify self-management behaviours associated 
with fatigue. This chapter also describes the development of the SMSFS-A. The 
results of the expert panel reviews and the pilot test are also reported. Chapter Six 
presents the results from analyses of a prospective longitudinal study designed to 
address the key research questions in this study.  
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Chapter Seven is a discussion of the major findings of this study. The results of 
this study are reviewed in light of those from previous studies. The chapter includes 
conclusions and implications that can be drawn from the findings, and suggests how 
these can be applied to future research and practice. 
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Chapter 2: Literature Review: Fatigue in 
patients with advanced cancer 
2.1 INTRODUCTION 
Fatigue is one of the most frequently experienced8-10, 37 and distressing 
symptoms6, 7 reported by patients with advanced cancer. The evidence base regarding 
the pathophysiology of cancer-related fatigue (CRF), patients’ experience of this 
symptom, and potentially effective interventions for patients experiencing CRF has 
been growing over the past few decades38, 39. However, the high prevalence of CRF 
in patients with advanced cancer indicates that CRF remains a phenomenon that is 
not well understood or managed in this population. The purpose of this study is to 
examine the role of self-management in alleviating fatigue in patients with advanced 
cancer. In this chapter, the scope of the problem (the prevalence, impact, associated 
aetiologic factors of fatigue) and current management strategies for fatigue (both 
pharmacologic and non-pharmacologic) are discussed. 
 
2.2 PREVALENCE OF FATIGUE 
Knowledge of symptom prevalence is particularly important in caring for 
patients with advanced cancer, as it enables health professionals to anticipate 
problems, plan care for patients, educate clinical staff, directly assess health care 
needs, and plan services40. Although the prevalence of fatigue has been extensively 
studied in advanced cancer populations, fatigue can often be under-recognised by 
health professionals41, 42. This may be due to health professionals focussing more on 
pain and other symptoms more obvious than fatigue43, lack of awareness of how 
distressing this symptom can be for patients6 and of effective treatments for this 
symptom42.  
Data on fatigue in the advanced cancer population indicate prevalence rates 
that range from 32% to 90%9. This variation in prevalence data is primarily due to 
the diversity of cancer populations studied, as well as the use of different fatigue 
measurements and definitions44-47. Indeed, early theorists argued that fatigue needs to 
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be differentiated from other concepts such as ‘lack of energy’, ‘tiredness’ and 
‘asthenia’, and stressed that failure to do so would have clinical management and 
research ramifications48, 49. However, these terms are still used interchangeably in 
many instances in current literature50. 
A recent systematic review that pooled 19 studies on fatigue prevalence in 
patients with advanced cancer reported a prevalence of 74% in the sample of 6727 
patients with advanced cancer in 17 studies and a prevalence of 88% in 120 patients 
who were in their last one or two weeks of life8. Studies with palliative populations 
often present methodological challenges for prevalence studies, due to the 
heterogeneous nature of samples, which often comprise different cancer sites and 
different stages of disease51, 52. Hence, an international collaborative study was 
undertaken in 1996 to investigate fatigue prevalence by primary sites among 1640 
patients with cancer receiving palliative care44. Fatigue was reported as more 
prevalent in patients with lympho-haematological cancer (75%) than in patients with 
colorectal (68%), oesophageal (64%), lung (60%), stomach (58%), breast (57%), 
gynaecological (56%), prostate (53%) and other or unknown cancers (35%)44.  
Other studies have shown that, apart from cancer site, the prevalence of fatigue 
also varies among patients in different palliative care settings. Rates in the 
community (42%) are reported as higher than in other settings including hospice 
(24%), outpatient settings (18%) and hospital (7%)53. These different prevalence 
rates could be explained by the stage of disease of individuals in these differing 
settings. A Japanese longitudinal study undertaken in 2008 reported that a cohort of 
terminally ill patients with cancer experienced progressively higher prevalence of 
fatigue from the time of attending the palliative outpatient department until their 
admission to the palliative care unit for end of life care54. It was observed that more 
patients experienced fatigue as their disease progressed. Sixty-four per cent of 
patients experienced fatigue at the second visit to the specialist palliative care 
outpatient department, 65.9% at three weeks and 82.2% on admission to the 
palliative care unit. 
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2.3 FATIGUE AS A DYNAMIC SYMPTOM  
Symptom experiences are dynamic phenomena in patients with cancer. 
Examining the patterns of fatigue can allow us to understand the factors underlying 
changes in fatigue severity and distress in patients. Several longitudinal studies have 
been conducted to investigate the patterns of fatigue associated with different 
chemotherapy regimens55-57 and also amongst elderly patients with a new cancer 
diagnosis58. Limited research has investigated the patterns of fatigue in patients with 
advanced cancer, and the available studies vary in their conclusions. For example, 
one study investigating the patterns of fatigue severity in 434 patients with advanced 
cancer with less than nine months of life expectancy, identified a static decrease in 
fatigue levels from baseline to four weeks, three months and six months59. In 
contrast, another longitudinal study of patients with cancer receiving palliative care 
at home (n=102) reported a fluctuating pattern of fatigue severity scores60. These 
different findings may be explained by the use of more frequent measurements 
undertaken in the latter study.   
A pattern of increasing fatigue has also been observed in patients with 
advanced cancer at end of life61, 62. According to one study by Tsai and colleagues 
(2006), severity scores for fatigue reported no difference from the day of admission 
to the palliative care unit to one week after admission. However, fatigue levels did 
rise significantly at two days before death63. Similarly, a trend showing increasing 
fatigue severity was reported in a Canadian study of 198 patients over the last 4 
months of life before death62.  
None of the studies discussed investigated the factors that influence or predict 
these patterns over time60-62. One Japanese longitudinal study investigated factors 
which influence fatigue over time in a sample of terminally ill patients with cancer. 
The study period assessed patients at referral to a palliative care service (baseline), at 
three weeks (time 2), and at admission to the palliative care unit (time 3)54. The study 
identified that fatigue scores increased significantly between baseline and time 3. 
Regression modelling in this study revealed that changes in higher psychological 
distress, lower performance status and higher dyspnoea were significantly associated 
with higher fatigue (from baseline to time 3) after adjustment for fatigue at 
baseline54. Such findings highlight the importance of thorough assessment of each 
symptom at referral to the palliative care service, as changes in other symptoms can 
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be associated with increasing fatigue over time. Research investigating patterns of 
fatigue and the factors contributing to these patterns in patients is scant. 
Understanding factors affecting changes in fatigue over time has the potential to 
identify areas for intervention and the best timing of these interventions.  
 
2.4 AETIOLOGIC FACTORS ASSOCIATED WITH FATIGUE IN 
PATIENTS WITH ADVANCED CANCER 
The aetiology of CRF is complex and remains unclear in patients with 
advanced cancer64. The literature indicates that aetiologic factors associated with 
CRF could comprise, but are not limited to, cachexia, infection, anaemia, 
neurological changes, psychological distress, metabolic and endocrine disorders, 
over-exertion, medications, side-effects of anti-neoplastic treatment and 
paraneoplastic neurological syndromes65. Understanding of the biological 
mechanisms causing CRF has increased in recent years. Proposed mechanisms 
include cytokine dysregulation, hypothalamic-pituitary- adrenal axis dysfunction, 
five hydroxyl tryptophan (5HT) neurotransmitter dysregulation, circadian rhythm 
disruption, alterations in adenosine triphosphate and muscle metabolism, and vagal 
afferent activation66. These biological pathways are still not fully understood and 
have limited application in clinical practice until further research is conducted66. In 
recent years, the role of a number of biological response modifiers (e.g. interferon, 
tumour necrosis factor, IL-1 and IL-6)67, 68, and the patient’s genetic makeup69 in 
CRF have also been explored. Although these studies have focused on people 
experiencing cancer treatment-related fatigue, there is preliminary evidence to 
indicate relationships between genetic makeup, cytokine markers and symptoms in 
patients with cancer and their family caregivers69. One recent study, for example, 
reported an association between a functional promoter polymorphism in the TNF-α 
gene with the severity of both sleep disturbance and morning fatigue69.  
Available evidence further indicates that the aetiologic factors associated with 
CRF could vary between those in the earlier stages of the cancer trajectory compared 
to those who are at the more advanced stage. For example, although it is repeatedly 
reported that anaemia is associated with fatigue in patients undergoing treatment, an 
association between haemoglobin levels and fatigue in patients with advanced cancer 
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is not consistently reported52, 70, 71. In addition, although fatigue is thought to be a 
common side effect of anti-neoplastic treatment in patients with cancer, anti-
neoplastic treatments received by patients with advanced cancer normally aim to 
improve symptom control and quality of life, and can in some cases alleviate their 
fatigue and other symptoms72, 73. Additionally, certain cancer-related comorbidities 
that cause fatigue can be more prevalent in patients with advanced cancer than in 
those in the early stages of cancer74. For instance, hypogonadism is a more common 
condition in male patients with advanced cancer compared to those with early 
cancers, with up to 50% of this population presenting with hypogonadism (low 
concentrations of testosterone) before receiving chemotherapy75, 76. Recent evidence 
suggests that hypogonadism is significantly associated with fatigue in this 
population77.  
One UK observational study of 122 patients with advanced cancer provided 
further empirical evidence of potential differences in contributors to CRF between 
people at early and later stages of disease71. The study reported no relationships 
between the level of fatigue and age, sex, diagnosis, presence or sites of metastases, 
anaemia, dose of opioid or steroid, or a range of haematological markers or 
biochemical indices (except urea), but did identify significant associations between 
fatigue, pain and dyspnoea scores71. Recent studies that have investigated the inter-
relationship between fatigue and other symptoms78-81 similarly emphasise the 
significance of symptom burden as a contributor to fatigue in patients with advanced 
cancer. In particular, one recent retrospective study of 1778 patients with advanced 
cancer attending an outpatient palliative care clinic reported that improvement in 
fatigue severity at the first follow-up appointment was associated with improved 
appetite81. Moreover, this study also reported a significant association between 
fatigue and a number of factors at baseline including pain, depression, appetite, 
nausea, drowsiness, well-being, shortness of breath, and low albumin level81. These 
findings suggest that interventions that target concurrent symptoms are potentially 
effective for improving fatigue in this population.  
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2.5 THE IMPACTS OF FATIGUE ON PATIENTS WITH ADVANCED 
CANCER 
Fatigue is associated with impaired health-related quality of life in patients at 
all stages of cancer, particularly for those whose disease is more advanced82-85. For 
example, a study of 40 patients with advanced cancer admitted to an academic 
palliative care unit reported a high correlation between fatigue within 24 hours of 
admission and individual quality of life scores at seven days85. The impact of fatigue 
can be tremendous at many different levels39. Specifically, one qualitative study of 
patients with advanced cancer described how fatigue affected the physical, 
psychological, social and spiritual aspects of their lives86. These individuals often 
found that they were unable to do much and they struggled to manage fatigue43, 87, 88. 
Patients often find this symptom unavoidable. The perception that “nothing can be 
done” for their fatigue is often shared by families and health professionals87. As a 
result, the effect of fatigue on patients can be significant, which they express in terms 
of the burden they impose on others, their inability to participate in family and other 
social activities, and cognitive impairments such as memory loss and loss of ability 
to concentrate43, 86-89. Moreover, patients with advanced cancer are more likely to 
associate fatigue with the process of adjusting to living with a progressive illness and 
ultimately death86, 89. Individuals with advanced disease could thus perceive fatigue 
in different ways to those individuals who experience fatigue primarily associated 
with curative treatment for their disease90, 91.  
In 1996, Sutchilffe-Chidegey and Holme’s cross-sectional survey offered 
insights into perceived distress levels associated with fatigue in patients with 
advanced cancer, where 49% (n=100) of participants perceived fatigue as a 
distressing symptom6. This study also reported that the level of perceived distress 
varied among patients, professionals and bereaved carers, with only 9% of 
professional carers (n=60) and 17% of bereaved carers (n=30) perceiving fatigue as a 
distressing symptom6. Such findings suggest that people other than the patient could 
have limited insight into such a subjective experience.  
For some patients with advanced cancer, fatigue could also be perceived as 
necessary or unavoidable in the terminal phase of life50. Some have suggested that 
treatment of fatigue is no longer indicated at end of life as fatigue might provide 
protection and shielding from suffering50. While there is some agreement that fatigue 
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negatively influences quality of life among patients with advanced cancer, the 
association between fatigue and quality of life and negative emotions could change 
during the last days and weeks of life92. However, while attitudes towards fatigue 
might change over time, it is still a burdensome symptom even during the last week 
of life93 and therefore worthy of further investigation. Such understanding is needed 
to determine how interventions need to change over time. 
Other studies involving patients with advanced cancer report that the decline in 
performance status common in advanced cancer is associated with increased fatigue 
levels. For example, one study reported that as performance status declined, fatigue 
interfered with subjects’ physical activities such as walking (36.3%, n=157), normal 
work (31.8%), mood (21.7%) and enjoyment of life (19.1%)94. Several studies 
confirm that fatigue is highly and negatively correlated with performance status95-99. 
A Japanese longitudinal study offered some insights into the specific physical and 
psychological factors correlated with fatigue in terminally ill patients with cancer 
over three time points54. At baseline (the second visit to the palliative outpatient 
department), higher fatigue was significantly correlated with higher psychological 
distress, lower performance status, higher dyspnoea and higher appetite loss. At time 
2 (one week after baseline), higher fatigue was significantly correlated with higher 
psychological distress, and lower performance status at baseline. Fatigue was also 
positively correlated with deterioration in psychological distress, performance status, 
and dyspnoea severity during the period between baseline and time 3. Another study 
that attempted to differentiate factors that affected fatigue and physical function in 
lung cancer patients did so cross-sectionally100. Using multiple regression analysis, 
the researcher identified that performance status scores, weakness and depression 
scores correlated independently with fatigue. Hence, while studies report that CRF is 
an almost universally distressing and disruptive symptom, the experience and impact 
of fatigue for people with advanced cancer as compared to early stage cancer has 
some unique dimensions. These unique features are associated with the particular 
meanings and declining performance characteristics of progressive and life-limiting 
disease. 
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2.6 THE MANAGEMENT OF CANCER-RELATED-FATIGUE IN 
PATIENTS WITH ADVANCED CANCER 
The management of CRF in patients with advanced cancer is complex and can 
involve a range of measures associated with pharmacologic and non-pharmacologic 
interventions64. These measures aim to target potentially reversible aetiologic factors 
and impacts that are known to be associated with CRF64. 
  
2.6.1 Pharmacological management 
A range of pharmacologic agents have been used to treat CRF. These agents 
include psychostimulants (e.g. methylphenidate), haemopoietic growth factors (i.e. 
erythropoietin and darbopoietin), paroxetine and progestational steroids (e.g. 
megestrol acetate). The effectiveness of each class of medication and related 
concerns is discussed below.  
 
Psychostimulants 
Research on symptomatic treatment of fatigue in patients with advanced cancer 
has concentrated on stimulant drugs such as methylphenidate and donepezil. 
Methylphenidate was reported to be effective in several uncontrolled trials or 
retrospective studies that investigated fatigue in patients with advanced cancer101-103. 
In 2005, one randomised placebo-controlled trial of 152 patients with breast cancer 
reported favourable results for methylphenidate, which was significantly more 
effective than placebo in improving fatigue after chemotherapy. However, this study 
did not report on the stage of the disease of this sample of women with breast cancer. 
In 2006, a randomised placebo-controlled trial led by Bruera of 112 patients with 
advanced cancer receiving palliative care, reported no difference in fatigue outcomes 
between placebo and methylphenidate104. In 2013, another recent placebo-controlled 
trial conducted on 141 patients with advanced cancer by the same research group 
confirmed the findings with similar negative results. In light of these equivocal 
findings, further trials are required to establish the benefits of methylphenidate in 
various homogenous populations of patients with advanced cancer105. One meta-
analysis that did not include the results from the latter Bruera trial106, recommended 
the use of a dose of 10 to 20 mg per day titrated to response107. In this meta-analysis, 
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it was suggested that serious adverse effects were minimal but contra-indications 
should be reviewed before prescribing108, 109. 
The effects are still not clear regarding patients with advanced cancer who use 
donepezil. Although donepezil was reported as effective in the treatment of opioid-
induced sedation in an uncontrolled trial110, one recent randomised placebo-
controlled trial of 142 patients with advanced cancer also reported that it was not 
superior to placebo111. Another recent randomised, double-blinded, placebo-
controlled trial conducted on 39 patients with advanced cancer reported potential 
benefits from using dexamphetamine112. Specifically, the use of 10mg twice daily for 
eight days was well tolerated with minimal side effects and improved fatigue levels 
on day two, but not at the end of the study. These results suggest uncertainty about 
the effectiveness of dexamphetamine beyond day two. With the consideration that 
the current tested dosing was well tolerated, further investigations with higher dosing 
are warranted. 
 
Haemopoietic growth factors 
While some evidence in relation to the treatment of CRF also suggests that 
haemopoietic growth factors (e.g. erythropoietin and darbopoietin) are effective in 
relieving CRF in anaemic patients undergoing chemotherapy107, there are safety 
concerns with these treatments113. A recent meta-analysis of 53 randomised 
controlled trials (RCT) concluded that treatment with erythropoiesis-stimulating 
agents in patients with cancer increased mortality during active study periods and 
worsened overall survival113. Further, there is little evidence demonstrating the 
effectiveness of these medications in anaemic patients not receiving 
chemotherapy108. These treatments are unlikely to benefit patients with advanced 
cancer who are at end of life with a short life expectancy, as it could take up to 12 
weeks to take effect50. As such, haemopoietic growth factors should not be 
recommended for treatment of CRF. 
 
Paroxetine, progestational steroids, acetyl-L-carnitine and other 
In 2010, two meta-analyses of paroxetine and progestational steroids were 
conducted in a Cochrane systematic review107. The meta-analysis of two studies 
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(n=625) was conducted for paroxetine and indicated no difference between 
paroxetine and placebo for the treatment of CRF in patients with advanced cancer107. 
Similarly, the meta-analysis of four studies (n=587) investigating the effect of 
progestational steroids on CRF also reported that it was not superior to placebo107. In 
addition to paroxetine and progestational steroids, clinical researchers have also 
tested the effects of a number of agents on CRF in patients with advanced cancer. 
Acetyl-L-carnitine was compared against placebo in a double-blind RCT with 
patients with advanced cancer and was not superior to placebo114. Similarly, a recent 
RCT testing the effect of adenosine 5’triphosphate (ATP) infusions also reported no 
benefits in improving CRF in patients with advanced cancer115. 
 
2.6.2 Non-pharmacological management  
A range of non-pharmacological management strategies is used in the 
management of CRF 20. This section discusses the evidence base for each of the non-
pharmacologic management strategies as recommended by the National 
Comprehensive Cancer Network (NCCN), and their potential application for patients 
with advanced cancer25. The NCCN guideline is a high quality evidence-based 
clinical resource, updated on a yearly basis25. Due to the lack of direct evidence for 
patients with advanced cancer, some of the recommended strategies in the NCCN 
guidelines are based primarily on evidence for patients with early stage cancer25. 
Their application to patients with advanced cancer is yet to be tested in randomised 
trials. The key strategies reviewed in this section include exercise, sleep and rest, 
energy conservation, complementary therapies and psychosocial interventions. 
 
Exercise 
A Cochrane review by Cramps and Daniel (2008) of 28 RCTs that studied 
patients with cancer at all stages concluded that moderate exercise appears to have 
benefit in the management of CRF both during and after active cancer treatment116, 
particularly in patients with breast and prostate cancer. However, there is insufficient 
evidence to determine the best type or intensity of exercise for reducing CRF116. 
Further, this review identified only a few studies that included samples with patients 
who had advanced cancer116. 
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The few available studies suggest that at least some groups of patients with 
advanced cancer can also benefit from exercise-based interventions. A Norwegian 
study of 63 patients with advanced cancer receiving palliative care pilot-tested an 
exercise program and reported that the exercise participants had increased walking 
distance and significantly less physical fatigue117. This program consisted of two 50-
minute sessions twice a week for six weeks. A combination of strength building, 
standing balance, and aerobic exercise was used in this program. Another small pilot 
study was conducted by Porock and her research team in 2000 to evaluate an 
exercise program for nine patients with advanced cancer who were enrolled in a 
home hospice program118. In this intervention, a physical therapist guided 
participants to perform a range of strategies throughout the day (e.g. walking, 
performing arm exercises with resistance, marching in place, and dancing). All 
participants were able to increase their activity level over a 2-week period without 
increased fatigue. There was also a trend toward increased quality of life and 
decreased anxiety. In 2003, a 12-week exercise program was tested on 82 men with 
locally advanced/metastatic prostate cancer receiving androgen deprivation therapy, 
as compared to a wait-list control group119. Patients who were in the exercise group 
reported less interference of fatigue with daily activities (p = .002) and better quality 
of life (p = .001). In addition, they also demonstrated higher levels of upper body (p 
= .009), and lower body (p< .001) muscular fitness than men in the control group. 
Although some preliminary evidence now suggests the benefits of exercise in 
patients with advanced cancer, the evidence is not yet conclusive due to the lack of 
RCTs. Three recent RCTs of patients with advanced cancer120-122 reported 
contradictory results with regards to the benefits of exercise on fatigue for patients 
with advanced cancer. One possible explanation could be that the more effective 
intervention evaluated by Headley et al (2004) required patients to participate in a 
less intense program (a 30-minute seated exercise program, three times a week, with 
a one week break between sessions)121, as compared to the interventions of Brown et 
al (2006) and Oldervoll et al (2011) that required patients to participate in more 
intense programs involving a longer duration for each session and more types of 
exercises120, 122. Although Oldervoll’s study did not report benefits in terms of 
reduced fatigue, patients in the intervention group did report improvement in 
physical performance status at 8 weeks122. While such findings suggest that a 30 
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minute seated exercise regimen is a feasible management strategy for patients with 
advanced cancer, further RCTs are needed to duplicate these results in the various 
populations of patients with advanced cancer.  
The literature specific to the effects of exercise interventions in patients with 
advanced cancer remains thin. All three trials discussed above are structured rather 
than tailored exercise programs. It is important to note that patients with advanced 
cancer face a number of unique challenges such as; bone metastases and increased 
risks of thrombocytopenia, anaemia, fever/active infection and falls/stability25. The 
uniqueness of patients with advanced cancer might justify the need for tailored-
exercise prescription for this population. Further research efforts should also be 
directed towards understanding the effects of tailored exercise interventions, how 
patients respond to these recommendations for exercise therapy, their confidence 
level with regards to carrying out the exercises, and the factors that influence the use 
of exercise.  
 
Sleep and rest 
In general, patients with cancer can experience disruptions in both the quantity 
and the quality of their sleep123, 124. Due to the close relationship between sleep 
disturbance and fatigue125, health care professionals commonly recommend strategies 
for improving sleep quality to patients with CRF126, and they could be the most 
frequent self-management activities patients perform20, 127, 128. Although there is 
compelling evidence suggesting the effectiveness of sleep hygiene programs for 
insomnia129-132, there have been a limited number of trials testing non-
pharmacological strategies in managing sleep disturbance in patients with advanced 
cancer. In the one RCT available, forty-six patients with advanced cancer receiving 
hospice care were allocated to three groups: massage group, combined aromatherapy 
and massage group, and control group, in a hospice setting in the UK133. The results 
of this study demonstrated significant clinical improvements in sleep disturbance and 
depression scores for both the massage group and the combined group. However, the 
sample was too small to detect statistically significant differences in sleep 
disturbance.  
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Some preliminary evidence now exists that highlights the potential benefits of 
an eight-week Carlson’s Mindfulness-based Stress Reduction program in patients 
with early stage cancer134. This pre-test and post-test study involving 63 patients with 
early stage cancer evaluated a program with components of body scan meditation, 
sitting, walking, meditation and hatha yoga. The number of participants with total 
sleep scores over eight (≥ 5 indicates sleep disturbance with the use of PSQI) was 
reduced from 70% at baseline to 49% post-intervention134. Other than the structured 
programs mentioned above, literature has documented a list of strategies undertaken 
by palliative/cancer care professionals. These strategies range from avoiding 
stimulating substances (such as caffeine, nicotine) before bedtime, to light exercise 
during the day124, 135. Such interventions have not yet been formally tested in this 
population, despite a prevalence of sleep alterations in patients with advanced cancer 
of approximately 71%136-138. A recent UK study using comprehensive patient reports 
and objective measures such as actigraphy reported the manifestations for patients 
with advanced cancer are high levels of sleep fragmentation and movement during 
sleep, rather than the length of sleep139. It is important that appropriate sleep 
therapies are formally evaluated in patients with advanced cancer. 
 
Energy conservation 
Energy conservation is defined as “the deliberate, planned management of an 
individual’s personal energy resources to prevent their depletion”140. The goal of 
energy conservation is to balance rest and activity during times of high fatigue so 
that valued activities and goals can be maintained. Energy conservation involves a 
number of strategies: taking additional rest periods, priority setting, delegation, 
pacing oneself, and planning high-energy activities at times of peak energy. A multi-
site RCT of 396 patients with various cancers at different stages undergoing 
chemotherapy and radiotherapy reported that the intervention group that used these 
strategies experienced a greater decrease in fatigue over time compared with the 
control group (p < .01)140. A further recent study reported the experiences and 
outcomes of a fatigue clinic in a comprehensive cancer centre126. This study reported 
that energy conservation was recommended to 98.5% of patients with CRF (n=260), 
regardless of the cancer stage. However, the authors also reported that they faced 
challenges in encouraging patients to delegate tasks to family or hire help. While 
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some patients were reluctant to seek help, families were enthusiastic about 
participating in treatment plan recommendations126. The NCCN guideline for CRF 
recommends energy conservation as a “general strategy for management of fatigue” 
for patients with advanced cancer and their caregivers. However, there is a lack of 
research suggesting its effectiveness in patients with advanced cancer who are not 
undergoing treatment.  
 
Complementary therapies 
Complementary therapies such as massage therapy141, 142, yoga143, breathing 
exercises144, 145, muscle relaxation146, 147, and mindfulness-based stress reduction 134, 
148-150 have been evaluated in pilot studies. A recent non-blinded RCT of 302 patients 
with breast cancer demonstrated the benefits of acupuncture for reducing CRF151. 
Preliminary data suggest that these therapies could have an effect in reducing fatigue 
in patients with cancer. These strategies have also been recommended for the 
management of CRF in a number of clinical guidelines for the management of 
CRF50, 64, 152. However, these interventions were either supported by indirect 
evidence153, 154 or a case report155, or tested with benefits in patients who were not in 
an advanced stage of disease146, 151. 
 
2.6.3 Other complex interventions 
Psychosocial interventions 
The NCCN guideline for CRF management recommends that patients should 
be counselled about coping and educated on how to deal with anxiety and 
depression, which are commonly associated with fatigue during cancer treatment25. 
A recent 2009 Cochrane systematic review involving 27 studies of a total of 3324 
participants, reported limited evidence that psychosocial interventions are effective 
in reducing fatigue during active treatment in patients with cancer156. Of those 27 
included studies, only seven140, 154, 157-161 demonstrated effectiveness in alleviating 
fatigue, with effect sizes ranging from 0.17140 to 1.07159. Three studies reported a 
maintained effect at follow-up of up to one month140, 158 and four months159. Two of 
these three interventions consisted of three brief (less than 60 minutes) individual 
 24 Chapter 2: Literature Review: Fatigue in patients with advanced cancer 
sessions provided by oncology nurses140, 158. One intervention consisted of nine 90-
minute sessions with a social worker with training and experience in cognitive 
behavioural therapy159. The general content of these interventions included education 
about fatigue, self-care or coping techniques, and learned activity management. To 
date, there is scant evidence to support the effectiveness of psychosocial 
interventions in patients with advanced cancer162.  
 
Interventions targeting other symptoms to alleviate fatigue 
In 2013, a non-blinded RCT conducted by de Raaf and colleagues on 152 
Dutch patients with advanced cancer reported significant improvement of fatigue in 
patients who received a nurse-led monitoring and protocol-guided treatment of 
physical symptoms (pain, nausea, vomiting, constipation, diarrhoea, lack of appetite, 
shortness of breath, cough, dry mouth)163. Patients who received this intervention 
experienced a significant improvement over time in general fatigue at both the one 
and two month follow-up. This intervention involved four appointments with a nurse 
specialist, in which a protocol-guided treatment plan was initiated based on the cause 
of fatigue determined by the oncologists and the nursing assessment of individual 
patients. Another recent RCT conducted in 2013 on 141 American patients with 
advanced cancer by Bruera and colleagues106 did not find any benefits of a nursing 
telephone intervention that involved systematic symptom assessment of a number of 
concurrent symptoms and management including psychosocial education in fatigue 
reduction, compared to those who received a control telephone intervention 
conducted by a non-professional. The control telephone intervention was non-
therapeutic in nature.  
These contradictory results could be attributed to several factors. Firstly, de 
Raff’s trial was non-blinded, which might have resulted in bias in the results. 
Secondly, the control telephone intervention could be as effective as the nursing 
telephone intervention. Although the control intervention was not therapeutic in 
nature, the non-professional did direct the patients to discuss concerns raised during 
the telephone session with their physician. The results of Bruera’s trial indicate that a 
regular reminder from a non-professional might be a less costly alternative that is just 
as effective. Thirdly, Bruera’s trial might not have been sufficiently powered to 
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detect the difference in fatigue reduction. The authors acknowledged that instead of 
the planned accrual of 215 patients, 190 were accrued; and only 141 were analysed. 
Fourthly, the two studies were likely to have included patients of different 
populations. The de Raff trial included patients with a range of solid tumours with 
locally advanced and metastatic disease, whereas the Bruera trial did not describe 
what constituted an advanced cancer at all, and did not describe the participants 
sufficiently. Therefore, it is very difficult to speculate whether the intervention could 
be more effective for some patient groups. Conducting research on CRF with a 
heterogeneous group of patients with advanced cancer remains controversial. Stone 
argued that it is too early to conclude that any intervention from the current literature, 
including trials that have been conducted predominantly with a heterogeneous 
population, is ineffective for managing CRF105. Such findings indicate the need for 
further research to be conducted using a relatively homogenous population with 
specific known aetiologies.  
 
2.7 SUMMARY 
Despite advances in understanding and managing CRF, these advances have 
been primarily for patients with cancer undergoing primary or adjuvant treatment. 
Prevalence data for CRF suggest that this symptom is not well managed in patients 
with advanced disease. While the evidence base relating to the management of 
cancer treatment related fatigue is a useful starting point for identifying strategies to 
manage fatigue associated with advanced cancer, differing aetiologies and 
experiences mean that management strategies should be tailored for this population. 
Researchers have tested a number of interventions, both pharmacological and non-
pharmacological, with the aim of reducing the severity and impact of CRF. As a 
result, a number of management strategies are recommended for patients with 
advanced cancer, in spite of the fact that the evidence they are based upon is not 
robust (see Table 2.1). Most of these interventions require patients to respond with a 
number of health behaviours (e.g. taking medications, exercising, delegating tasks). 
Such responses are not well understood. For patients with advanced cancer, further 
rigorous research is required to investigate the effectiveness of available 
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interventions. Such information will assist with the design of appropriate supportive 
interventions for CRF in this population.  
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Table 2.1.  Current evidence for the management of CRF in patients with advanced cancer 
Interventions Benefits for reducing 
CRF in patients with 
advanced cancer 
NHMRC Level 
of evidence 
The appropriateness 
of evidence for 
patients with 
advanced cancer 
Remarks
Pharmacological     
Methylphenidate Potential benefits Level I Direct evidence108 A meta-analysis favoured the use of a dose of 10 to 
20 mg per day titrated to response108
Donepezil Not superior to placebo Level II Direct evidence111  
Dexamphetamine Potential benefits Level II Direct evidence112 The results of a RCT suggest uncertainty about the 
effectiveness of dexamphetamine beyond day two112  
Paroxetine Not superior to placebo Level I Direct evidence107  
Progestational steroids Not superior to placebo Level I Direct evidence107  
Acetyl-L-Carnitine Not superior to placebo Level II Direct evidence114  
     
Non-pharmacological     
Exercise Undetermined due to 
contradictory results
Level I Direct evidence120, 121 The most appropriate intensity of exercise yet to be 
determined in patients with advanced cancer120, 121 
Sleep/rest Potential benefits Level II Indirect evidence124, 135  
Energy conservation Potential benefits Level II Indirect evidence140  
Complementary therapies 
 
Potential benefits Level II, III or 
level IV  
Indirect evidence134, 141-
150,151 
 
     
Other complex 
interventions
    
Psychosocial interventions Potential benefits Level I Indirect evidence156  
Interventions targeting 
other symptoms to 
alleviate fatigue
Undetermined due to 
contradictory results 
Level II Direct evidence106, 163  
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Chapter 3: Conceptual framework and 
literature review 
3.1 INTRODUCTION 
A number of potentially effective measures supported by at least level II 
evidence are available to improve management of cancer-related fatigue (CRF) in 
patients with advanced cancer. Most of these measures require behavioural responses 
on the part of patients. However, there is limited information about the uptake of 
these measures by patients. In this chapter, enabling the role of self-management in 
bridging the evidence-based management of CRF is discussed. A literature review of 
self-management behaviours associated with CRF, and factors influencing self-
management behaviours are also presented in this chapter. Additionally, the 
operational definitions for self-management and self-management behaviours for 
CRF, and the commonly used health behaviour models/theories are discussed. Using 
the Self and Family Management Framework164 as the conceptual model for this 
study, the potential factors influencing self-management behaviours are also 
explored.  
 
3.2 THE ROLE OF SELF-MANAGEMENT IN CHRONIC CONDITIONS 
In recent years, there has been increasing recognition of the importance of self-
management in managing chronic conditions such as cancer. Focussing on medical 
treatment prescriptions is no longer sufficient to cope with the disease burden 
imposed by chronic conditions165, 166. Systematic reviews have reported that 30-50% 
of people do not comply with their prescribed treatment (medical or behavioural 
lifestyle changes) irrespective of disease, prognosis or setting165, 166. Studies indicate 
that one-fifth of patients with cancer do not adhere to some part of their prescribed 
treatment (e.g. medications, screening, exercise, health behaviour appointments and 
diet interventions)166. This suggests that simply dictating treatment and expecting the 
patient to follow it, largely without question, is not sufficient. Rather, health 
professionals need to understand the patient’s viewpoint and the self-management 
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behaviours patients engage in165. Such recommendations are consistent with the use 
of self-management as a health care model in managing chronic illness, as self-
management emphasises that patients should be empowered to take control in 
monitoring and managing their conditions as much as possible.  
As cancer is recognised as a chronic illness167, self-management has been 
identified as integral to person-centred cancer care20, 127, 168, 169. Over recent decades, 
self-management has become even more important due to the shift of cancer care to 
the community and home170. This shift has created a pressing need for patients to 
self-monitor and self-manage impacts of their cancer, treatment-related side effects 
and cancer-related symptoms. Despite the importance of self-management in cancer 
care20, 127, 168, research on self-management in patients with progressive advanced 
cancer is limited in current literature21. This is in part due to an assumption that 
patients with cancer at the advanced stage of disease cannot engage in self-
management because they are too unwell and they are all at the last weeks of life. 
Such assumptions deprive patients with advanced cancer of the support required to 
enable engagement in self-management.  
 
3.3 THE OPERATIONAL DEFINITION OF SELF-MANAGEMENT 
The concept of self-management is ill-defined in the literature12, 22, 36, 171, 172, 
particularly in cancer care172. The terms self-management, coping, self-monitoring, 
self-care, self-regulation and self-treatment, are used interchangeably in the 
literature20, 173-176. This study uses the self-management related definitions provided 
by an Australian Government endorsed document titled Capability for Supporting 
Prevention and Chronic Condition Self-Management17.  
The Capability for Supporting Prevention and Chronic Condition Self-
Management document conceptualised self-management as a process that includes a 
broad set of attitudes, behaviours and skills17. It is directed towards managing the 
impact of the condition on all aspects of living by the patient experiencing the 
condition (e.g. cancer). This process is believed to contribute to the monitoring and 
managing of symptoms of the condition (e.g. CRF)17. According to these definitions, 
effective self-management should encompass the ability of an individual to monitor 
his or her condition and to effect the cognitive, behavioural and emotional responses 
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necessary to maintain a satisfactory quality of life36. Optimal self-management is 
achieved through a successful process of change in attitudes, behaviours and skills to 
achieve desired health outcomes17. Therefore, patients are encouraged to take an 
active role in their choices for managing their condition177. The self-management 
model expects shared expertise between health professionals and active patients, 
whereby health professionals are regarded as experts about the disease and patients 
the experts about their lives. In management of chronic conditions, the patient sets 
goals and the professional helps the patient make informed choices. The patient 
identifies problems and the professional teaches the patient problem solving skills to 
help solve problems177.  
When self-management is used as a health care model, interventions can be 
strategies undertaken by health professionals in either educating or supporting 
patients in their self-management. Self-management education complements 
traditional patient education in supporting patients to achieve the best possible 
quality of life with their chronic condition by teaching patients problem solving 
skills, whereas traditional patient education focuses on condition-related information 
and technical skills17. The Capability for Supporting Prevention and Chronic 
Condition Self-Management document provides a framework that recognises self-
management support as what health professionals, carers and the health system do to 
assist the patient to manage their condition17, 178 and collaboratively develop a self-
management care plan.  
The reason for selecting the definitions provided by Capability for Supporting 
Prevention and Chronic Condition Self-Management is two-fold: firstly, the 
definitions provided in this document are specifically designed for the Australian 
population through broad consultations with organisations representing Australian 
patients, caregivers, health professionals and educators. Therefore, these definitions 
are likely to be suitable for use in the Australian population. Secondly (and most 
importantly), these definitions are appropriate for use in the context of cancer-related 
symptom self-management, because they recognise a number of key issues and 
suggest potential means for health care professionals to provide appropriate self-
management support. More specifically, one feature of this definition is that patients 
can initiate behaviours in response to their condition (e.g. cancer) or the impacts of 
their condition (e.g. cancer-related symptoms), however, not all these behaviours are 
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necessarily evidence-based. A number of studies now suggest that patients with 
cancer do initiate a range of behaviours (whether it is evidence-based or not) in 
response to their distressing symptoms18, 20, 179-181. For example, patients with cancer, 
even at the advanced stage, can initiate changes in their eating habits in response to 
their loss of appetite without any input from their health professionals182.  
Regarding self-management of cancer related symptoms, Dodd and colleagues 
highlighted a number of issues that require careful attention and consideration175. 
These issues included: How do we understand timeliness of these behaviours? How 
are appropriate and inappropriate strategies handled? Are the behaviours effective or 
ineffective (if so, to what extent)? Are these behaviours detrimental to the health of 
the patient? Is there a conflict between the patient and the provider about self-
management choices? Who determines the dose (intensity, duration, frequency) of 
the self-management strategy? The Capability for Supporting Prevention and 
Chronic Condition Self-Management document provides a number of frameworks 
and definitions concerning self-management support to aid Australian health 
professionals in examining these questions. 
 
3.4 SELF-MANAGEMENT BEHAVIOURS FOR CANCER-RELATED 
FATIGUE 
Over the past two decades, the literature has reported a number of behaviours 
used by patients in response to CRF. Table 3.1 includes a number of commonly 
reported fatigue behaviours with supporting qualitative and quantitative evidence. Of 
these studies, five studies examined the frequency of self-management behaviours 
used by patients19, 20, 127, 183, 184. Four studies examined the effectiveness of these self-
management behaviours from the perspective of patients with cancer19, 20, 183, 184. 
Four were conducted on patients with cancer undergoing anti-cancer treatment 
(China19, UK20, 127, and Nepal183). One was conducted on patients after haemopoietic 
stem cell transplantation in Hong Kong184. Table 3.2 illustrates the five most 
effective and most frequently used behaviours in patients in these studies. Although 
discrepancies exist across the results of these studies19, 20, 127, 183, 184, it is evident that 
some behaviours such as rest/sleep behaviours and relaxation strategies are 
consistently reported as being effective and frequently used among patients with 
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cancer in these studies. The discrepancies are possibly related to the use of different 
research instruments as well as the different populations being studied. 
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Table 3.1. Self-management behaviours for CRF in patients with cancer undergoing active treatment 
Self-management behaviours and references
Resting Barsevick et al (2001), Magnusson et al (1999), Messias et al (1997), Pearce and Richardson (1996), Armes (1995), 
Richardson et al (1997), Fitch et al (2008), Graydon et al (1995), Lou (2011), Chalise et al (2012), So et al (2005) 
Relaxing tasks Magnusson et al (1999), Pearce et al (1996), Lou (2011)
Reading Richardson et al (1997), Graydon et al (1995), Chalise et al (2012)
Taking medications Barsevick et al (2001), Holley (2000), Lou (2011) 
Going to work Richardson et al (1997), Borthwick et al (2003) 
Conserve energy Richardson et al (1997),  Fitch et al (2008), Messias et al (1997), Holley (2000), Pearce et al (1996), Ferrell et al 
(1996), Armes (1995), Chalise et al (2012)
Watching TV Richardson et al (1997), Graydon et al (1995), Lou (2011), Chalise et al (2012), So et al (2005)
Exercise Fitch et al (2008), Richardson et al (1997), Magnusson et al (1999), Messias et al (1997), Graydon et al (1995), 
Chalise et al (2012), So et al (2005)
Walking Richardson et al (1997), Magnusson et al (1999), Graydon et al (1995), Lou (2011), Chalise et al (2012), So et al 
(2005)
Planning/pacing/doing a task in stages Richardson et al (1997), Fitch et al (2008), Magnusson et al (1999),  Messias et al (1997), Ream (1997), Lou (2011) 
Nutrition/eating a balanced diet Richardson et al (1997), Fitch et al (2008), Holley (2000), Chalise et al (2012), So et al (2005)
Doing household chores Richardson et al (1997), Chalise et al (2012)
Accepting help from family/friends Fitch et al (2008), Graydon et al (1995)
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Table 3.2. Research studies examining the use/frequency/effectiveness of fatigue self-management behaviours in patients with cancer 
 Richardson et al 
(1997)
Borthwick et al 
(2003)
So et al (2005) Lou (2011) Chalise et al (2012) 
Country UK UK Hong Kong China Nepal
Design Longitudinal survey Cross-sectional 
survey
Cross-sectional 
survey
Cross-sectional survey Cross-sectional survey 
Participants 109 patients with 
cancer undergoing 
chemotherapy 
46 patients 
undergoing 
radiotherapy for 
non-small cell lung 
cancer
105 patients post 
haemopoietic stem 
cell transplantation 
271 patients with cancer 
undergoing chemotherapy and/or 
radiotherapy 
100 patients with 
cancer undergoing 
chemotherapy and/or 
radiotherapy 
Most effective self-
management 
behaviours for 
relieving fatigue (Top 
5) 
1. Went to bed early 
(only the most effective 
self-management was 
reported) 
N/A 1. Sleep
2. Nap 
3. Lie down 
4. Massage 
5. Stop what 
you’re doing 
1. Got fresh air
2. Watched TV, listen to music to 
get distracted 
3. Got walking or more exercise 
4. Muscle massage 
5. Got up later than usual
1. Exercise
2. Visiting a doctor 
immediately 
3. Drinking water 
4. Resting 
5. Going to garden/field 
Most 
commonly/frequently 
used self-management 
behaviours (Top 5) 
1. Rest/napping during 
the day 
2. Reading 
3. Walking 
4. Watching TV 
5. Sleeping for most of 
the day 
1. Resting
2. Watching TV 
3. Sleeping 
4. Walking 
5. Chores 
 
1. Lie down
2. Sit down 
3. Nap 
4. Sleep 
5. Stop current 
activity 
1. Went to bed earlier than usual
2. Got fresh air 
3. Watch TV, listen to music to 
get distracted 
4. Increase the amount of naps at 
day time 
5. Got up later than usual
1. Takes rest
2. Takes night-time 
sleep 
3. Avoids smoking and 
taking alcohol daily 
4. Takes iron rich-diet 
5. Takes day-time nap 
Examining factors 
associated with 
fatigue self-
management
Χ Χ Χ √ Χ
Total number of 
assessed behaviour
31 9 13 11 24
Note. N/A: Did not assess or report; √: examined or reported; X: Did not examine or report
 Chapter 3: Conceptual framework and literature review 35 
 
 
 
 
Understanding the use, frequency and perceived effectiveness of fatigue self-
management behaviours and the factors influencing these outcomes is important and 
could have significant implications for self-management support provision. In a 
collaborative self-management care plan, health professionals and patients discuss 
defined goals, action plans, education, resources, and community support to optimise 
the frequency of and the skills required for use of evidence-based self-management 
behaviours. It can also reduce/eliminate the use of behaviours that are not evidence-
based, which could have detrimental effects to desirable health outcomes and 
maintain/eliminate/reduce behaviours that are not evidence-based but not 
detrimental17. For example, patients’ perceptions of effective fatigue self-
management behaviours are not always consistent with evidence-based guidelines or 
advice from their health professionals175. A French study of 160 patients with cancer 
(mixed types and stages) reported only a quarter of the patients perceived exercise as 
beneficial for improving fatigue185. This finding highlights the discrepancy between 
patient perceptions and evidence-based guidelines for CRF that emphasise activity 
enhancement as a beneficial intervention for management of CRF25, 185.  
A Nepalese study on patients with cancer undergoing active anti-cancer 
therapy identified that patients did perceive exercise as the most effective self-
management behaviour for managing fatigue183. However, they did not necessarily 
use this behaviour frequently183. Health professionals can assess the knowledge, 
skills, attitude, impacts of the condition, lifestyle risk factors, barriers to self-
management, and provide self-management support accordingly17. In such cases, the 
reasons for not using this behaviour or using this behaviour insufficiently could be 
explored and addressed collaboratively between the health professional and the 
patient. Potential reasons for the discrepancy could be fatigue itself, other physical 
problems such as dyspnoea and muscle weaknesses, problems related to cancer 
treatment such as post-operational side effects, environmental factors, or the lack of 
time, a partner, professional guidance or perceived benefits, 186.  
Thus, in-depth understanding of the use, frequency, perceived effectiveness 
and factors influencing these outcomes are required for effective and informed 
fatigue self-management support. Of the five studies described above19, 20, 127, 183, 184, 
only one prospective cross-sectional study on Chinese patients with cancer19 
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explored the factors influencing the initiation of all self-management behaviours and 
the perceived effectiveness of some fatigue self-management behaviours. This study 
reported that higher self-efficacy scores, higher support from the neighbourhood and 
earlier stages of cancer were the potential influencing factors associated with fatigue 
self-management outcomes19. Such understanding can inform the design of 
supportive care interventions in this area. While this study, with the use of a cross-
sectional design, provided useful preliminary findings suggesting associations 
between these variables and fatigue self-management outcomes, only longitudinal 
studies can provide an empirical basis allowing for the prediction of fatigue self-
management outcomes187.  
In addition, it is also worth noting that none of these five available studies 
provide information about self-management behaviours specifically concerning 
patients with advanced cancer. There are three key reasons for warranting separate 
investigation of self-management in patients with advanced cancer. Firstly, patients 
with earlier stages of cancer are likely to have very different aetiologies for fatigue 
compared to patients with advanced cancer. The behaviours used and their associated 
effectiveness are likely to be influenced by the aetiology of fatigue in patients with 
advanced cancer163, 175. Secondly, it is likely that patients with advanced cancer, 
possibly as a result of their declining cognitive function and functional status, are 
less able to use certain self-management behaviours compared to their counterparts 
with early stages of cancer. A multivariable analysis of a study of Chinese patients 
with cancer undergoing anti-cancer therapy reported that patients with advanced 
disease used significantly less activity enhancement behaviours compared to those 
with early stages of cancer (p<.03). Finally, patients with late stage cancer reported 
less effectiveness as they undertook activity enhancement strategies when compared 
to those with early stage cancer (p=.01). Although the usefulness of these findings 
are limited as the author did not define how stage of cancer (early, advanced and 
late) was measured, these findings suggest that patients with advanced cancer are 
likely to have less favourable fatigue self-management outcomes in terms of 
frequency of use and effectiveness. While some might think that patients with 
advanced cancer do not engage in self-management because they are too ill, 
empirical evidence indicates that patients with cancer182, 188-190, even at the advanced 
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stage, still want and are able to use a number of behaviours to control their cancer-
related symptoms. These gaps in the available literature (Figure 3.1) are the focus of 
the current study, which was to examine using a longitudinal design, the frequency of 
use, perceived effectiveness, and factors influencing self-management behaviours 
and associated outcomes for patients with advanced cancer. 
 
 
Figure 3.1. Gaps in the literature concerning fatigue self-management in patients with advanced 
cancer 
 
3.5 FACTORS INFLUENCING SELF-MANAGEMENT BEHAVIOURS 
3.5.1 Models/theories of health behaviour 
An Australian Government endorsed document titled Capability for Supporting 
Prevention and Chronic Condition Self-Management suggests that the use of human 
health behaviour models and theories can help health professionals understand 
human behaviour and how to change it17. There are a number of health behaviour 
models and theories in the literature191. These models and theories enable the 
understanding of health behaviour in terms of the mechanisms involved in the 
choices people make in their lives, and how to engage them in the process of change. 
The more common theories used in self-management research, including the Health 
Many studies
•examined fatigue SM behaviours in patients undergoing anti‐cancer therapies
Less than 5 
studies
•examined the frequency (n=5) and the perceived effectiveness (n=4) of fatigue 
SM behaviours
1 Study
•examined the factors influencing fatigue SM outcomes
No or limited 
research
•examined fatigue SM specifically in patients with advanced cancer.
•used a longitudinal design to examine predictors of fatigue SM outcomes.
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Belief Model, the Theory of Planned Behaviour, the Transtheoretical Model and 
Social Cognitive Theory, are discussed in this section17, 191.  
 
Health Belief Model  
The Health Belief Model (HBM)192 was developed in the 1950s to ascertain 
why people do not use health services such as immunisation and screening. The main 
constructs of this model focus on the perceptions of susceptibility, severity, benefits 
and barriers192. Perceived susceptibility (or perceived vulnerability) is the perceived 
risk of an individual contracting a disease if he or she were to continue with the 
current course of action. Perceived severity refers to the seriousness of the disease 
and its consequences as perceived by the individual. Perceived benefits are the 
perceived advantages of the alternative course of action in terms of the extent the 
action can reduce the severity of its consequence. Perceived barriers refer to the 
potential perceived disadvantages of adopting the recommended action as well as 
perceived hindrances that could prevent its successful performance. Therefore, high 
susceptibility, high severity, high benefits and low barriers are assumed in this model 
to lead to high probability of adopting the recommended health behaviour.  
A key criticism of the HBM is its ‘unrealistic optimism’193. Unrealistic 
optimism occurs when an individual perceives his/her own health outcomes as being 
more positive than other people in similar circumstances193. For example, Clarke et 
al conducted a study to identify the reasons people fail to engage in cancer 
screening193. This study reported that patients with breast and prostate cancer 
overestimated the positive health outcomes, demonstrating that a person’s action is 
not always driven by perceived susceptibility and severity. Another criticism of 
HBM is that it does not take into account emotional, social, economic and 
environmental factors194. Such factors are suggested as being especially important in 
the context of self-management in patients with cancer19, 195-19716, 167, 171.  
 
Theory of Planned Behaviour 
The Theory of Planned Behaviour (TPB)198 is an extension of the Theory of 
Reasoned Action199. The TPB assumes that health behaviours are under volitional 
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(voluntary) control, and that a person’s intention to engage in a behaviour is both the 
immediate determinant and the single best predictor of that behaviour198. The model 
is also based on the assumption that people rationally consider all available 
information and the implications of their actions198. In this model, attitudes towards 
the behaviour (the individual’s evaluation of performing the behaviour) and 
subjective norms (the individual’s belief about the expectations of others with regard 
to the individual performing the behaviour in question) are the two determinants of 
intention198. That is, people will have strong intentions to perform a behaviour if they 
evaluate it positively and believe that others expect them to perform it.  
Another key component of this model is that it considers perceived behavioural 
control. Behavioural control refers to a person’s perception of how easy or difficult it 
is to perform the behaviour, depending on their past experiences198. Perceived 
behavioural control is comparable to Bandura’s self-efficacy concept198, 200. Ajzen 
asserted that a person’s perception of control is situation-specific. That is, where two 
individuals in a similar situation have similar intentions and make similar efforts, the 
person with stronger perceived behavioural control is more likely to master the 
behaviour, and thus is more likely to succeed198. Several meta-analyses of the 
application of TPB across a wide range of health behaviours (smoking, condom use, 
breast cancer screening) report that intention can explain between 40% to 50% of the 
variance in intention and 19% to 38% of behaviours201, on average. Although 
intention has been identified as a factor associated with health behaviours, the 
findings in the literature cannot claim causality of health behaviours202, 203.   
 
Transtheoretical Model 
The Transtheoretical Model (TTM) was developed from studies on processes 
of change in psychotherapy and smoking cessation204. The TTM mainly concerns 
one’s readiness for behavioural change. It is comprised of six-stages: pre-
contemplation (not thinking about change), contemplation (weighing benefits and 
costs of behavioural change), preparation (experimenting with small changes), action 
(taking action to change), maintenance (maintain new behaviour over time), and 
termination (such as stopping additive behaviours)205. According to this model, 
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behavioural change involves movement through a sequence of discrete and 
qualitatively distinct stages204. That is, a person’s behaviour is assumed to move in a 
predictable way through these stages, with some people moving more quickly than 
others, and some remaining at a particular stage (e.g. not thinking about change)206. 
Thus, the efficacy of interventions will be minimal if the interventions are not 
targeted at the stage of readiness for change. 
Bandura criticised the TTM as it mainly describes behaviour, but does not 
specify the determinants of the behaviour207. Bandura also proposed that human 
behaviour is variable and multidimensional, and as such categorisation of behaviour 
into stages is therefore inappropriate208. A comprehensive literature review by Sutton 
revealed a number of issues concerning research based on the TTM209. This review 
found that research using this model lacked standardisation of measures, particularly 
of the central construct of stages of change. The review also noted that there were 
gaps in terms of logical staging algorithms, adequate specification of the causal 
relationships between different constructs, clear interpretation of cross sectional data 
on stages of change, and clarity and guidance on the nature of the stages and how 
they should be tested. The findings above might suggest that the applicability of the 
TTM is limited. 
 
Social Cognitive Theory 
Bandura proposed that Social Cognitive Theory (SCT) views human 
functioning as being determined by a dynamic interaction of personal, behavioural, 
and environmental influences200, 210. Given that we can intervene directly on people’s 
personal, environmental and behavioural factors, a person’s behaviour can change. 
Bandura further suggests that outcome expectations are based largely on the 
individual’s self-efficacy expectations200, 210. The outcomes people anticipate 
generally depend on their judgments of how well they will be able to perform the 
behaviour. The SCT purports that the higher the individual’s efficacy-expectation 
levels towards a particular behaviour, the greater will they have to succeed in 
achieving a task181, 191. While people might believe that they can achieve tasks, 
people still cannot perform tasks beyond their abilities211. People with higher self-
efficacy would believe they can take action to solve a problem, and they would be 
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more committed to their actions211. In contrast, people with lower perceived self-
efficacy expectations are less likely to take action to solve a problem211. According 
to Bandura (1998), understanding the factors influencing a person’s own behaviour is 
required to overcome the impediments to form new lifestyle choices207. 
Perceived self-efficacies for self-management are developed and influenced 
through four main sources of information208. These sources of information are 
defined as direct mastery experiences (performing an activity), vicarious experiences 
(observing others similar to oneself successfully performing an activity), 
social/verbal persuasion (being influenced to believe in the capabilities to achieve a 
goal), and interpreting inferences from physiological and psychological states 
indicative of personal strengths and vulnerabilities to reach goals208. This theoretical 
construct has been used to explain a range of health behaviours associated with 
managing chronic conditions196, 197, 212-215. 
 
Summary 
Four key models/theories of health behaviour including the Health Belief 
Model, Theory of Planned Behaviour, Transtheoretical Model and Social Cognitive 
Theory were examined to assist with the identification of potential frameworks for 
guiding the conduct of this study. Health behaviour and behavioural change is 
complex; there is no one theory that can cover all aspects of health behaviours. Each 
theory has its contributions and limitations. Some theories place less emphasis on the 
psychological, social and environmental aspects of health behaviours, which may 
have been less useful in guiding this study as it aimed to understand the factors 
influencing fatigue self-management behaviours in patients with advanced cancer.  
Of the theories discussed above, Bandura’s SCT views were selected to 
provide a basis for theoretical understanding of health behaviours associated with 
fatigue in patients with cancer. This study aimed to examine self-management 
behaviours associated with fatigue, with the ultimate aim of informing future 
interventions that could improve fatigue severity through self-management 
behaviours. The SCT does not limit understanding of health behaviour to those 
determined by a dynamic interaction of personal, behavioural, and environmental 
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influences200, 210, it also provides practical guidance for translating knowledge about 
these determinants into effective strategies for promoting behaviour change216. In 
particular, Bandura asserts that self-management interventions based on perceived 
self-efficacy theory, a critical component of SCT, is key to effectiveness and 
efficiency in chronic illness management208. A number of studies have demonstrated 
a positive relationship between a person’s perceived self-efficacy (PSE) and his/her 
ability to manage cancer-related symptoms217-221. These findings suggest that the 
application of SCT holds promise in cancer-related fatigue self-management. 
In recent years, understanding about how the SCT can be applied to CRF 
management222 has increased. The perception of fatigue and cognitive appraisal 
formulate a behavioural response among patients. Specifically, people with cancer 
suffering fatigue undertake both primary and secondary appraisal, namely the 
person’s judgment about whether fatigue may cause negative consequences and in 
what way, and the person’s judgment of his/her ability to manage symptoms210, 222. 
Therefore, understanding and anticipating the person’s concerns and identifying the 
potential deficits in his/her perceived self-efficacy to manage fatigue can help target 
interventions that focus on perceived self-efficacy enhancement222. Additionally, 
another practical application is to address the gaps between a person’s PSE to 
manage fatigue and his/her actual ability to manage fatigue through the use of fatigue 
self-management behaviours208, 210, 222. For instance, the person’s level of PSE for 
managing fatigue may be initially over or underestimated due to insufficient or faulty 
knowledge, not having the necessary feedback information to regulate efforts to self-
manage, performing under different benchmarks from health care providers, or being 
hampered by a lack of resources208. The nurse or health care provider can therefore 
intervene to address these identified gaps.  
As discussed above, health behaviours are determined by a dynamic interaction 
of personal, behavioural, and environmental influences200, 210. To operationalise these 
influences in our investigation, a conceptual framework was selected to expand the 
understanding of how relevant psychological, social and environmental factors 
influence fatigue self-management. It was hoped that the testing of these variables 
could further inform future theory-based interventions for improving fatigue self-
management outcomes in patients with advanced cancer.  
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3.5.2 The conceptual model: Self and Family Management Framework 
The exploration of factors influencing self-management is an essential step to 
advance the development of self-management theories and theory-based 
interventions. For the purpose of this study, Grey and colleagues’ Self and Family 
Management Framework164 was used to guide the literature review and the conduct 
of this study on factors influencing fatigue self-management in patients with 
advanced cancer. The Self and Family Management Framework has been widely 
used to understand factors influencing individuals in their self-management of any 
chronic illness, such as heart failure and diabetes223-225. The framework was 
developed in 2006 by Grey and colleagues in the Centre for Self-Management 
Interventions at the Yale School of Nursing. The aim in developing this model was to 
provide direction for research, development and testing of a theory of self and family 
management in chronic diseases. The main premise of the model is that risk and 
protective factors can influence individuals’ and families’ abilities to manage chronic 
illness. The model also acknowledges that certain health outcomes might or might 
not be associated with effective self and family management. The five key 
assumptions of the Self and Family Management Framework are illustrated in Table 
3.3.  
 
Table 3.3.The five key assumptions of the Self and Family Management Framework164 
Assumptions of the Self and Family Management Framework 
 
1. Individuals perform self-management in the context of their families, communities 
and environment; 
2. Self and family management of chronic conditions is a dynamic process, as modified 
by individual outcomes and the influence of risk and protective factors; 
3. Interventions are multi-faceted and can be directed to selected risk or protective 
factors or to the management behaviours themselves; 
4. It is important to develop knowledge that addresses how self-management is 
manifested as both an individual and family construct; because self-management 
often takes place in a family context. 
5. It is important to situate self-management in the context of other, related concepts 
and to advance theory development related to self-management 
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Although this framework has not been widely used in the context of cancer 
care since its inception in 2006, it was selected to guide this study for four main 
reasons. Firstly, to the best of our knowledge, at the conception of this study there 
was no self-management theoretical framework specific to self-management of 
cancer-related symptoms in the published literature. Secondly, the theory 
underpinning this framework is the Social Cognitive Theory, which considers 
important aspects (social, psychological and environmental) of health behaviours. 
Thirdly, this framework provides a model that can operationalise the investigation of 
factors, explaining self-management behaviours in response to their chronic 
condition or the impacts of their condition. As the aim of this study was to explore 
the factors influencing self-management behaviours for managing fatigue in patients 
with advanced cancer, the components of the model that focus on risk and protective 
factors provided a particularly useful guide for the current study. Fourthly, the model 
clearly acknowledges the roles of the health professionals and family/caregivers as a 
support system for patients in the context of self-management, which was thought to 
be particularly important in the context of cancer care. Miaskowski and 
colleagues’189, 226, 227 vast experience in the design and evaluation of self-
management interventions for cancer pain suggested that the involvement of 
family/caregivers must be a key component in the provision of self-management 
support175. This suggestion is also consistent with the recommendations by the 
Australian government and a number of organisations representing Australian 
patients and health professionals17. 
According to the Self and Family Management of Chronic Illness model 
(Figure 3.2), risk and protective factors are believed to influence self-management 
behaviours, which in turn have an effect on the effectiveness of self and family 
management. The model posits that health status (e.g. severity of condition, regimen, 
trajectory), individual factors (e.g. age, gender, knowledge, psychosocial 
characteristics, diversity/culture), family factors (socioeconomic status, structure, 
function), and environmental factors (social network, community, health care 
system) contribute to self and family management behaviours. All four factors were 
further confirmed to be important in the context of symptom management by Dodd et 
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al’s symptom management model175. Dodd et al’s model proposed three domains 
(health and illness, person, and environment) that are the contextual variables 
influencing all dimensions of symptom management (symptom experience, 
component of symptom management strategies, and outcomes). The similarity 
between influencing factors as identified in these two frameworks further supports 
the appropriateness of using the Self and Family Management Framework to explore 
factors influencing fatigue self-management in this current study. The following 
section will discuss each of these factors and the potential relevance to this study. 
 
 
Figure 3.2. Self and family management of chronic illness model (Reprinted with permission, see 
license in Appendix 2) 
 
Health status 
In the Self and Family Management Framework, Grey and colleagues (2006) 
asserted that the focus of self-management is specific to the individual’s current 
stage of health status164. That is, self and family management is affected by the 
severity of the condition, the treatment regimen, and the phase of their disease 
trajectory164. In the context of this current study, health status refers to severity of 
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cancer-related symptoms, treatment regimen, and disease trajectory. These 
influencing factors are consistent with Dodd et al’s symptom management model175. 
 
Severity of condition 
According to the Self and Family Management Framework, the severity of the 
condition can be operationalised by health professionals as prognosis and symptom 
severity, or considered by patients as perceived disease burden164. In this study, it 
could refer to the primary cancer diagnosis, symptom severity, and comorbidity. In a 
fatigue self-management study of Chinese patients with cancer receiving active 
treatment19, the diagnosis of ovarian cancer was reported to be an independent 
predictor (p < .001) in a multivariable analysis, indicating that patients with ovarian 
cancer in that study used more fatigue self-management behaviours than patients 
with other cancers (breast, lung, colorectal, stomach and others). The possible 
differences between the cancer groups might be further explained by potential 
interactions between primary cancer diagnosis and other factors such as symptoms, 
socio-economic status, and cancer-related comorbidity. That is, while it is logical to 
ask if there is any difference in symptom self-management behaviour between 
patients with a primary tumour, it is also important to consider other factors or 
challenges unique to particular primary cancer groups. For example, patients with 
lung cancer could be more likely to develop bone metastases than other cancer. They 
could therefore be more likely to develop bone pain and increased risks for potential 
pathological fractures, which in turn restrict them from actively engaging in a range 
of self-management fatigue behaviours and using them effectively25. In another 
example, head and neck cancer diagnosis has been repeatedly reported to be 
associated with lower socio-economic status228, 229. Lower socio-economic status 
could then further influence fatigue self-management behaviours164. The potential 
relationships discussed above are speculative, further well-powered research will be 
required to understand the determinants of fatigue self-management outcomes and 
experiences specific to patients in different tumour groups.  
With regards to symptom severity, Dodd et al suggested that patients evaluate 
their symptoms by making judgements about the severity, cause, treatability, and the 
effects of symptoms on their lives, and in turn initiate responses to their 
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symptoms175. It is therefore important to recognise that the symptom experiences and 
responses of patients are dynamic230. For example, it has been reported repeatedly 
that fatigue is a dynamic symptom in patients with cancer, thus the severity of fatigue 
can fluctuate over time60-62. The changes of fatigue severity can present different 
meanings and challenges to patients through different time points, which can in turn 
influence the behavioural responses of patients. The dynamic nature of symptom 
experiences necessitates the conduct of longitudinal research to understand the 
relationships between these complex factors and self-management outcomes.   
In the context of cancer-related symptom management, it is particularly 
important to consider the severity of other concurrent symptoms230-234. A number of 
studies have proposed shared aetiology and underlying biologic mechanisms between 
symptoms79, 235. For example, a cluster involving fatigue, drowsiness, shortness of 
breath and pain can be explained by Cleeland’s Cytokine immunologic model of 
cancer symptoms236. Cleeland and colleagues proposed a set of physiologic and 
behavioural responses observed in animals after the administration of infectious and 
inflammatory agents or certain pro-inflammatory cytokines. These responses might 
include fatigue, cognitive dysfunction, anxiety, irritability, psychomotor slowing, 
anorexia, sleep alteration, and pain sensitivity236. Although it is acknowledged that 
concurrent symptoms might not necessarily share the same aetiology230, 235, it is 
reasonable to use the same strategy for managing concurrent symptoms when 
multiple symptoms share the same aetiology. Recent evidence has suggested that 
patients with cancer do at times use the same behaviour to manage more than one 
symptom19. For example, Lou (2011) reported that dietary modification was used by 
patients with cancer to manage three cancer-treatment related symptoms including 
nausea/vomiting, fatigue and oral mucositis19. Similarly, distraction and 
psychological relaxation were used for both fatigue and nausea/vomiting where they 
occurred at the same time19.  
 
Treatment regimens 
Treatment regimens refer to the particular treatment the patient is receiving for 
their condition/symptoms164. In the context of this study, treatment regimens refer to 
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the anti-cancer therapy (i.e. radiotherapy/chemotherapy/biotherapy) or other 
treatments for managing cancer-related symptoms (e.g. opioid for managing pain, 
methylphenidate for alleviating fatigue). For patients with advanced cancer, it is 
likely that their self-management behaviours could be influenced by their 
experiences with their prescribed treatment. In some cases, anti-cancer therapies with 
palliative intent could improve fatigue severity, as well as the severity of other 
symptoms72, 73. Apart from the pharmacologic or biologic effects of their anti-cancer 
therapy, some other factors associated with treatment regimens might also play a part 
in influencing self-management outcomes. Treatment regimen could directly or 
indirectly influence patient self-management outcomes. For example, a patient with 
advanced cancer experiencing fatigue might be receiving palliative chemo-radiation 
treatment. The patient’s energy level might be further depleted by travelling to the 
hospital for medical appointments associated with daily treatments. On the days that 
the patient attends appointments, he/she might not be able to do the light exercise 
that he/she usually does at home during the day. However, during treatment, the 
patient might receive more regular monitoring from nurses, and consequently some 
self-management advice for managing their fatigue237.  
  
Trajectory 
Disease trajectory refers to the disease stage of the patient (e.g. early vs. late 
stage of cancer). Taking symptom management as an example, the appearance of 
signs and symptoms can lead to crisis in the individual and the family164. Grey et al 
suggest that at this stage interventions promoting coping and stability may be 
necessary. When the intervention is effective, a stable phase might follow164. 
Ultimately, a downward phase can occur when the individual is terminally ill (at the 
dying phase), and this further limits their self-management ability164. The need for 
patients with cancer to self-manage their symptoms is therefore likely to change over 
time, throughout different stages of their illness trajectory. These stages might 
feature chronic health conditions with a number of acute events, complicating self-
management in this group of patients12. 
Lou (2011) also reported that functional status was an independent predictor 
for the amount of fatigue self-management used by patients in her study19, indicating 
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that patients with lower Karnofsky Performance Status (KPS) engage in a 
significantly lower number of fatigue self-management behaviours. Such findings are 
easily understood, as patients with lower functional status are less likely to be able to 
use the activity-based behaviours such as performing some types of exercise. For 
research involving patients with advanced cancer, especially for those studies that do 
not follow patients to end of life, it is particularly important to measure functional 
status as it can serve as an indicator for prognosis238, 239. A number of studies have 
investigated symptom profile longitudinally over time to end of life54, 240. These 
studies allow for the understanding of how the intensity of symptoms may intensify 
as patients approach end of life. However, there is very limited research that aims to 
understand how fatigue self-management might change over time in the advanced 
cancer population. Investigations including prognostic indicators (functional status or 
time to death) are expected to be clinically important as they can provide health 
professionals with useful information of the timeliness of particular self-management 
support.  
In addition to the changes of patient self-management ability as patients adjust 
to living with a terminal illness, the need for self-management might also change as 
the meaning of a symptom changes as patients approach end of life. For example, 
fatigue could be deemed normal in the terminal phase of an individual50. In such 
cases, people who are at their terminal phase may choose not to manage fatigue 
because of its ability to shield suffering or the impacts of other symptoms50. 
However, further investigation is needed to determine the levels of fatigue that might 
be considered normal or acceptable for this patient population. While there is some 
agreement that fatigue negatively influences quality of life among patients with 
advanced cancer, the association between fatigue, quality of life, and negative 
emotions can change during the last days and weeks of life92. The meaning of fatigue 
might change over time, but it could remain the most burdensome symptom even 
during the last week of life93. It is therefore important to understand patient 
preferences and the particular situation for its management, in order to provide 
appropriate recommendations for care. 
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Individual factors 
In Grey et al’s framework, individual factors are the non-physical personal 
factors including demographic factors and psychosocial characteristics. In the 
context of this study, these factors can include age, gender, education level, 
diversity/culture, and psychological characteristics164.  
 
Demographics factors 
The Self and Family Management Framework recognises that age and gender 
play an important role in determining the patient’s role in the family context. For 
example, it is reasonable to assume that the oldest person with a chronic condition in 
a family unit may be cared for mostly by the younger members in the family (except 
for children), as older people could often experience a decline in their functional 
status and their self-care abilities241. Moreover, factors such as diversity (ethnicity, 
racial background, culture, education level) could have an effect on the specific 
approach patients or family choose to manage their condition242. 
Culture provides a dynamic framework of values and beliefs that influence the 
patient and family’s approach to care243. It is likely that fatigue self-management can 
be influenced by the cultural preferences of the patients and their health 
professionals19, 126, 161, 164, 183. For example, behaviours such as “praying to God” and 
“listening to religious or political preaching” were identified as a self-management 
strategy for managing fatigue in Nepalese patients with cancer183. Another example 
is the use of traditional Chinese medicine among Chinese patients19. These medicines 
included fomes japonica Dendrobium, ginseng, spirulina, Naobai Jin (containing 
melatonin and oligose), soft-shelled turtles and loach19. These behaviours were not 
reported by the participants in the two studies involving patients with cancer in the 
western countries127, 168. Failure to take culture into consideration in the provision of 
self-management support may result in ineffective symptom management from the 
patient/family perspective243.  
Findings from a number of studies on patients with chronic disease have 
reported that education level is an important influencing factor in self-
management244-246. Specifically, two studies of patients with various types of chronic 
disease further reported that patients with a higher education level not only had better 
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self-efficacy outcomes, but also lower levels of fatigue244, 246. It is possible that 
people with higher education have high confidence, high health literacy to make 
informed choices about their use of self-management behaviours, and in turn have 
better self-management outcomes. However, the influence of education level is not 
yet demonstrated to be an important influencing factor in fatigue self-management in 
patients with cancer. Lou (2011) reported that education level was not a significant 
predictor for fatigue self-management use and levels of relief19. 
 
Psychosocial factors 
With regards to individual psychological characteristics, depression and self-
efficacy are considered to be the most relevant in the context of this study. These two 
characteristics have been highlighted by Grey et al to be particularly important in 
self-management164. Further, depression195 and low self-efficacy19, 196, 197 have been 
repeatedly reported to reduce the ability to self-manage chronic conditions. There is, 
however, a lack of studies investigating the relationship between these factors in 
patients with advanced cancer, the effectiveness of self-management behaviours and 
the approach they choose to undertake to manage their condition/symptoms.  
Self-efficacy is a social-cognitive theoretical construct first conceptualised by 
Bandura in 1977208. Bandura has made a significant contribution to the field of self-
management for people with chronic illnesses such as cancer208. Perceived self-
efficacy (PSE) refers to one’s confidence to carry out behaviour necessary to reach a 
desired goal. Self-efficacy is enhanced when patients succeed in solving patient-
identified problems. Bandura further proposed that “efficacy expectations determine 
how much effort people will expend and how long they will persist in the face of 
obstacles and aversive experiences” (p.194)35.  
Over recent years, the self-efficacy framework has been increasingly used in 
cancer care research217-221. For example, Porter’s cross sectional study surveyed 30 
patients with newly diagnosed lung cancer and reported that patients and family 
members with higher self-efficacy in managing their symptoms had lower symptom 
severity, including pain217. Other recent work undertaken by Liang and colleagues 
(2008) revealed the relationship between opioid-taking tasks self-efficacy and opioid 
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taking adherence and pain levels amongst patients with cancer218-220. Some other 
evidence also suggested that self-efficacy is a valuable construct that can explain the 
level of pain220, 221, pain behaviours220, levels of fatigue221, and symptom 
experiences221 in patients with cancer.  
Recent work by Hoffman and her research team focused on explaining how the 
theory of self-efficacy can be applied to the self-management of cancer-related 
symptoms247, 248. Hoffman proposed a mid-range theory, namely The Theory of 
Symptom Self-management (TSSM)248. The TSSM is derived from the Theory of 
Unpleasant Symptoms174, 249 and the Theory of Self-efficacy208. Hoffman argues that 
the TSSM can provide a practical theory for research and clinical practice in the area 
of symptom self-management248. In 2009, Hoffman and colleagues reported that 
perceived self-efficacy in 298 patients with cancer had a positive effect on the 
physical functional status of people with cancer while serving as a mediator between 
CRF severity and physical functional status. Such evidence suggests that it is 
sensible to investigate the potential of interventions that target increasing self-
efficacy in symptom management in cancer populations.  
A body of research reports an association between depression and poor self-
management ability in people experiencing chronic illness, especially diabetes250-254. 
For example, Egede and Ellis (2008) conducted a cross sectional study of 201 
patients with Type 2 diabetes and reported that participants who were depressed had 
more self-management problems in controlling their condition (p < .001), and less 
self-management ability than those who were not depressed (p < .001)254. 
Recommendations were made that diabetes self-management programs should 
address emotional well-being255. This association has also been reported in 
populations other than patients with diabetes. For example, a recent RCT of 250 
people with chronic musculoskeletal pain and depression reported that an optimised 
antidepressant therapy followed by a self-managed pain program yielded significant 
substantial effects on both pain and depression compared to usual care256. This two-
armed trial was limited in that it did not isolate the effects of the anti-depressant and 
the effects of self-management intervention. Still, such findings support that self-
management behaviour may be one of the modifying factors between depression and 
 
 
 
 
Chapter 3: Conceptual framework and literature review 53 
 
 
 
pain in patients with musculoskeletal pain. However, research replicating these 
findings in populations with cancer is lacking. 
Although non-depressed individuals may generally be more likely to engage in 
self-management and have better self-management outcomes, a recent study of 415 
patients with chronic illness including arthritis, asthma, chronic obstructive 
pulmonary disease, congestive heart failure, depression and diabetes mellitus, 
reported that individuals with more depressive symptoms may be more likely to 
experience self-efficacy gains from chronic illness self-management training than 
those with less depressive symptoms257. The data demonstrated that depressive 
symptoms may somehow have a moderating effect on self-efficacy via chronic 
illness self-management training/interventions.  
 
Family factors 
Due to the shift in past decades of cancer care to the community and home, it is 
particularly important to understand patients’ self-management in the context of the 
family and community in which it takes place16, 164, 170. It is well recognised that 
caring for someone with chronic illness has a significant impact on the carers, and on 
their interpersonal relationships with the person and with others, as well as causing 
inevitable changes in their own lives258. Family care literature has explored the 
impact on caregivers, as well as caregivers’ outcomes, as these in turn influence the 
person being cared for164. Therefore, supporting the family is an important area, 
particularly for people with advanced cancer16. Given and colleagues (2001) outlined 
some important areas for consideration when supporting family members of patients 
with advanced cancer16. Health professionals should assist the family to meet 
patient’s illness-related needs such as symptom management, medication 
management and mobility; as well as caregivers’ reaction to demands of care such as 
the burden imposed upon the caregivers, distress and lack of sleep.   
 The Self and Family Management Framework also hypothesises that better 
family functioning is associated with social support, adequacy of resources, 
hardiness, the ability to find positive meaning in the experience and fewer 
stressors259. It further suggests that the contribution of family variables to the 
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management of a family member’s chronic condition is crucial. The family variables 
of interest include family closeness, caregiver coping skills, mutually supportive 
family relationships, clear family organisation, and direct communication about the 
illness and its management, as each of these are linked with family and individual 
outcomes260. Such relationships may be applicable to the population with advanced 
cancer. For example, studies have reported that patients with cancer who are married 
or live with someone and had more education, experienced less sleep/wake 
disturbance240, 261, 262. However, a greater understanding of mechanisms involved 
between family structure and symptom severity is needed. It is reasonable to 
speculate that family members may facilitate the self-management process in a 
variety of ways, such as providing occasional advice, emotional support or tangible 
support that indirectly facilitates self-management (e.g. shopping for healthy food, 
buying medications for patients from the pharmacy when patients are too sick to go 
the pharmacy themselves)263. Dunbar and colleagues (2008) asserted that many self-
management interventions fail due to the lack of family and social considerations in 
chronic illness management224. Thus, more in-depth investigation focussing on 
family structure and its effects on self and family management may have 
implications for how family members can be better supported, in order to provide 
better self-management support for patients. 
Despite the importance of family structure and function being discussed, a 
Chinese study did not confirm that patients’ perceived levels of family support were 
independently associated with a number of fatigue self-management outcomes19. 
This could be due to the lack of content validity of the instrument (Chronic Illness 
Resource Survey) used for the population of interest. In this particular instrument, 
there were only three questions concerning this particular domain of interest: Have 
family or friends exercised with you? Have you shared healthy low-fat recipes with 
friends or family members? Have family or friends bought food or prepared food for 
you that was especially healthy or recommended? These questions were very specific 
and are not necessarily appropriate for use in patients with cancer. Further 
understanding about family functions and structures are required in patients with 
cancer.    
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Environmental context 
According to Grey and colleagues, environmental factors refer more broadly to 
relationships with the community, such as social network and their interactions with 
the health care system164. Their hypothesis was that a patient would be more likely to 
have better self-management outcomes if they have stronger and healthier social 
support. A number of studies have reported that this hypothesis is supported in 
patients with diabetes having better self-management outcomes264-267. The Capability 
for Supporting Prevention and Chronic Condition Self-Management outlined the 
importance of establishing self-management care plans that include community 
education programs or resources; community support networks and enhancement of 
the patient-health provider relationship17. For example, Lou (2011) reported that 
patients with higher perceived levels of support from their neighbourhood and 
community could independently predict the greater use and effectiveness of activity 
enhancement behaviours for relieving fatigue in patients with cancer19. These 
positive influences from a supportive social network may have beneficial effects on 
motivation, coping, and psychological wellbeing, with individuals who are motivated 
having greater morale, or who are less depressed being better self-managers263.  
Although it is reasonable to assume that social support from the community is 
desirable for optimal self-management in most cases, the social support theory also 
hypothesised that social interactions could have an unintentionally negative influence 
on self-management behaviour268, 269. For example, due to misconceptions or lack of 
understanding, friends and society could behave in unsupportive or inappropriate 
ways, offer unintended advice that conflicts with self-management 
recommendations, or directly or indirectly promote unhealthy behaviours (e.g. 
discouraging patients to take pain medications for pain due to misconceptions about 
addictive behaviours)263.  
For patients with advanced cancer, the knowledge of health services/other 
resources available to them may be a determinant for whether they access these 
services/resources or not270. An Australian study followed 181 patients with 
advanced cancer and 136 family caregivers and reported that community nursing was 
very well known, followed by social workers, physiotherapists and complementary 
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and alternative medicine services including acupuncturists and naturopaths270. The 
study also reported that government funded community programs including Home 
and Community Care (HACC), the Aged Care Assessment Team (ACAT), and 
Community Options were identified by only 10-25% in both groups. In the context 
of fatigue self-management, it is reported that patients with cancer may use strategies 
such as delegating tasks to others. Therefore there is a possibility that patients’ 
awareness of services or skills in accessing services may influence their ability to 
delegate tasks to others, especially for those who do not have family support. The 
Self and Family Management Framework proposes that patients should have better 
self-management outcomes if they have greater access to health services and 
community support. Increased consideration has been given to the social context of 
patients with advanced cancer and their family caregivers271-273. However, limited 
research has investigated how health care access and utilisation influences self-
management strategies with the aim of improving symptom outcomes.  
 
3.5.3 Hypothesised conceptual framework for the present study 
Grey (2006) hypothesised that a number of factors, including illness and 
individual, family and health care system factors, influenced the self-management 
behaviours of people with a chronic illness, which in turn could yield improved 
health outcomes164. This study aimed to understand self-management behaviours in 
patients with advanced cancer and whether a range of selected risk and protective 
factors could explain these behaviours. It was expected that gaining a more in-depth 
understanding of these issues would provide a basis for subsequent research to 
examine other aspects of the model, which focus on understanding how self-
management behaviours influence health outcomes. 
While a large list of hypothesised risk and protective factors were considered 
by Grey (2006) as relevant to self-management behaviours, the present project has 
taken a pragmatic approach by limiting the number of variables to the more 
important factors based on the literature review and the model for investigation. In 
this study, a number of important factors including demographic characteristics, 
diagnosis, self-efficacy associated with fatigue self-management, emotional state and 
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social support were selected for inclusion in the final multivariable model. Figure 3.3 
summarises the conceptual model for the multivariable analysis of this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Conceptual model for the multivariable analysis of this study 
 
Risk and protective factors 
 
Health status: 
Primary tumour type (Breast, Colorectal, Lung, 
Prostate) 
Treatment (types of anticancer therapies) 
Co-morbidities 
Fatigue severity 
Concurrent symptom severity 
Performance status 
 
Individual factors: 
Gender  
Age  
Anxiety 
Depression 
Self-efficacy 
Ethnicity 
 
Family factors: 
Income levels 
Living arrangements 
 
Environment context: 
Social support 
 
 
 
Self-management 
behaviours 
 
Frequency of undertaking 
self-management 
behaviours associated 
with fatigue 
 
Patient perceived 
effectiveness of self-
management behaviours 
associated with fatigue 
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3.5.4 Summary 
In summary, most of the factors identified in Grey et al’s Self and Family 
Management Framework influencing self-management have been hypothesised as 
important in patients with chronic conditions. Some of these potential factors have 
been further supported by direct or indirect empirical evidence in cancer care 
literature. However, some studies reported contradictory findings, indicating the need 
for further research to allow in-depth investigation into how these factors may 
contribute to the management of various issues across different cancer populations. 
To the best of our knowledge, there is limited research investigating factors 
influencing fatigue self-management in patients with cancer who are undergoing 
active treatment19, 222, 274. Further, there has been no research undertaken specific to 
patients with advanced cancer.    
 
3.6 CHAPTER SUMMARY 
There is growing interest in utilising self-management as a health care model 
for managing chronic conditions such as cancer. It is evident that research 
development in this area specifically related to patients with cancer is still at the 
infancy stage, compared to other chronic conditions such as diabetes and asthma. 
The evidence base is currently growing in relation to self-management in patients 
with cancer, however, there remains little information available concerning self-
management in patients with advanced cancer. To understand how to best support 
self-management in patients with advanced cancer, research efforts should be put 
into understanding factors influencing self-management outcomes.  
The Self and Family Management Framework was used as the conceptual 
framework to understand how self-management is undertaken by patients in the 
context of their family and health care system. A number of factors, as hypothesised 
by the Self and Family Management Framework, were expected to have an influence 
on self-management of people with chronic conditions. However, little is known 
about the factors that can potentially influence self-management behaviours in 
patients with cancer, particularly in those with progressive disease. The evidence 
base regarding factors influencing self-management behaviours will need to be 
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developed further to ensure that supportive care interventions are appropriate and 
effective for this population. Social determinants such as demographics, one’s level 
of self-efficacy, the presence of depression, and levels of social support could affect 
one’s self-management behaviour. It is imperative that further studies investigating 
self-management behaviour consider such social determinants.  
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Chapter 4: Methods 
4.1 INTRODUCTION 
In Chapters Two and Three, the literature relating to CRF in patients with 
advanced cancer and self-management as a conceptual model was reviewed. It was 
emphasised in Chapter Two that fatigue remains a distressing and unresolved 
problem in patients with advanced cancer despite advances in this field. Chapter 
Three highlighted the gap in literature on the self-management of fatigue in this 
population. To further advance understanding about ways to manage fatigue, the 
purpose of this study was to investigate self-management behaviours in patients with 
advanced cancer. Findings of this study have the potential to advance self-
management theory development, and have theoretical and practical implications. 
This chapter provides details of the research plan for this study, including the 
population, sample, analytical methods and data collection methods and instruments. 
The ethical issues associated with this study are also discussed.  
 
4.2 AN OVERVIEW OF THE RESEARCH DESIGN 
To explore the research questions, this study was divided into two stages.  
 
4.2.1 Stage One: development of the Self-efficacy in Managing Symptoms Scale 
- Fatigue Subscale for Patients with Advanced Cancer (SMSFS-A) 
In 2001, Yates and her research team developed the Self-efficacy in Managing 
Symptoms Scale - Fatigue Subscale (SMS-F) to assess self-management behaviours 
for symptoms and treatment-related side effects in patients with cancer undergoing 
anti-neoplastic therapy23. The SMS-F is attached in Appendix 4. This fatigue 
subscale was one of ten scales developed from data resulting from five focus groups 
of Australian patients with cancer experiencing chemotherapy or radiotherapy-
related symptoms. Specifically, this subscale aimed to assess the perceived 
effectiveness of a number of self-management behaviours for relieving fatigue, how 
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difficult patients found the behaviours and how confident they felt about using the 
behaviours. Effectiveness was rated from 0-4 (0=not used; 1=used, but no relief; 
2=used, a little relief; 3=used, some relief; 4=used, completely relieved). The 
difficulty and confidence levels were rated from 1-10, ranging from “not difficult” to 
“extremely difficult” and “not confident” to “extremely confident”.  
 The literature review for this thesis (Chapter Two) has suggested that the 
experiences, aetiologic factors and management of fatigue in patients with advanced 
cancer are likely to be different from those who are at early stages of their disease or 
those who are receiving active treatment with curative intent. Therefore, the items in 
this scale might not be suitable for use in patients with advanced cancer. Hence, the 
first stage of the study aimed to develop a new instrument for assessing self-
management behaviours in patients with advanced cancer by adapting the SMS-F 
using a number of procedures outlined in Figure. 4.1. Firstly, a literature review and 
ten semi-structured interviews of patients with advanced cancer were conducted. 
From this process, a number of self-management behaviours were identified as 
relevant to patients with advanced cancer. These items were then used to modify the 
items of the SMS-F. Secondly, an expert panel and a pilot test were used to assess 
the content validity, face validity and reproducibility of the instrument. At the 
completion of Stage One, the newly adapted tool was titled the “Self-efficacy in 
Managing Symptoms Scale - Fatigue Subscale for Patients with Advanced Cancer” 
(SMSFS-A). 
Internal consistency reliability and confirmatory factor analysis were not 
assessed for the SMSFS-A. These analyses are undertaken to disentangle complex 
interrelationships among variables and identify variables that go together as unified 
concepts or latent constructs such as attitudes, traits, intelligence, or perceptions275, 
276. Such analysis is impossible as the SMSFS-A was designed to assess the 
frequency and respective perceived effectiveness and perceived self-efficacy 
corresponding to 16 discrete behaviours associated with fatigue. No participants in 
this study were expected to use all 16 behaviours over the preceding seven days. If 
patients did not use a particular behaviour over the preceding seven days, they were 
not asked to answer the questions regarding respective effectiveness and self-efficacy 
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levels. This made the conduct of internal consistency reliability and factor analysis 
impossible as these analyses required large sample sizes with sufficient data for the 
testing of each variable277. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Procedures for the development of the SMSFS-A 
 
4.2.2 Stage Two: main study 
Stage Two involved an interviewer-administered longitudinal survey that 
elicited levels of fatigue severity, fatigue interference, distress and self-management 
behaviours associated with fatigue in patients with advanced cancer. Data were 
collected at three time points (baseline, time 2: 4 weeks, and time 3: 8 weeks) to 
investigate the relationships between these behaviours and a range of selected risk 
1. Initial development of items relevant to patients with advanced cancer 
- A literature review 
- Semi-structured interviews (n=10)  
 
2. Replacing the items of SMS-F with the newly developed items to form  
the SMSFS-A 
4. First modification of the items of the SMSFS-A 
5. Pilot testing (n=10) 
- Assessing face validity and feasibility 
3. Expert Panel Review (n>3) 
- Assessing content validity of the SMSFS-A 
- Repeat the expert panel review if the minimum level of agreement for was 
not achieved (Item CVI for relevance <1) 
6. Final modification of the items of the SMSFS-A 
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and protective factors that were hypothesised to influence self-management 
behaviours associated with fatigue in this population.  
 
4.3 SEMI-STRUCTURED INTERVIEWS 
4.3.1 Aim 
The aim of the semi-structured interviews was to identify behaviours that best 
described self-management behaviours associated with fatigue in patients with 
advanced cancer.  
 
4.3.2  Setting 
Participants were recruited from the Cancer Care Services at the Royal 
Brisbane and Women’s Hospital (RBWH), the largest tertiary cancer care centre in 
Queensland, Australia.  
 
4.3.3 Sampling frame 
The sampling frame for this part of the study was limited to all individuals 
diagnosed with an advanced cancer who fulfilled the following recruitment criteria: 
Inclusion criteria: 
 diagnosed with at least one distant metastasis;  
 reported an average fatigue intensity score of 4 and above on a 0-10 
numerical rating scale in the past 7 days;  
 were over 18 years of age;  
 were, in the opinion of the treating team, able to provide informed 
consent; 
 had completed first-line therapy since the first diagnosis of cancer; 
 had a life expectancy of more than two months. 
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Exclusion criteria: 
 were, in the opinion of the treating team, unable to provide informed 
consent;  
 were unable to speak and understand English;  
 were deemed by treating clinicians to be “too ill” or had “altered 
cognition” and not able to participate. 
 
4.3.4 Method 
During the first phase of tool development, semi-structured interviews were 
conducted to scope the range of activities patients with advanced cancer undertook to 
self-manage their fatigue. The interview questions were guided by the Self and 
Family Management Framework as the conceptual framework. This framework and 
its relevance for patients with advanced cancer were reviewed and discussed in detail 
in Chapter Three. The design of this part of the study was guided by the following 
assumptions of the Self and Family Management Framework:  
 Patients with advanced cancer perform self-management in the context 
of their environment; 
 Self-management of CRF can be a dynamic process, and can be 
influenced by a number of individual risk and protective factors.  
 
4.3.5 Sampling strategy and procedures 
The investigator provided in-service education sessions to explain the study to 
medical staff, nurses and other health professionals of the Cancer Care Services 
(CCS) at the RBWH. Information was also made available in written form and 
distributed to all professionals working in the CCS. The researcher visited work areas 
in CCS daily (Department of Radiation Therapy, Outpatient Day Therapy Unit, 
Outpatient Clinics and Oncology Inpatient Unit) to facilitate the referral process. 
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Eligible patients were approached by a clinician and were asked for agreement for 
their information to be passed to the researcher. Upon agreement, the clinician then 
referred the patient to the researcher for the consent process.  
After a referral was received, the researcher approached the patient to confirm 
eligibility against the inclusion and exclusion criteria as outlined in Section 4.3.3. 
The eligible patient was provided with a Participant Information Sheet and Consent 
Form (PICF) (Appendix 9), and time to read it and consider participating in this 
study. The information provided included, but was not limited to: who was 
conducting the study, how the participants would be involved, what data would be 
collected and what would happen to the data. Participants were encouraged to ask 
questions, and were asked whether they had read and understood the information. 
Non-English speaking patients were not enrolled as the project did not have 
resources for translation. If consent was given, participants received a duplicate copy 
of the PICF, and a leaflet acknowledging their participation, with details about how 
to contact the researcher for further information or to withdraw.  
 
4.3.6 Rigour of the interviews and transferability of findings 
Careful planning of the interview structure and sequence was essential to 
ensure that a focus on the topic area (self-management behaviours associated with 
fatigue) was maintained throughout. A semi-structured interview guide, involving a 
series of open-ended questions, was used. Patients were initially asked four open-
ended questions (See Table 4.1). 
Table 4.1. Question prompt list (part one) used in the semi-structured interviews 
Question Prompt List- Part One
 
1. Many people with cancer feel tired. What makes you feel tired?  
2. When do you find that you are most tired?  
3. Are there certain things that make it worse? 
4. When patients with cancer feel tired, they do certain things to reduce their tiredness. 
Could you tell me about what you personally do to reduce your tiredness?  
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Subsequently, a number of prompts were used to elicit more comprehensive 
data from patients in terms of what they did to manage fatigue (see Table 4.2). These 
prompts were developed in collaboration with the Principal Supervisor who 
specialises in cancer nursing research. Although these prompts included a number of 
self-management behaviours associated with fatigue as reported in the literature 
(Table 3.1), it is possible that patients perform these behaviours as general coping 
behaviours, and that they are not specific to fatigue. Therefore, participants were 
asked if they undertook certain behaviours to manage fatigue and whether it was 
useful in reducing it. Where any doubt arose, further prompts encouraged the 
participants to clarify whether their responses were specific to their management of 
fatigue, as opposed to general coping. 
 
The purpose of the interviews was to inform item generation for the SMSFS-A. 
As such, the interviews were not designed to be a single piece of qualitative inquiry, 
rather findings of the interviews were used as part of a larger data triangulation 
exercise to confirm content validity of the SMSFS-A. Transferability of findings 
(e.g. whether the findings can be transferred to other patients with advanced cancer) 
was nevertheless an important consideration. According to  Lincoln and Guba278, 
transferability refers to the degree to which the results can be transferred to or would 
hold in other similar contexts, as understood by the reader of the research278. In this 
study, transferability was supported by testing of content validity in subsequent 
phases of the research process.  
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Table 4.2. Question prompt list (part two) used in the semi-structured interviews   
Questions Prompt List- Part Two
 
1. When people are tired, some people do things such as take naps/sleep. Is this something that you do? Can you describe to me a time when you did 
this? Was it helpful? 
2. When people are tired, some people do things such as participate in an exercise program. Is this something that you do? Can you describe to me a 
time when you did this? What type of exercise/activity did you engage in? Was it helpful?
3. When people are tired, some people do things such as pace themselves; plan their day. Is this something that you do? Can you describe to me a time 
when you did this? What types of things did you do to plan? Was it helpful?
4. When people are tired, some people do things such as watch TV, or do things to take their mind off it. Is this something that you do? Can you 
describe to me a time when you did this? What type of things did you do to take your mind off the tiredness? Was it helpful?
5. When people are tired, some people do things such as think positive thoughts, try relaxation, or do other things to cope/feel better. Is this something 
that you did? Can you describe to me a time when you did this? What types of things help you to cope with your tiredness emotionally? Was it 
helpful?
6. When people are tired, some people do things such as spend time with loved ones. Is this something that you do? Can you describe to me a time when 
you did this? What types of things did your family/friends do to help when you were tired? Was it helpful?
7. When people are tired, some people do things such as delegate household tasks or other chores to other people. Is this something that you do? Can 
you describe to me a time when you did this? What types of things did you delegate to others? Was it helpful?
8. When people are tired, some people do things such as change the foods they eat. Is this something that you do? Can you describe to me a time when 
you did this? What types of foods did you eat to help you when you were tired? Was it helpful?
9. When people are tired, some people do things such as take medications or other complementary therapies. Is this something that you do? Can you 
describe to me a time when you did this? What types of medications/complementary therapies did you use? Was it helpful?
10. If you do a number of things to help you to reduce your tiredness, are there certain things that you prefer? What makes you decide to try different 
things?
11. (It may not be necessary if answered previously) Is there anything you would say that helps you reduce your tiredness? Can you describe how/when 
did you do those things? 
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There are no universal rules that determine the sample size of qualitative 
studies279, 280. Some qualitative studies use a data saturation method for determining 
the sample size. However, this method has been heavily criticised due to the fact that 
new data will always add something new, and the cut off between adding or not 
adding to emerging findings might be considered arbitrary281. Marshall (1996) 
suggested that an appropriate sample size for a qualitative study is one that 
adequately answers the research question281. Sandelowski (1995) argued that 
adequate sample size in qualitative research method is ultimately a matter of the 
judgement of the researcher, who is best placed to evaluate the quality of the 
information collected against the uses to which it would be put282. For this reason, a 
purposive sample of ten patients with advanced cancer and a fatigue severity score 
higher than three was interviewed. The reason for this criterion was that patients with 
a fatigue severity score lower than four would not be able to offer insights to the 
topic of interest. The results of the interviews supplemented the existing sources of 
information about self-management behaviours (literature review and expert panel 
review), to ensure that all potential self-management behaviours associated with 
fatigue specifically for patients were considered for the purpose of this study. A clear 
description of the characteristics of the participants in the semi-structured interviews 
is reported in Table 5.1.  
 
4.3.7 Data analysis 
The data obtained from the interviews were audio-recorded and transcribed. 
Data were managed with the use of the audio and transcribing functions of the 
NVivo software, and a number of manual coding procedures283. Lacking sufficient 
current knowledge of self-management behaviours in patients with advanced cancer, 
a content analysis was conducted to gain knowledge about what patients with 
advanced cancer do to manage fatigue284. The content analysis subsequently 
informed the modification of the SMS-F, which developed items suitable for initial 
testing in patients with advanced cancer. 
This study took a positivist stance, with the aim of generating results that were 
generalisable and applicable to future supportive care interventions for this 
population. In the past, there have been arguments concerning whether content 
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analysis is qualitative or quantitative285. According to Yin (1989) and Morgan 
(1993), the distinction between the use of a qualitative or quantitative approach to 
content analysis is based on what the data are to be used for285, 286. That is, a 
quantitative approach to content analysis seeks to answer questions about what and 
how many, whereas a qualitative approach seeks to answer questions about why and 
how the patterns in question came to be285. In this study, the analysis of data in this 
stage pragmatically focussed on generalisability (i.e. identifying codes representing 
patients’ self-behaviours), rather than identifying patterns (i.e. why patients perform 
certain behaviours) 285. The procedures for content analysis in the study were guided 
by Johnson and La Montagne (1993), as outlined below283:  
 
Preparing the data for analysis 
After data collection was completed, all digitally-recorded interviews were 
transcribed into text using NVivo on the same day as the interview or very soon 
thereafter. All transcriptions were rechecked against the original audio data for word-
for-word accuracy.  
 
Becoming familiar with the data 
At this stage, the researcher familiarised himself with the data through repeated 
reading of the transcripts279, as no insights could arise from the data without a 
complete familiarisation with it279. As the repeated reading of the transcripts took 
place, notes were made on ideas and potential categories of behaviours for later 
stages of the analysis. 
 
Identifying units of analysis 
The unit of analysis was subsequently determined by reading through all of the 
transcriptions and underlined sections of texts, words, phrases, sentences, or 
paragraphs275, 287, 288. The transcripts were then divided into various codes 
representing individual self-management behaviours275, 287, 288. Given that the aim of 
the semi-structured interviews was to generate items for the SMSFS-A, these codes 
had to be behaviours that patients recalled having performed over the previous seven 
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days. All statements (quotes) in the transcripts that related to behaviours performed 
by patients to manage fatigue were marked. Self-management behaviours not used 
for fatigue were not marked. Subsequently, the coded self-management actions were 
considered “level one codes”285, 288. These codes were descriptive words about 
specific behaviours used by the participants themselves280. 
 
Defining tentative categories for coding the responses 
The researcher read through the level one codes and combined behaviours that 
seemed to describe the same type of behaviours. He then organised these related 
behaviours into a list that could be categorised as level two codes (broader categories 
of behaviours). During this process, these categories had to be as mutually exclusive 
as possible, so that each unit of analysis would fit into only one category. Although 
these behaviours could conceptually overlap with each other, decisions were made at 
the discretion of the researcher to allocate the behaviours to the category that best fit. 
Thus coding emerged by repeatedly reading and fully comprehending the behaviours. 
Significant words and phrases were categorised. 
 
Refining categories 
Once the level two coding was completed, descriptions of specific or broader 
behaviours as discussed by the participants became available. Next, coded 
behaviours (level one codes) were compared within and between transcripts, to 
verify whether they described the same or different behaviours. At times, responses 
would not fit into an existing category. The categories were then refined by 
discarding inappropriate ones and creating new categories to integrate the items that 
did not fit into previous categories. The revised categories were used to repeat the 
process until all the responses were appropriately coded. Finally, all level two codes 
were further categorised into broader concepts (level three codes). 
 
Establishing category integrity 
To enhance the validity of the analysis and the synthesis of categories of self-
management behaviours, the Principal Supervisor was asked to verify the accuracy 
of the categories. After discussion with the Principal Supervisor, minor alterations to 
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the codes and categories were undertaken. Some of the original categories were 
refined or deleted to yield the final version of the codes and categories. 
Lastly, a categorisation matrix was used to present the data287. The matrix 
demonstrated how different behaviours were coded during the analysis. It was 
expected that such strategies would increase the trustworthiness of the study by 
linking the results and the data275, 288. At this stage, the items of SMS-F were 
modified by adding relevant self-management behaviours and removing irrelevant 
self-management behaviours, as informed by the results of the semi-structured 
interviews. This modified version of SMS-F was entitled the “Self-efficacy in 
Managing Symptoms Scale - Fatigue Subscale for Patients with Advanced Cancer” 
(SMSFS-A).  
 
4.4 EXPERT PANEL FOR ASSESSING THE CONTENT VALIDITY OF 
THE SMSFS-A 
Content validity is a crucial factor in instrument development, in that it 
addresses whether items within an instrument adequately measure a desired domain 
of content289, 290. To ensure the SMSFS-A had content validity for patients with 
advanced cancer, five experts were contacted and asked if they would participate as 
expert panellists. Criteria for selection of the panellists included having: (i) a 
minimum education level of a Master’s Degree, (ii) a minimum of three years of 
previous experience in cancer nursing, or previous experience with instrument 
development for the assessment of self-management in patients with cancer. These 
criteria were consistent with the recommendations of Grant and Davis289. A 
minimum number of three experts was used as advised by Lynn when using the 
Content Validity Index (CVI) method to assess content validity290. To enhance the 
accuracy, appropriateness, and relevance of the items for patients with advanced 
cancer, the panellists were asked to add, delete, or alter questions to further modify 
the instrument as applicable to the context of self-management associated with 
fatigue in patients with advanced cancer. The evaluation also included suggestions 
for format, clarity of items and relevance of items. Panellists were asked to give their 
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permission in writing to print their names, experience and qualifications in this 
dissertation. 
Each item of the SMSFS-A was reviewed for relevance and clarity. A cover 
letter was used to elicit panel members’ participation, together with instructions for 
the assessment process of the content validity of SMSFS-A289. In addition, the 
panellists were asked to rate each of the proposed items’ relevance in assessing self-
management associated with fatigue in patients with advanced cancer using a CVI290, 
291. The CVI included a four-point ordinal scale: 1 = not relevant, 2 = unable to 
assess relevance without item revision, 3 = relevant but needs minor alteration, 4 = 
very relevant. In addition, the CVI including a four-point ordinal scale to assess the 
clarity of each item used, with 1 = very unclear, 2 = unclear, 3 = clear, 4 = very clear. 
A CVI score was then calculated for each item using the following formula: 
 
CVI or % agreement = number of experts agreeing on items rated as 3 or 4/  
Total number of experts 
 
For the relevance of the items, Lynn (1986) recommended that the CVI at the 
item level should achieve “1” when less than five people are in the expert panel290. 
Items were to be modified or deleted if a CVI of “1” was not achieved for the 
relevance of the item. If any of the items did not achieve a CVI of “1” for item 
relevance, a repeated expert panel review was to be conducted to obtain sufficient 
content validity290. For the clarity of items, if a CVI of “1” was not achieved in any 
of the items, the items were to be modified to add clarity on the basis of the feedback 
provided by the panellists. 
 
4.5 PILOT TEST ASSESSING THE FACE VALIDITY AND 
REPRODUCIBILITY OF THE SMSFS-A 
The revised SMSFS-A was piloted with a convenience sample of 10 
participants. It was expected that a sample of 10 participants would provide a valid 
analysis of measurement error for the purpose of evaluating reproducibility. This 
analysis would estimate the mean error and its confidence interval. Without any 
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knowledge about an a priori difference, or how big a difference in error constitutes 
too much error, no sample size could be estimated. The sampling frame and 
participant recruitment procedures for this stage was the same as for Stage Two of 
the study, as described in Section 4.3. The PICF is attached in Appendix 10. This 
pilot-test aimed to assess the feasibility, the face validity, and the reproducibility of 
the instrument275. Face validity was assessed by measuring the time needed to 
complete the assessment tool, and asking patients about their views on the clarity of 
the questions, whether they could understand all items, whether the questions were 
easy to answer, and what other self-management behaviours they undertook for 
fatigue that were not yet included in the tool. Further adjustments of the items were 
then made according to the comments given by patients. After one week patients 
were contacted via the telephone to complete the questionnaire again, in order to 
examine the reproducibility of results. The one-week interval was chosen as it was 
recommended by Summers (1993) that the second test should not be more than two 
weeks after the first test292. This is to ensure that patients give a valid measurement 
in the second test without necessarily remembering the answers that were given 
during the first test. 
 
Data analysis 
All analyses were conducted using SPSS version 17. Descriptive statistics were 
calculated including means, standard deviations (or median and range if not normally 
distributed), and frequency distributions, to create a profile of the sample 
participating in this pilot test. For reproducibility, Bland and Altman’s measurement 
error calculation over a one-week interval (or within subject standard deviation) was 
calculated using the two main outcomes of the SMSFS-A (i.e. “the frequency of self-
management strategies used over the past seven days” and “the overall level of 
effectiveness of self-management for fatigue”)293. In addition, the Bland-Altman 
plots are presented (Figures 5.1 and 5.2)293.  
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4.6 STAGE TWO - MAIN STUDY 
Stage Two involved a prospective survey administered at baseline and monthly 
over two months, to investigate the frequency of identified self-management 
behaviours used by patients, ratings of the perceived effectiveness of these self-
management behaviours, and to determine the factors related to these outcome 
variables.  
 
4.6.1 Aims 
For patients with advanced cancer, the aims of the study were to examine: (i) 
self-management behaviours associated with fatigue, (ii) the frequency of self-
management behaviours, (iii) the perceived effectiveness of these behaviours, and 
(iv) the factors influencing the use of these self-management behaviours. The study 
focussed on expanding understanding of how self-management behaviours changed 
for patients in terms of frequency of use, perceived effectiveness of these behaviours 
and the factors influencing use of these behaviours over a two month period 
(baseline, time 2: 4 weeks and time 3: 8 weeks). Due to the lack of information in the 
literature regarding behavioural change in patients with advanced cancer, this study 
took an exploratory approach to investigate behavioural change in this patient group 
over a two month period, with monthly data collection.  
 
4.6.2 Research questions 
For patients with advanced cancer, 
Level 1- Descriptive 
1. What are the patterns of fatigue severity over a two month period? 
2. What are the patterns of behaviours undertaken by patients to manage 
fatigue over a two month period? 
3. What are the levels of perceived effectiveness of self-management 
behaviours in relieving fatigue over a two month period?   
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Level 2- Bivariate 
1. What are the relationships between the perceived effectiveness of self-
management behaviours and symptom severity at baseline? 
2. What are the relationships between selected risk and protective factors 
associated with the use and the perceived effectiveness of self-
management behaviours (demographics, symptom severity, level of 
social support, levels of depression, anxiety and self-efficacy) and  
a. The frequency of self-management behaviours that patients 
undertake at baseline? 
b. The number of self-management behaviours that patients 
undertake at baseline? 
c. The perceived effectiveness of self-management behaviours at 
baseline? 
Level 3- Multivariable 
1. Can the frequency of self-management behaviours over a two month 
period be explained by the risk and protective factors associated with 
self-management behaviours (demographics, clinical characteristics, 
levels of symptom severity, social support, depression and self-
efficacy)?  
2. Can the levels of perceived effectiveness of self-management 
behaviours over a two month period be explained by the risk and 
protective factors associated with self-management behaviours 
(demographics, clinical characteristics, levels of symptom severity, 
social support, depression, and self-efficacy)? 
 
4.6.3 Sampling frame 
In order for the data analysis to be meaningful, efforts were made to ensure the 
participants in this study were as homogeneous as possible. Therefore, the sampling 
frame for this study was limited to all those who were diagnosed with an advanced 
cancer and fulfilled the recruitment criteria listed below. A consecutive sample of 
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eligible patients was recruited over a period of 12 months at the RBWH. Patients 
were eligible for enrolment in the study if they met the following criteria: 
Inclusion criteria:  
 had a primary diagnosis of breast, lung, colorectal or prostate cancer;  
 were diagnosed with at least one distant metastasis; 
 had an average fatigue intensity score of > 3 on a 0-10 numerical rating 
scale in the past seven days;  
 were over 18 years of age;  
 were able to give consent to the study; 
 had completed first line therapy for their disease; 
 had a life expectancy of more than two months. 
Exclusion criteria: 
 were unable to give consent;  
 were unable to speak and understand English;  
 were deemed to be “too ill” or had “altered cognition” by treating 
clinicians to participate in the study. 
 
4.6.4 Sample size and feasibility 
The sample size calculation was based on the proposed multivariable analysis 
that examines factors influencing the frequency and the perceived effectiveness of 
self-management behaviours. The initial sample size calculation estimated that 130 
participants would be required (degree of freedom of independent variables x 10) to 
remain in the study at time 3 (Table 4.3)294. This estimation was directed by 
Tabachnick and Fidell (2012) in the absence of knowledge of pilot data in the area294. 
While it was not possible to accurately predict the attrition rate based on local data, a 
recent Australian longitudinal study of 163 patients with advanced cancer 
successfully retained 75% of the participants at week 12270. The attrition rate for this 
study was thus predicted to be approximately 25% at week 12. This population 
included 31% of patients with regional or local metastases and 69% of patients with 
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distant metastases. With this data in mind, this study took a more conservative 
estimation of an attrition rate of 35% at 8 weeks (time 3 of the present study). 
 
Table 4.3. Sample size calculation 
Degree of freedom 
required 
Supposed sample 
size by time 3 (n) 
Estimated attrition 
rate by time 3 
Number of patients 
required at baseline (n) 
13 130 35% 200 
 
In terms of the feasibility of recruitment, the estimated number of patients with 
advanced cancer with fatigue severity of greater than three out of ten on a numeric 
analogue scale and the estimated response rate was considered. In 2005, Bradley and 
her research team reported that 69% of patients with advanced cancer receiving 
radiotherapy (n=1296) experienced fatigue with a severity of 3/10 or above on a 
numeric analogue scale295. In 2009, another cross-sectional study investigating the 
patterns of fatigue in a population of patients with advanced cancer achieved a 
response rate of 65%296. With reference to the data discussed above, the researcher 
estimated that 446 patients would need to be approached (Table 4.4).  
During the design of the study, no local system existed that collected 
information on the total number of patients with advanced cancer treated by the CCS 
at the RBWH. The most relevant statistics in relation to patients with advanced 
cancer were the number of patients with cancer referred to the Specialist Palliative 
Care Service and the number of patients with cancer receiving radiotherapy with 
palliative intent. According to the local registry (HBCIS), the Specialist Palliative 
Care Service at the RBWH received 570 referrals of patients with advanced cancer in 
Year 2009297. According to the local registry of the Queensland Radium Institute 
(powered by Mirrabooka Systems), the total number of patients with metastatic 
cancer who received palliative radiotherapy at the RBWH was 606 in Year 2007 298. 
These numbers did not include all patients with advanced cancer treated by the CCS 
at the RBWH. Although these statistics were not specific to the targeted primary 
tumour groups in this study, these statistics indicated that it would be possible to 
approach 446 patients over a period of less than 12 months. 
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Table 4.4. Feasibility calculation 
Number of patient 
required at 
baseline (n) 
Percentage of 
patients with 
fatigue severity 
over 3/10 on a 
NRS 
Estimated response 
rate 
Number of eligible 
patients required to 
approach 
200 69% 65% 446 
 
Strategies to reduce attrition 
All reasons for attrition were recorded for this study. All available data were 
analysed and any potential bias due to attrition and drop outs are reconciled in 
Chapter Seven of this dissertation. While some reasons for attrition, such as death, 
could not be prevented, a range of strategies were employed to improve compliance 
and reduce attrition in research involving vulnerable populations299. Strategies such 
as allowing flexibility in scheduling the telephone follow-up interviews, having a 
second contact number for the participants/caregivers, conducting the research in a 
comfortable environment for participants and demonstrating a non-judgmental 
attitude were employed in this study300. Given that the research process with 
vulnerable populations is complex, stressful and time consuming for the researcher, 
the researcher had to prepare for foreseeable issues during data collection301. The 
researcher had six years of previous clinical experience in the capacity of an 
advanced practice nurse, providing palliative care and consultations in both inpatient 
and outpatient settings. Therefore, the researcher was prepared to optimise retention 
rates during both face-to-face and telephone interviews. 
 
4.6.5 Sampling strategy and procedures 
The investigator provided in-service education sessions to explain the study to 
the medical staff, nurses and other health professionals of the CCS at the RBWH. 
Information was also made available in written form and distributed to all 
professionals working in the CCS. The researcher visited the work areas in CCS 
daily (Department of Radiation Therapy, Outpatient Day Therapy Unit, Outpatient 
Clinics and Oncology Inpatient Unit) to facilitate the referral process. Eligible 
patients were approached by a clinician and were asked for agreement for their 
information to be passed to the researcher. Upon agreement, the clinician then 
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referred the patient to the researcher for the consent process. The recruitment 
procedures for this part of the study were the same as those for the semi-structured 
interviews as described in Section 4.3.5. After patient consent was obtained, baseline 
data were collected and the patients were also asked what time would best suit them 
for telephone follow-up interviews to occur. Patients were assured that the time for 
the interview would remain flexible, but would be as close as possible to 4 and 8 
weeks from the initial interview. Dates for all interviews were recorded.  
For this stage of the study, two researchers (the doctoral candidate and a 
research assistant) were involved in data collection. The research assistant was a 
cancer care nurse with clinical experience in caring for patients with advanced 
cancer. She held a Graduate Certificate of Cancer Nursing, and was provided with 
training and a standard script to ensure consistency throughout all telephone 
interviews. No inter-rater reliability analysis was conducted as no duplicate 
interviews or assessments were conducted by both data collectors. Duplicate 
interviews were avoided as it would further increase the burden on the participants.  
 
4.6.6 Dependent variables 
The dependent variables in this study were the frequency of self-management 
behaviours taken by patients (i.e. how often self-management strategies were used 
over the past seven days), and the perceived effectiveness of self-management 
behaviours in relieving fatigue. The final version of the SMSFS-A (Appendix 15), 
developed at Stage One, was used to collect data on these variables. 
 
4.6.7 Independent variables 
A list of independent variables and the respective data collection tools is 
presented in Table 4.5.  
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Table 4.5. Independent variables and respective data collection tools and sources 
Variables Data collection tool Source 
Individual factors   
Gender (M/F) 
Age (Continuous) 
Pre-designed data 
collection tool 
Medical records 
Medical records 
Anxiety and depression HADS Patient survey 
Self-efficacy SMSFS-A Patient survey 
Condition factors   
Tumour type 
Tumour sites 
Co-morbidities 
Treatment regimen 
(Chemotherapy, radiotherapy) 
Pre-designed data 
collection tool 
CCI 
 
 
Medical records 
Medical records 
Medical records 
Medical records 
 
Performance status AKPS Patient Survey 
Psychosocial characteristics/family 
factors 
  
Ethnicity 
Education 
Religion  
Living arrangements 
Income  
Pre-designed data 
collection tool 
 
 
Medical records 
Medical records 
Medical records 
Patient survey  
Patient survey 
Social support MOS Social Support 
Survey 
Patient survey 
Symptom experience/quality of life   
Fatigue  
Other concurrent symptoms 
(physical symptoms and 
psychological symptoms) 
BFI/ESAS
ESAS 
 
 
Patient survey 
Patient survey 
Note: AKPS- Australia-modified Karnofsky Performance Status; Charlson Comorbidity Index; HADS- Hospital 
Anxiety and Depression Scale; ESAS- Edmonton Symptom Assessment System; BFI- Brief Fatigue Inventory; 
MOS Social Support Survey – Medical Outcome Study Social Support Survey 
 
Demographic and medical information sheet 
A demographic and medical information sheet was developed to collect data 
on:  
i. demographic variables: age, gender, ethnicity, education, living 
conditions, living arrangement, income, marital status, settings 
(outpatient or inpatient)  
ii. treatment and symptom related variables: chemotherapy, radiation 
therapy, other concurrent treatment  
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iii. disease information: comorbidity, primary site of cancer, and sites 
of distant metastasis.  
 
Brief Fatigue Inventory 
The Brief Fatigue Inventory (BFI) contains nine items, each of which assesses 
the severity of fatigue and its effects on the patient’s ability in activities of daily 
living on a ten-point scale26. The BFI has been widely used on patients with cancer 
including those with advanced disease302. This tool was commended for its simplicity 
and reproducibility, and is therefore appropriate for patients with advanced cancer60, 
112, 303. The BFI also allows the categorisation of fatigue severity to levels 1-3 fatigue 
(indicating mild), levels 4-6 fatigue (indicating moderate), and levels 7-10 fatigue 
(indicating severe). This allows the identification of patients with severe fatigue as 
compared to those with moderate and mild fatigue. For this study, this tool could be 
particularly useful in identifying the difference between self-management behaviours 
in those with severe fatigue and those with moderate to mild fatigue. Permission was 
granted from the developers to use the tool in this study (Appendix 18). 
The tool assesses fatigue severity “in the last 24 hours”, “in past week” and 
“right now”. The interference items assess how much fatigue has interfered with 
different aspects of the participant’s life during the past 24 hours. The interference 
items included in this present study were general activity, mood, walking ability, 
normal work, relations with other people, and enjoyment of life. Each interference 
item was scored on an eleven-point rating scale from 0 (“does not interfere”) to 10 
(“complete interference”). A mean BFI score was calculated as the mean of the 
intensity and interference items. The inventory had a high internal consistency 
(Cronbach’s alpha coefficient of 0.96)302. The convergent validity with the POMS-F 
and Cancer Fatigue Scale were high, r=0.60-0.84302, 304. This scale had cut off scores 
to differentiate between mild, medium and severe fatigue. However, these cut off 
scores were not validated and should be used for screening purposes only 302. 
Although the limitation of the BFI is that it measures only the severity dimension, it 
is short and easy to use, involves the least number of questions and has demonstrated 
good psychometric properties302, 304, 305. 
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Fatigue Distress- Numerical Analogue Scale (NAS) 
A number of scales, which measure broader dimensions of the fatigue 
experience, including distress and impact, are long and can be cumbersome for 
patients with advanced cancer30, 33, 306. Therefore, a single item numeric analogue 
scale, ranging from 0 to 10 was used, to provide information on the distress level 
caused by fatigue over the past seven days307. In this scale, “0” represents “No 
distress” and “10” represents “A great deal of distress”. 
  
Edmonton Symptom Assessment System 
The Edmonton Symptom Assessment System (ESAS) is used for screening and 
assessing the severity of fatigue, pain, activity, nausea, depression, anxiety, 
drowsiness, appetite, well-being and shortness of breath27. The symptom severity 
scores and the change in these severity scores over time were used as independent 
variables in this study. Serial ESAS scores over time would thus provide a measure 
of an individual’s symptom profile. This tool was free for use without permission 
required. A recent review by Richardson and Jones (2009) confirmed that at least 33 
studies of over 5000 oncology patients have used the ESAS308. The reliability by 
test-retest within one day is generally high, exceeding 0.80308. Due to the dynamic 
nature of symptoms in the context of advanced cancer, repeated measures over a 
longer period may vary in their reliability. Each factor had internal consistency of 
Cronbach’s alpha values ranging from 0.68 to 0.80308. Some researchers have 
suggested that the emotional symptoms are poorly captured by the depression and 
anxiety items in the ESAS308. Therefore, the HADS was also used to measure 
depressive/anxiety symptomatology in this study, rather than relying on the ESAS 
alone.  
 
Australia-modified Karnofsky Performance Status (baseline only) 
The Australia-modified Karnofsky Performance Status (AKPS) is a modified 
version of the Karnofsky Performance Status (KPS)239. The KPS is considered the 
gold standard scale for assessing performance status in cancer care238, 309, 310. The 
AKPS is considered appropriate for clinical settings that include multiple venues of 
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care such as palliative care. This tool has been well used on patients with cancer, 
including those receiving active treatment for curative intent311, those with 
progressive cancer312 and those receiving palliative care313. The AKPS is a health 
professional administered scale that assesses the functional status of patients, ranging 
from 0 (death) to 100 (normal functioning without evidence of disease)312. This tool 
was free for use without permission required. 
 
Hospital Anxiety and Depression Scale (baseline only) 
The Hospital Anxiety and Depression Scale is a 14-item self-assessment tool. It 
consists of separate scales for anxiety (HAD-A) and depression (HAD-D). This tool 
is brief (it can be completed in two to five minutes314) and is appropriate for patients 
with advanced cancer315. The scale was originally developed for use on hospital in-
patients316. It has been well used and tested on patients with advanced cancer (in both 
in-patient and outpatient settings)71, 317-319 in the past. Scores on each subscale can 
range from 0 (no symptoms of depression/anxiety) to 21 (numerous and severe 
symptoms). The scale can also be used for screening in medically sick populations. A 
cut-off score of 11 or greater on either subscale is taken to indicate a ‘probable case’ 
of anxiety or depression320. A systematic review reported that the sensitivity and 
specificity for both HADS-A and HADS-D is approximately 0.80321 with a positive 
predictive value (PPV) of 0.48 when used against the GHQ-12 (General Health 
Questionnaire)314. The correlations between HADS and other commonly used 
questionnaires were in the range of 0.49 and 0.83321. A license was purchased for use 
with 200 participants for the purpose of this study (Appendix 17). 
 
The Short Medical Outcomes Study Social Support Survey (SSS) Scale 
(baseline only) 
The Short Medical Outcomes Study Social Support Survey (SSS) is a self-
administered tool containing 19 items322. This is a multidimensional measure of 
functional aspects of perceived social support, developed for use with chronically ill 
patients. There are four categories of social support including: tangible support 
(TAN), affectionate support (AFF), positive social interaction (POS), and 
emotion/information support (EMI). This questionnaire was developed to measure 
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social role functioning and the perception of social support. Some evidence shows 
that these factors help people in coping with stress and illness322. Each item is 
responded to on a 5-point Likert-type scale ranging from 1 (none of the time) to 5 
(all of the time) indicating how often the respondents receive the support; thus, the 
total score can range from 0 to 100. This instrument demonstrated good 
psychometric properties and has been well used on patients with advanced cancer323-
325. Reliability and validity reports are good. Internal consistency is high (alpha = 
0.97)322. Reproducibility is also high (0.78) and item-scale corrections all exceed 
0.72322. Correlations between the four subscales are 0.69 to 0.82322. This tool was 
free for use without permission required. 
 
The Charlson Comorbidity Index (baseline only) 
The Charlson Comorbidity Index (CCI) was used to collect information on co-
morbidities326. The CCI is the most widely used comorbidity index to date326-328. It 
was designed by Mary Charlson and colleagues in 1987, with the data from an 
internal medicine inpatient service326. This index was selected for use in this study 
because the CCI is easy to use327, is well validated in the cancer populations329 and 
can even serve as prognostic marker for some cancer populations329-331. 
 
4.6.8 Data collection 
The procedures for data collection are illustrated in Figure 4.2. 
 
Baseline data 
Patients were recruited from both inpatient and outpatient settings. After 
informed consent was obtained, baseline data including the SMSFS-A, HADS, 
ESAS, BFI, fatigue distress NAS, AKPS, MOS-Social Support Survey, 
demographics and other characteristics (medical diagnosis, treatment, CCI) were 
collected directly from patients or from medical records as outlined in Table 4.2.  
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Monthly follow- up 
At 4 and 8 weeks, a survey comprising only the SMSFS-A, fatigue distress 
NAS, BFI and the ESAS were used. Face-to-face interviews were conducted for all 
inpatient participants or outpatients who had scheduled appointments at the clinics or 
outpatient therapy unit. Telephone interviews were conducted for all other outpatient 
participants. After their baseline interviews, all patients were given an additional 
hard copy of the questionnaire to aid in future telephone interviews. Thus, the 
participants could see the scales visually as the phone interview was occurring. 
 
Telephone interviews 
Telephone interviews for clinical consultations and research use were expected 
to be feasible as they are commonly used in patients with advanced cancer332, 333. For 
research purposes, patients with advanced cancer normally prefer to minimise 
unnecessary travel to the hospital334. The benefits of telephone interviews included 
not having to commute to the hospital or clinic for the purpose of this study, having a 
sense of comfort from being in their own home and more privacy, and flexibility 
regarding the time of the interview334. Indeed, a telephone follow-up approach was 
not only appropriate, but also feasible and could provide valid data. For example, in 
2008, Okuyama and colleagues54 conducted a longitudinal study investigating the 
patterns of fatigue and the factors correlated with fatigue in a similar population as 
that proposed in this study. Two hundred patients with cancer were recruited from a 
palliative care service through face-to-face contact, and 129 patients were followed 
up via the telephone and successfully completed the interviews at time 2 and time 3 
(admission to a palliative care unit).  
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Figure 4.2. Procedures for data collection for Stage Two- Main Study 
 
4.6.9 Bias 
This study focussed on patients with advanced cancer in a tertiary cancer centre 
in Brisbane. While I acknowledge that it may not be a true representation of all 
patients with advanced cancer, the demographics, medical and treatment 
characteristics are discussed accordingly in Chapters Five and Six of this 
dissertation. 
 
4.6.10 Data Management and Analytic Plan 
Each subject was allocated an ID number to maintain confidentiality. 
Information on the questionnaire was coded and entered into the SPSS data file. The 
researcher entered all data twice to eliminate data entry error. Data were checked for 
missing values, outliers, and typing errors. Data cleaning procedures included 
descriptive procedures, scatter plots and histograms. 
Recruitment 
(Screening and 
informed consent) 
Baseline (30 minutes) T2 (4 weeks) 
(20 minutes) 
T3 (8 weeks)  
(20 minutes) 
Face-to-face Telephone/
Face-to-face 
Telephone/ 
Face-to-face 
Demographics and medical 
characteristics (including 
CCI) 
MOS-SSS 
HADS  
ESAS  
BFI  
SMSFS-A 
AKPS 
 
 
 
ESAS  
BFI 
 SMSFS-A 
 
 
 
 
ESAS  
BFI  
SMSFS-A  
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The analytical plan for this study was designed for the purposes of this study 
(Table 4.6). All analyses were conducted using SPSS version 17. The patterns of 
fatigue severity, self-management behaviours associated with fatigue (including the 
frequency of behaviours and the perceived effectiveness) were 
described statistically to summarise mean scores, standard deviations and a 95% 
confidence interval (CI) at each time point. Percentages were used to describe the 
frequency of behaviours undertaken at each time point. Subsequently, bivariate 
analysis such as Pearson correlation coefficient and analysis of variance (ANOVA) 
(or Kruskal-Wallis if non-parametric) were conducted to examine if there were any 
relationships between a list of independent variables, patients’ perceived levels of 
effectiveness and the patterns of fatigue severity scores. Lastly, multivariable 
modelling (a Generalised Estimating Equation) was used to examine factors 
influencing the frequency of use of self-management behaviours and the 
effectiveness of those behaviours.  
General Estimating Equations (GEE), first introduced by Liang and Zeger 
(1986), have become popular in the biological, epidemiological and health 
disciplines over the past two decades335. GEEs provide a framework for the analyses 
of continuous, ordinal, polychotomous and dichotomous data, and relax several 
assumptions of traditional regression models336. The GEE method is based on quasi-
likelihood theory and no assumption is made about the distribution of response 
observations337. GEEs require three specifications: a link (mean function, a variance 
function, and a “working correlation matrix)337, 338. The link function connects the 
expected value of the dependent variable and the linear combination of the parameter 
and explanatory variables338. GEE also uses a variable function that describes the 
dependence of the variances on the mean. The correlation matrix is carried out by 
assuming a priori, a certain “working” correlation structure for the repeated 
measurements of the outcome variable. There are a number of possible correlation 
structures (e.g. independence, exchangeable and autoregressive correlation 
structures, and unstructured structures)338. GEE is the preferred analysis as it is 
robust against wrong choice of correlation matrix, and no matter which structure is 
used, the result is similar 335, 337. The GEE was selected for use in this study due to its 
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several advantages, including robustness against the potentially wrong choice of 
correlation matrix, the ability to use all available data for analysis, and wide 
availability in a number of statistical software packages338. 
In multivariable modelling using GEE, the frequency of self-management 
behaviours associated with fatigue and the perceived effectiveness of self-
management strategies associated with fatigue were entered as dependent variables. 
There is no gold standard to guide the inclusion of variables in multivariable 
analysis339. Independent variables including gender, age, anxiety and depression, 
self-efficacy, primary tumour type (breast, colorectal, lung and others), number of 
co-morbidities, fatigue severity, other concurrent symptom severity, living 
arrangement and level of social, that are associated with the outcome at a P value of 
< 0.25 were entered into the multivariable analysis339. The Quasi Likelihood under 
Independence Model Criterion (QIC) was used to determine the best model fit. The 
QIC was selected because it involves using the quasi-likelihood constructed under 
the working independence model and the naïve and robust covariance estimates of 
estimated regression coefficients340. Moreover, QIC allows the use of any general 
working correlation structure to estimate the parameters in GEE340. 
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Table 4.6. Research methods and analytical approaches corresponding to the research questions 
Research methods Data collection 
time point 
Related analysis
Interviewer administered Longitudinal 
survey (over 2 months)  
Demographic characteristics and 
medical information including 
medical diagnosis, treatment and 
comorbidities  
Australia-modified Karnofsky  
Performance Status (AKPS) 
Brief Fatigue Inventory (BFI) 
Fatigue Distress numerical 
analogue scale (NAS) 
Edmonton Symptom Assessment 
System (ESAS) 
Self-efficacy in managing 
symptoms and treatment of side-
effects scale- revised fatigue 
Subscale (SMSFS-A) 
MOS Social Support Survey (T1 
only) 
Hospital Anxiety and Depression 
Scale (HADS) (T1 only) 
Baseline
Time 2 (4 weeks) 
Time 3 (8 weeks) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Q.1-3 Patterns/perceived 
effectiveness: 
Descriptive (mean, 
standard deviation, 
95%CI) 
 
Q.4-5. Bi-variate analysis 
(Pearson Correlation and 
ANOVA/Kruskal-Wallis) 
 
Q6-7. Multivariable 
modelling (i.e. General 
Estimating Equation ) 
 
 
 
 
4.6.11 Management of missing data 
The management of missing data is a challenging and frequently experienced 
issue in research involving people who are terminally ill341, 342. Participants in these 
studies might drop out of the study, die, or be lost to follow-up338. There are several 
approaches to dealing with this in longitudinal data analysis, including complete data 
analysis, available data analysis and imputation338, 342. Complete data analysis may 
lead to omission of many participants, as few people have complete data over time in 
clinical research settings338. Available data analysis is the approach of including all 
the subjects, regardless of whether the subject has provided complete data or not. 
Modern methods for analysing longitudinal data such as GEE and mixed effects 
regression model use available data analysis338. Imputation of missing data (e.g. 
single/multiple imputations) is a process whereby a reasonable alternative value is 
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substituted for one that is missing342. However, this approach can be problematic as it 
involves creating a data element where none exists338 and it can underestimate the 
variances or standard deviations of the data 342. GEE was selected for the analysis of 
the longitudinal data of this study, as it corrects the missing data by adding a dummy 
variable (missing versus not missing), for a less biased estimation of the regression 
coefficients343.  
 
4.7 ETHICAL CONSIDERATIONS 
Ethics approvals were granted by The Royal Brisbane and Women's Hospital 
Health Service District Human Research Ethics Committee (HREC), and The 
Queensland University of Technology Human Research Ethics Committee (UHREC) 
(Appendices 8 and 9).  
 
4.7.1 Informed consent 
People with advanced cancer may be considered vulnerable, however, gaining 
knowledge about them is necessary for high-quality care344. Indeed, patients with 
advanced disease are at times motivated to participate in research due to altruism, 
gratitude, concerns about care, the need to have somebody to talk to, and the need for 
information or access to services345. Patients with advanced cancer and carers are, in 
most cases, capable of deciding whether to participate in interviews and negotiating 
how they want the interviews to happen, except where cognitive, psychological 
impairments are present345. Therefore, patients with terminal illness should have as 
much right to participate in research as any other individuals under conditions of 
informed consent344. Acknowledging that people with advanced cancer are in a 
vulnerable position, the process of informed consent in this study ensured that 
patients were given sufficient information about the proposed research, were capable 
of understanding the information and had the power of free choice to allow them to 
either give or withhold consent to participate346. They were also assured that they 
could withdraw from the study at any time. They were advised that although this 
study did not have any direct benefits to them, the results of the study could 
potentially help future patients with cancer who suffer from fatigue301. 
  
Chapter 4: Methods 91 
 
 
 
   
4.7.2 Confidentiality  
To address confidentiality issues during data collection, all interviews took 
place in private. All confidential records associated with this study will be kept in a 
locked cabinet for five years within Cancer Care Services, RBWH. Participants’ data 
were only accessible to the members of the research team. All information on 
computer hard disks was protected by password. To ensure anonymity, no 
identifying names or information was included in any surveys, research reports or 
publications after the completion of the study.  
 
4.7.3 Burden of research 
Consideration was given to the number and length of the tools. Telephone 
interviews were used as a strategy to reduce burden associated with research at 4 and 
8 weeks for outpatients who did not have any scheduled appointment to return to the 
clinic. The results of stage 1B of the study indicated that the interview at baseline 
generally took up to 25 minutes, and the subsequent interviews took less than 15 
minutes. Routinely collected chart data were used where possible so as to reduce the 
need to collect the same data from participants. Caregivers were not asked to 
complete the interviews if patients were too frail to answer the questions themselves. 
Evidence suggests that fatigue is a highly subjective experience and therefore 
caregivers and health professionals can offer little insight6.  
 
Potential risks associated with psychological distress 
For this type of non-interventional study, the risks were expected to be 
minimal347. The potential risks were (i) greater self-knowledge than the participant 
was able to cope with regarding their condition and; (ii) greater understanding of the 
severity of the patients’ situation348. The researcher had experience in conversing 
with and counselling patients in the palliative care and cancer care settings. If the 
participants or caregivers developed such psychological distress, the researcher 
would facilitate access to counselling services provided by the Royal Brisbane and 
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Women’s Hospital as required. However, there were no such issues over the duration 
of the study. 
 
4.8 RISK MANAGEMENT AND HEALTH AND SAFETY ISSUES 
4.8.1 Potential risks for the researchers 
This research project involved interviews with patients with chronic illnesses 
(i.e. advanced cancer). The researchers were aware that there was a potential for the 
investigating team members to develop psychological distress during the research 
process. The doctoral candidate and the research assistant met together regularly to 
discuss issues over the duration of the data collection period.  
The research team had extensive experience in caring for patients with 
advanced cancer in both research and clinical capacities. If such cases of 
psychological distress arose, the Hazard Identification and Control Form and other 
relevant documentation would be completed as required as per the standard operating 
procedures at QUT. In addition, the researchers were to seek counselling services 
from a registered psychologist provided by the Queensland University of Technology 
or the Royal Brisbane and Women’s Hospital. However, no such need arose over the 
duration of the study. 
 
 
  
Chapter 5: Development of the Self-efficacy in Managing Symptoms Scale-Fatigue subscale for Patients with 
Advanced Cancer 93 
Chapter 5: Development of the Self-efficacy 
in Managing Symptoms Scale-
Fatigue subscale for Patients 
with Advanced Cancer 
5.1 INTRODUCTION 
This chapter describes the process involved in the development of the Self-
efficacy in Managing Symptoms Scale - Fatigue subscale for Patients with Advanced 
Cancer (SMSFS-A). The chapter first presents the initial development of the items of 
SMSFS-A, which involved findings from the semi-structured interviews and the 
literature review. Secondly, the processes and findings from the expert panel reviews 
are discussed. Finally, findings from the pilot test designed to assess the face validity 
and reproducibility of the instrument are described. An overview of all procedures 
for the development of the SMSFS-A is illustrated in Figure 5.1.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. An overview of procedures for the development of the SMSFS-A 
 
Initial development of 
the SMSFS-A from 
multiple sources:  
1. Semi-structured 
interviews (n=10) 
2. Literature review 
 
First round of 
expert panel review: 
  
1. Results and 
amendments 
made (n=4) 
 
Second round of 
expert panel 
review:  
1. Results and 
amendments 
made  (n=4) 
 
Pilot test (n=10):  
 
 
1. Face validity 
assessment 
2. Reproducibility 
assessment 
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5.2 INITIAL DEVELOPMENT FOR THE SMSFS-A 
5.2.1 Semi-structured interviews 
5.2.1.1. Sample characteristics of the semi-structured interviews 
Ten patients with advanced cancer (five women and five men) from Cancer 
Care Services (CSS) at the Royal Brisbane and Women’s Hospital (RBWH) 
participated in the semi-structured interviews. The median age of the sample was 67 
(range 44-81). These patients had diagnoses including breast, lung, ovarian, prostate 
and head and neck cancer. All ten patients had distant metastatic disease and had 
finished first-line treatments for their cancer. The educational levels of these patients 
varied from having completed primary schooling to having completed tertiary 
education. Table 5.1 provides a summary of the demographic and clinical 
characteristics of participants. 
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Table 5.1. Semi-structured interviews: sample characteristics (n=10) 
Characteristics Participants 
(n=10) 
 Median (Range) 
Age (years)  
Median 
 
67 (44-81) 
  
 N (%) 
Gender 
Male 
Female 
 
5 (50%) 
5 (50%) 
Ethnicity 
Caucasian 
 
10 (100%) 
Education 
Completed primary schooling 
7-12 years 
Completed high school 
Post-secondary school 
Tertiary education 
 
3 (30%) 
2 (20%) 
3 (30%) 
0 (0%) 
2 (20%) 
Living Arrangement 
Live with partner 
Live with other family member or friend 
Alone 
 
5(50%) 
2 (20%) 
3 (30%) 
Income (per annum) 
<20,000 
20,001-30,000 
 
7 (70%) 
3 (30%) 
Marital status
Married 
Divorce 
De facto 
Widowed 
Single 
 
5 (50%) 
3 (30%) 
0 (0%) 
1 (10%) 
1 (10%) 
Primary tumour site 
Lung 
Breast 
Colon 
Head and Neck 
Prostate 
Ovarian 
 
1 (10%) 
2 (20%) 
2 (20%) 
2 (20%) 
2 (20%) 
1 (10%) 
Current anti-cancer therapy
Chemotherapy 
Radiotherapy and targeted therapy 
Chemotherapy and targeted therapy 
Targeted therapy only 
No current anti-cancer therapy 
 
6 (60%) 
1 (10%) 
1 (10%) 
1 (10%) 
1 (10%) 
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5.2.1.2. Findings from the semi-structured interviews 
The data were analysed using methods recommended by Johnson and La 
Montagne (1993)283, as described in Chapter Four. Once the categories from the data 
were identified, a search for associations between categories and grouping of 
categories was undertaken. 
Nine categories of behaviours were identified which reflected the core 
behaviours patients undertook for managing fatigue: rest, managing medications, 
doing relaxing tasks, exercise, keeping busy, managing workload, optimising 
nutritional intake, keeping positive and accepting help from others. A summary of 
categories (of behaviours) and coded actions (individual behaviours) is presented in 
Table 5.2. The various behaviours relating to these categories are presented with 
supporting quotations from interviewees in the following section. 
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Table 5.2. Categories of behaviours associated with CRF 
Broader categories 
of behaviours 
(level 3 codes) 
Categories of 
behaviours (level 2 
codes)
Behaviours/actions (level 1 codes)
Cognitive Doing relaxing 
tasks/Distraction 
 reading magazines 
 watching TV  
 reading 
 doing puzzles 
 reading newspaper 
Activity Exercise  walking 
 jogging 
 doing weights  
 participate in a walking program
 Keeping busy  going to work  
 spending time with loved ones 
 spending time with friends 
 doing household chores 
 Managing workload  pacing oneself 
 taking breaks during a task  
 conserving energy for later tasks
 Accepting help from 
others 
 delegating tasks 
 receiving home help service 
 sharing housework with family 
 accepting help from family 
 Rest  taking naps 
 sleeping 
 lying down 
 sitting
Nutrition Optimising nutritional 
intake 
 taking nutritional supplement  
 maintaining healthy/balanced diets
Medication Managing 
medications 
 taking medications 
 taking pain relief 
 reducing the dose of pain relief
 
 
Cognitive 
Cognitive behaviours refer to patients engaging in a number of activities such 
as relaxation349, 350 and distraction351, 352. The aim of such strategies is to reduce 
attentional fatigue, a form of cognitive fatigue manifested by a decreased ability to 
focus attention351, 352. In this study, patients with advanced cancer described engaging 
in a number of relaxation strategies or distraction strategies for managing fatigue. 
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These strategies included watching TV, reading, and using a number of hobbies. For 
example: 
I would either sit down there watching TV or do cross word puzzles or 
something like that (Patient 2) 
I do artistic painting in the carport (Patient 3) 
I would just sit down and pick up a magazine, and just slip through the 
magazine and then get moving again. I do a lot of meditation as well, with music, 
affirmation, and meditation. I find that it relaxes me as well. (Patient 5) 
I read. I like watching sport in the television. Now, there is really a channel for 
the whole day. Rugby league and football. I used to play them. (Patient 9) 
 
Activity 
Studies involving diverse samples of patients with cancer reported that patients 
used a range of activities for managing fatigue such as exercising18, 20, 349, 353, 354, 
keeping busy173, 349, 353, managing workload18, 20, 349, 354, accepting help from others18, 
353, and rest18, 20, 173, 349, 350, 353-355.  
 
Exercise 
In the present study, patients with advanced cancer reported engaging in 
exercise such as jogging, walking or participating in walking programs for managing 
fatigue. For example: 
 I go jogging. It is around 1km jog at the present, I just felt like, just do it um… 
half an hour. I try to do it every second day. About three times a week. It sort of 
varies, you know. But I would like to build that up again like before I had cancer… 
(Patient 6) 
Once every couple of days, once every morning, I go down to where I used to 
work. There a lot, it is just around 2km from home. In terms of exercise, I just walk, 
half a km every morning. (Patient 8) 
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Some patients mentioned that they undertook exercise with a family member or 
in a group: 
We (patient and husband) do walks three mornings a week, a quarter of an 
hour. We have a walking group with the Heart Foundation in Dalby. We have three 
groups. We have three different directions that we go. (It is) roughly around two to 
three kilometres. (Patient 2) 
We live near a beach, so 2-4 km per day. It is about 2.5 miles. That’s about it. 
We have been doing that for several years. Just the two of us. We do it every day. 
(Patient 9) 
 
Keeping busy 
In this study, some patients described that they kept themselves busy to 
manage fatigue. For example:  
If I wake up in the morning, I wake up and do whatever I want to do. To me, it 
is important that I do something, not just sitting around. If you sit around, you get 
even more tired. (Patient 9) 
 Every day, I accomplish something, it keeps me going, it keeps me focussed, 
otherwise, you sit down and waste your life away, don't you? You got to accomplish 
something. That's what works for me, you can't sleep your life away. You have got 
cancer, you got to get out there, and live a life.” (Patient 5) 
When you can do things, you feel good, you are physically doing something. It 
does help when you are tired. (Patient 10) 
 
In addition, patients also socialised, and spent time with friends and family to 
keep themselves busy as a means to manage fatigue. For example: 
The other day, someone rang up, and I tidied up the house, and they came 
around. Instead of me lying around doing nothing, I spend time with my friends. 
Keeping myself busy and it helps. (Patient 6) 
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Yeah, I have two neighbours, and I got mates from the club. I used to drink at 
the bowls club. Sometimes 4-5 of them might come around, up in the yard, you know. 
I just make some friends. (Patient 8) 
I talk (with my wife). She does the talk, I do the listening. (Patient 9) 
 
Rest 
Some patients described a variety of resting activities when they were fatigued. 
For example:  
I sit down and rest for a while, put my feet up and head back (Patient 1) 
 
Similar statements were made by other patients: 
I just slowed down and I sat down. In the afternoon, I tend to stretch out on the 
lounge, and I can fall asleep for about 20 minutes. (Patient 4) 
I went to lie down and go to sleep, if I am at home, up to half an hour or an 
hour, just a cat nap. You sort of do two things and you hit the wall, and your legs get 
tired, and you want to lie down, so I get a book out and 5 minutes, I am asleep. 
(Patient 3) 
 
Managing workload 
Patients with advanced cancer in this study described using a number of 
strategies to manage the workload of the tasks they needed to engage in. These 
strategies included taking breaks during a task, pacing themselves and planning. For 
example:  
 (I) do so much, and go and sit down for a while (Patient 2) 
If I feel tired, I would just go in inside, and have a sit, yeah, what I was doing, I 
was sweating, so I went inside, I had some swigs of Gatorade, and sit down for 15 
minutes, then go back again. Have a drink, and kept going. So I wouldn't make 
myself I am frightened of getting exhausted, because I am on my own, so I am just 
kind of sensible about it. If I am tired, I would sit down and have a drink, and once I 
feel rested. I would just go back, it might take 15 minutes (Patient 4) 
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I still mow the lawn. It depends how long the weeds are. I have a backyard and 
a footpath. I can normally do it both in one hit. But when it is a bit long, I do it over 
two days. I take a little break in between. (Patient 10) 
 
Others mentioned that they paced themselves or conserved energy over a 
period of time (a day or a week). For example: 
I do (pace myself), I am very careful nowadays, I won't set myself too high a 
goal, and I try to pace it out over the week, rather than trying to do every on my own 
(Patient 1) 
I normally do it first thing in the morning when I get up, but then, by the time 
you hang it up, you are ready to take a rest, it could be taking an hour or so 
 (Patient 3) 
I normally do it (the housework) by myself. By myself, washing, washing the 
plates and stuff, I can leave it for two days. Then, I do it then, like yesterday I 
couldn’t sleep, so I was doing it at 4am in the morning. …When I feel like it and 
when I can do it, so I wash the clothes, washing and all that. I can do it, I do it, 
because the next day, I might be tired. (Patient 8) 
 
Accepting help from others 
For the management of fatigue, patients in this study also accepted help from 
others. Some noted that they accepted help from their family or shared their 
workload with the family. For example:  
 (I delegate) when I don’t feel like doing it. I try to delegate shopping. It’s the 
walking around in the shopping centre. At home, it is only a small shopping centre, 
you just walk into a shop. Here, you have to walk and walk. You can’t get to a shop, 
you gotta walk through the shopping centre to get into a shop. (Patient 7) 
I do most of it (housework), she is supposed to be my carer, well, she was 
supposed to come today, but she is not well, so she did not come. I usually do the 
most of it, but we do share it. (Patient 3) 
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…when I am doing the washing he (my husband) will hang it out for me 
 (Patient 2) 
My families come around, they know that I am independent. My son in law 
came in a week ago and mowed the yard for me (Patient 8) 
Some patients accepted home help from nursing or home-help agencies. For 
example:   
I do have somebody to help me with the housework. We have Oz Care coming 
in to shower my husband, 5 days a week, and I do it the other two days. My GP 
organised a lot of things for me. (Patient 1) 
We do most of it (housework), but Blue Care comes in every fortnight, and do 
vacuum and they do it every fortnight, but otherwise, I cook for ourselves.  
 (Patient 3) 
Through the Blue Nurses, I have a lady coming in an hour a fortnight, she does 
my bathroom and my floors, clean the shower and toilets. (Patient 4) 
 
Medication 
Managing medications 
Managing medications refers to patients adjusting medications to alleviate 
fatigue. Some patients took medications to relieve other symptoms (such as sleep 
disturbance, pain, itching and depression), and these medications were in turn 
perceived by patients to improve fatigue. For example:  
It (haloperidol) makes me feel more cheerful. I take it in the morning and 
afternoon. It certainly wakes me. It is an antidepressant. (Patient 7) 
Sometimes, I can’t sleep due to the itch. And I have aloe vera cream, when I 
put it on, the itch is gone, then I can sleep. It’s just the dryness of the skin I think.  
(Patient 10)  
 
  
Chapter 5: Development of the Self-efficacy in Managing Symptoms Scale-Fatigue subscale for Patients with 
Advanced Cancer 103 
Another patient mentioned that she would reduce opioids for pain, even when 
she had breakthrough pain. For example: 
I take oxycontin for some pain, for some nerve pain that I have, I know, since I 
taken that, I feel more tired, I know it is the drug that add towards that. I take two 
(endone) a day. 
Researcher: Do you sort of juggle the dose of your endone, and maybe even 
just accept some pain, rather than feeling tired?  
Yes, I have done that actually. I would take less endone even when I still had 
pain (Patient 1) 
 
Nutrition 
Optimising nutritional intake 
Optimising nutritional intake is one of the behaviours patients with cancer use 
for managing fatigue18, 20, 356. Patients with advanced cancer mentioned that they took 
nutritional supplements or attempted to eat healthy diets to manage fatigue. For 
example:  
I have certain food, like anything with high protein, like yoghurt and dairy 
products, and I put back on the weight that I lost. Sometimes, I make a milkshake or 
something like that, those kind of things. (Patient 2) 
I take ensure. It helps. It gives extra energy in the body. About 2 per day, I am 
supposed to take 3 or 4. But I find it difficult. (Patient 6) 
 
5.2.1.3. Conclusion 
The patients in this study performed a range of self-management behaviours to 
manage fatigue. The reported behaviours could be further categorised into four 
broader groups of behaviours: activities, cognitive, medication and nutrition. While it 
is a common belief that “nothing can be done” for CRF in this patient group87, 88, the 
findings of this study suggest otherwise. Indeed, patients do engage in self-
management activities for their fatigue, even at advanced stages of their disease. 
Moreover, these findings confirm that patients with advanced disease often 
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spontaneously engage in a number of behaviours with or without the prescription of 
the health professionals. 
 
5.2.2 Integrating items from the literature review and interviews into the initial 
scale 
This stage of the study focussed on generating items for the self-efficacy scale 
from the literature review and the themes identified from semi-structured interviews. 
For inclusion in the scale, the item must fulfil at least one of the following criteria: 
 is identified from semi-structured interviews to be a strategy used by 
patients with advanced cancer; 
 is recommended in the NCCN Clinical Practice Guidelines in 
Oncology: Cancer-Related Fatigue as “general strategies for the 
management of fatigue” for patients with advanced cancer; 
 is identified from a systematic review (level I evidence as defined by 
the National Health and Medical Research Council) or a randomised 
controlled trial (level II evidence as defined by the National Health and 
Medical Research Council) to be a strategy performed by patients with 
cancer for relieving fatigue, whether effective or ineffective; 
 is identified in observational studies or scholarly papers in the literature 
as a strategy used by patients with cancer; 
 is, in the opinion of the PhD candidate and supervisors, an essential 
behaviour to be included. 
 
Twenty-two items were identified using these criteria during the initial 
development of the SMSFS-A. The initial SMSFS-A was comprised of 22 items 
(self-management behaviours) reflecting the seven groups of behaviours: (activities, 
medications, complementary therapies, cognitive, psychological, nutrition and 
overall) (Appendix 5). Table 5.3 lists each of the original items and provides a 
summary of the supporting literature to support their inclusion. 
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Table 5.3. Preliminary items developed from multiple sources 
Categories Items of self-management behaviours 
associated with fatigue 
Corresponding 
SMSFS-A 
items 
Reasons for 
inclusion 
Examples 
Activities - Napping 1 I+L+N Borthwick et al (2003), Graydon et al (1995), Richardson et al (1997), 
So et al (2005) 
- Resting 2 I+L Graydon et al (1995), So et al (2005) 
- Aerobic activities (e.g. walking 
or jogging) 
3 I+L+N Walking: Borthwick et al (2003), Cramp et al (2010), Drouin et al 
(2005), Fitch et al (2008), Graydon et al (1995), Mock et al (1994, 
1997, 2005), Mutrie (2007), Richardson et al (1997), Segal et al (2001), 
Windsor (2004) 
Stationary cycling: Cramp et al (2010), Dimeo et al (2004)   
- Stretching and flexibility exercise 
(e.g. stretching training, yoga) 
4 L+E+N Stretching/flexibility training: Courneya et al (2003), Mckenzie 
(2003), Headley et al (2004), Cramp et al (2010) 
Yoga: Cohen et al (2004), Culos-Reed et al 2006 
- Strength and resistance exercise 
(e.g. weights, chest press, leg 
press) 
5 I +E+N Strength/resistance exercise: Segal et al 2003, Segal 2009 
- Delegating tasks 6 I+L+N Barsevick et al (2004), Fitch et al (2008), Graydon et al (1995), Pearce 
et al (1996), Magnusson et al (1999) 
- Pacing self 7 I+L+N Barsevick et al (2004), Fitch et al (2008), Magnusson et al (1999),  
Messias et al (1997), Ream (1997), Richardson et al (1997),   
Medications - Taking prescribed medications 
that reduce fatigue 
8 I+L+E Barsevick et al (2001), Holley (2000), Minton (2010) 
- Taking non-prescribed 
medication that reduce fatigue 
9 I+L+E Barsevick et al (2001), Holley (2000), Minton (2010) 
- Reducing opioid/ stopping 
medications that cause fatigue  
10 I N/A 
Complementary 
and alternative 
medicine 
- Taking alternative medications 
(e.g. herbal medicines, vitamins)  
11 L Lectin-Standardised Misteltoe Extract: Schumacher et al (2003) 
Levocarnitine: Graziano et al (2002), Cruciani et al (2004) 
- Using complementary therapies  
(homeopathic remedies, 
acupuncture, aromatherapy, 
reflexology) 
11 L Homeopathic remedies: Richardson et al (1997) 
Acupuncture: Richardson et al (1997), Vickers et al (2004),  
Aromatherapy/reflexology: Kohara et al (2004) 
Cognitive - Doing relaxing tasks (e.g. games, 
music, watching TV, reading, 
hobbies and socialising) 
12 I+L+N Hobbies: Borthwick et al (2003), Richardson et al (1997), So et al 
(2005) 
Socialising: Borthwick et al (2003), Graydon et al (1995), Richardson 
et al (1997), So et al (2005) - Using distraction 13  
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Listening to music: Graydon et al (1995), Richardson et al (1997), So 
et al (2005) 
Reading: Richardson et al (1997), 
Watching TV: Borthwick et al (2003), Graydon et al (1995), 
Richardson et al (1997), So et al (2005) 
 - Planning activities 14 I N/A 
Nutrition - Eating balanced diet (e.g. eating 
vegies/fruit, eating food with 
protein, eating dairy products, 
eating carbohydrates) 
15-18 I+L+N Richardson et al (1997), Fitch et al (2008), Holley (2000) 
- Drinking more water or fluid 19 P N/A 
- Drinking beverages with caffeine 20 P N/A 
- Taking nutritional supplements 
(e.g. energy drinks, high protein 
drinks) 
21-22 I+L Richardson et al (1997), Fitch et al (2008), Holley (2000) 
Note: I: Stage One interviews, L: observational studies or scholarly papers in the literature, E: randomised controlled trials or systematic reviews, N: NCCN Clinical Practice 
Guidelines in Oncology: Cancer-Related Fatigue, P: Recommended by the PhD supervisors
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5.2.2.1 Scaling format and scoring procedures during the initial development 
of the SMSFS-A 
The aim of the SMSFS-A is to assess three domains of self-management 
associated with fatigue in patients with advanced cancer. For each item (self-
management behaviour), three domains including the frequency of using the self-
management behaviour, the perceived levels of effectiveness and the levels of self-
efficacy associated with the self-management behaviours, are assessed. During the 
initial development of the SMSFS-A, the scale of frequency was rated as 0 = not 
used, 1 = occasionally, 2 = often, 3 = very often and 4 = all the time. The levels of 
effectiveness of the behaviours in relieving fatigue were rated from 1 to 10, with “1” 
indicating “not at all effective” and “10” indicating “completely relieved”. For the 
measurement of self-efficacy, individuals rated the strength of their belief in their 
capability to execute a series of items. The strength of self-efficacy refers to 
judgment of how certain one is of one’s ability to perform a specific task in these 
situations208. There is evidence that a single-judgment format for measuring the 
strength of one’s ability provides essentially the same information as the dual-
judgment format, and is more convenient to use208. Single judgement self-efficacy 
formats can also produce higher correlations with hypothesised antecedents and 
outcomes when compared with dual judgment formats357, 358. Therefore, the single-
judgment format was selected for this instrument; whereby individuals could rate the 
strength of their perceived efficacy from “1” indicating “not confident at all” to “10” 
indicating “extremely confident” for every item in the scale. Each item in the scale 
was rated for the frequency of use, the levels of perceived effectiveness and the 
levels of self-efficacy associated with the behaviour. Higher scores on the scales 
indicated higher frequency of use, levels of perceived effectiveness and levels of 
self-efficacy. 
In addition to specific self-management behaviours, two additional questions 
assessed the global level of effectiveness of fatigue self-management behaviours and 
the global level of confidence. These items were: “Overall, over the past 7 days, how 
would you rate your effectiveness in relieving your fatigue” (1 = not effective at all, 
10 = extremely effective); and “Overall, over the past 7 days, how would you rate 
your confidence in managing fatigue” (1 = not confident at all, 10 = extremely 
confident).  
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5.2.3  Expert review of the scale 
5.2.3.1 First expert panel review 
Five experts were invited to review the relevance and clarity of the items 
proposed for the SMSFS-A. All experts fulfilled the pre-determined criteria for 
selection as panellists, which included having a minimum education level of a 
Master’s degree, a minimum of three years of previous experience in cancer nursing, 
or previous experience with instrument development for assessment of self-
management in patients with cancer. These criteria were pre-determined during the 
design of the study and were consistent with the recommendations by Grant and 
Davis (1997)289. All experts agreed to participate and were given instructions prior to 
their review. For the SMSFS-A, the rating for relevance of items ranged from 1 = 
“not applicable” to 4 = “completely applicable”. Similarly, the rating for the clarity 
of items ranged from 1= “very unclear” to 4 = “very clear”. Four experts reviewed 
the instrument and returned their reports. One expert initially agreed to be part of the 
expert panel, but did not return her report and did not reply further after two 
reminders via email. The final number of experts (n = 4) fulfilled the minimum 
number of three experts as advised by Lynn (1986) when using the Content Validity 
Index (CVI) method to assess content validity290. 
According to Lynn (1986), the CVI at the item level should achieve “1” when 
less than five people are in the expert panel290. The CVI scores (percentage of 
agreement) were calculated and are presented in Table 5.4. Thirteen of 23 items did 
not fulfil a CVI of “1” for relevance in at least one of the questions (frequency of the 
strategies over the past seven days, levels of effectiveness or levels of confidence). 
Therefore, they were reviewed for item revision or removal.  
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Table 5.4. Content Validity Index for the relevance and clarity on each item of the initial SMSFS-A: the first expert panel review  
Items Frequency of using the 
strategy 
Levels of effectiveness Levels of confidence 
 CVI for 
relevance of 
items 
CVI for 
clarity of 
items 
CVI for 
relevance of 
items 
CVI for clarity 
of items 
CVI for 
relevance 
of items 
CVI for 
clarity of 
items 
1. Naps* 1 .50 1 .50 1 .25 
2. Resting* 1 .50 1 .50 1 .50 
3. Aerobic exercise (e.g. walking, jogging) 1 1 1 1 1 1 
4. Stretching/flexibility exercise (e.g. stretching, yoga) 1 1 1 1 1 1 
5. Strength/resistance exercise (e.g. weights, chest press, leg press) 1 1 1 1 1 1 
6. Delegating tasks 1 1 1 1 1 1 
7. Pacing yourself* 1 .50 1 .50 1 .75 
8. Taking prescribed medications that reduce fatigue* .50 .75 .50 .75 .50 .75 
9. Taking non-prescribed medications that reduce fatigue* .75 .75 .75 .75 .75 .75 
10. Reducing/stopping medications that cause fatigue* .50 .75 .50 .75 .50 .75 
11. Using complementary and alternative therapies (e.g. 
acupuncture, aromatherapy, massage, reflexology)* 
1 1 
 
1 1 1 .75 
12. Doing relaxing things (e.g. music, watching TV, reading, 
hobbies, and socialising) * 
.50 .25 .75 .75 .75 .50 
13. Doing things that distract you from fatigue* .50 .25 .50 .25 .75 .50 
14. Planning activities 1 1 1 1 1 1 
15. Eating food with protein such as meat, peas or beans* .25 .50 .75 .50 .25 .50 
16. Eating dairy products* .50 .75 .50 .75 .50 .75 
17. Eating veggies or fruit* .25 .50 .25 .50 .25 .50 
18. Eating carbohydrates (e.g. bread, cereal, pasta, rice)* .50 .75 .50 .75 .50 .75 
19. Drinking more water or fluid* .75 .50 1 .50 .50 .50 
20. Drinking beverages with caffeine 1 .75 1 .75 .75 .75 
21. Drinking energy drinks* .75 .25 .50 .25 .50 .50 
22. Taking nutritional supplements (e.g. drinking high protein/ 
vitamin drinks) 
1 1 1 .75 .75 .75 
Overall 1 1 1 1 1 1 
Note: *Items that did not achieve “CVI= 1” in any questions for the relevance and clarity of items 
  
Chapter 5: Development of the Self-efficacy in Managing Symptoms Scale-Fatigue subscale for Patients with 
Advanced Cancer 111 
 
On the basis of feedback from the expert panel, three major modifications were 
made to the instrument. These changes, in summary, were: 
1. There were some safety concerns regarding the inclusion of some self-
management behaviours, particularly the medication-related 
behaviours. The definition of self-management behaviours was revised 
to include any behaviour ‘self-initiated by the patient to manage the 
symptom’. As such, the behaviours included in the instrument are not 
necessarily evidence-based, but could include those actions that patients 
themselves spontaneously implement. Given this revision of the 
definition of self-management and the lack of efficacy of most 
prescribed medications for managing fatigue, actions associated with 
taking medications were removed. 
2. The clarity of items that related to more general behaviours was 
improved by providing examples. 
3. All the rating scales were modified to include a “0”.  
 
In total, 17 items were amended; one was retained without any amendment; 
seven were removed and three were added. The details of all amendments are 
presented in Table 5.5. The modified SMSFS-A comprising 18 items was 
subsequently sent to the four experts for the second round of expert panel review 
(Appendix 12). 
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Table 5.5.Amendment report outlining changes and the rationales for the changes after the first expert panel review 
Item Amendments Rationale
1. Naps Take short sleeps during the day - “during the day” was included and the wording 
was changed to add clarity 
2. Resting Rest during the day (without falling asleep) - “during the day” was included to add clarity 
- “(without falling asleep)” was included to 
differentiate this item from Item 1
3. Aerobic exercise (e.g. walking, 
jogging) 
Do aerobic exercise (e.g. walking/stair climbing/ 
swimming) 
- “jogging”, as an example, was replaced  
Patients with advanced disease most likely 
cannot jog or run
4. Stretching/flexibility exercise (e.g. 
stretching, yoga) 
Do stretching/flexibility exercises (e.g. stretching/ 
yoga/Pilates) 
- Pilates was included as an example to add 
clarity
5. Strength/resistance exercise (e.g. 
weights, chest press, leg press) 
Do strength/resistance exercises (e.g. weights/ 
chest press/leg press) 
 
N/A
6. Delegating tasks Delegate tasks N/A
7. Pacing yourself Pace your day to day activities over time - “day to day activities over time” was included 
to add clarity
8. Taking prescribed medications that 
reduce fatigue
Deleted - There were some safety concerns around the 
inclusion of these three medication-related 
behaviours. Given the lack of efficacy of most 
prescribed medications for managing fatigue to 
date, this tool is limited to only include self-
initiated behaviours that patients 
spontaneously implement, rather than 
behaviours prescribed by health professionals.  
9. Taking non-prescribed medications 
that reduce fatigue 
Deleted
10. Reducing/stopping medications that 
cause fatigue 
Deleted
11. Using complementary and alternative 
therapies (e.g. acupuncture, 
aromatherapy, massage, reflexology)
Use complementary or alternative therapies (e.g. 
acupuncture/ aromatherapy/massage/ reflexology) 
N/A
12. Doing relaxing things (e.g. music, 
watching TV, reading, hobbies, and 
socialising)  
Do relaxing things (e.g. listen to music and 
reading) 
- Some examples were similar to the examples 
given for Item 13. 
- Socialising may not be relaxing for some 
patients
13. Doing things that distract you from 
fatigue
Do things that distract you from fatigue (e.g. 
hobbies/socialising) 
- Two examples “e.g. hobbies/socialising” were 
added to add clarity.
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14. Planning activities N/A N/A
15. Eating food with protein such as meat, 
peas or beans
Eat a balanced diet (e.g. eat different food groups) - There were some concerns about the dietary 
items being contraindicated in some patients 
with cancer. Given there is little evidence to 
support dietary management of fatigue, we 
combined items 14 to 17 into one item: “Eat a 
balanced diet (e.g. eat different food groups)” 
16. Eating dairy products Deleted
17. Eating veggies or fruit Deleted
18. Eating carbohydrates (e.g. bread, 
cereal, pasta, rice) 
Deleted
19. Drinking more water or fluid Drink more water or fluid than usual - “than usual” was included to include a 
direction to the behaviour
20. Drinking beverages with caffeine Drink beverages with caffeine (e.g. coffee/tea/ 
coke/®Red-Bull) 
- Examples “(e.g. coffee/tea/coke/®Red-Bull)” 
were included in this item.
21. Drinking energy drinks Deleted - This item has been combined with item 19 
after the amendment
22. Taking nutritional supplements (e.g. 
drinking high protein/vitamin drinks)
Drink nutritional supplements (e.g. high protein/ 
vitamin drinks) 
- Wording was changed to add clarity 
Overall No change N/A
Additional items: Do things to improve your sleep at night (e.g. 
reduce noise and light; avoid caffeine before bed) 
- Sleep hygiene behaviours can reduce fatigue in 
patients with cancer 
 Plan your activities to make the most of your 
energy levels through the day 
- This item has been included as a psychological 
activity to complement Item 7.
 Talk to someone about your fears and concerns 
about fatigue 
- This behaviour has been recommended by a 
PhD Thesis on fatigue management for 
patients with advanced cancer.43
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5.2.3.2 Second expert panel review 
All four panellists returned their reports for the second round of expert panel 
review. However, one of the four panellists did not provide scorings for relevance 
and clarity of items, but provided qualitative feedback instead. Three participants is 
the minimum number recommended for using CVI290. The CVI scores were 
calculated for each item and are summarised in Table 5.6. Only item 1 (Take short 
sleeps during the day) and item 15 (Drink more water or fluid than usual) did not 
achieve CVI scores of 1 for item clarity. On the basis of the feedback provided by the 
expert panel, amendments were made to these items. Table 5.6 illustrates all the 
amendments made and the rationale for these changes.  
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Table 5.6. Content Validity Index for the relevance and clarity of the items of SMSFS-A: the second expert panel review  
Items CVI for 
relevance of 
items
CVI for clarity 
of items 
Changed to Rationale
1. Take short sleeps during the day * 1 2/3 (0.66) Take short sleeps during 
the day (fall asleep for <3 
hours) 
 To provide a clear 
definition of short 
sleeps/naps 
 The NCCN Clinical 
Practice Guidelines 
recommend for patients 
with cancer to take less than 
3 hours of naps each day 25.  
2. Rest during the day (without falling asleep) 1 1 No changes  
3. Do aerobic exercise (e.g. walking/stair 
climbing/swimming) 
1 1 No changes  
4. Do stretching/flexibility exercises (e.g. 
stretching/yoga/Pilates) 
1 1 No changes  
5. Do strength/resistance exercises (e.g. 
weights/chest press/leg press) 
1 1 No changes  
6. Delegate tasks 1 1 Delegate tasks to others  “to others” was included to 
add clarity
7. Pace your day to day activities over time 1 1 Pace your activities 
throughout the day 
 The wording was changed 
to add clarity
8. Do things to improve your sleep at night 
(e.g. reduce noise and light; avoid caffeine 
before bed) 
1 1 No changes  
9. Use complementary or alternative therapies 
(e.g. acupuncture/aromatherapy/massage/ 
reflexology) 
1 1 No changes  
10. Do things that distract you from fatigue 
(e.g. hobbies/socialising) 
1 1 Do things that distract you 
from your fatigue (e.g. 
hobbies/ socialising)
 Adding “your” to add 
clarity 
11. Plan your activities to make the most of 
your energy levels through the day 
1 1 No changes  
12. Do relaxing things (e.g. listen to music and 
reading) 
1 1 No changes  
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Note: *Items that did not achieve CVI scores of 1 for either relevance or clarity 
13. Talk to someone about your fears and 
concerns about fatigue 
1 1 No changes  
14. Eat a balanced diet (e.g. eat different food 
groups)*  
1 2/3 (0.66) Eat a balanced diet  Patients might not 
understand terms such as 
food groups, carbohydrates, 
protein etc. 
15. Drink more water or fluid than usual * 1 1/3 (0.33) Deleted  This item was judged to be 
unclear by the experts. 
Given the source of this 
behaviour was anecdotal, 
this item was deleted. 
16. Drink beverages with caffeine (e.g. 
coffee/tea/coke/®Red-Bull) 
1 1 No changes  
17. Drink nutritional supplements (e.g. high 
protein/vitamin drinks)  
1 1 No changes  
18. Overall 1 1 No changes  
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During the second round of expert panel review, the panellist who provided 
qualitative feedback expressed concern that the inclusion of some items that were not 
evidence-based might not be appropriate, as participants completing the SMSFS-A 
could interpret this to mean that such behaviours are supported by health 
professionals. To address this concern, an explicit statement was added to the 
instrument. This statement was read to participants before the administration of the 
tool: “The aim of this questionnaire is to find out what patients with cancer do to 
manage their tiredness. The questionnaire includes a list of things that patients with 
cancer may do. It does not mean that all behaviours are suitable for you.” 
In addition, one of the panellists questioned the usefulness of the terms used in 
the frequency scale. It is expected that each person has a different thought process. 
For example, some people might assign a different meaning to the same word; 
“often” to one person could be once or twice a week and to another it could be a few 
times a week359. Hence, a number of mutually-exclusive qualifiers were included in 
the frequency scale to add clarity: 0 = “not used”, 1 = “used occasionally” 
(once/twice), 2 = “often” (3-4 times), 3 = “very often” (5-6 times/week), 4 = “all the 
time” (7 times or more)359. The final version of the modified SMSFS-A is attached as 
Appendix 15.  
 
5.3 PILOT TEST ASSESSING THE FACE VALIDITY AND 
REPRODUCIBILITY OF THE SMSFS-A  
5.3.1 Sample characteristics of the pilot test 
Ten patients with advanced cancer (nine women and one man) from the CCS in 
the RBWH participated in the pilot test. The mean age of the sample was 62.6 (SD= 
9.1). At baseline, five of the participants were inpatients and five were outpatients. 
These patients had diagnoses including breast and lung cancer. All ten patients had at 
least one distant metastasis and had finished first-line treatments for their cancer. The 
educational levels of these patients varied from having completed primary schooling 
to having completed tertiary education. The mean Australian Karnofsky Performance 
Status (AKPS) for this sample was 74 (SD=18.38). The mean fatigue numerical 
analogue score on average over the past seven days was 5.6 (SD=1.71). Tables 5.7 
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and 5.8 summarise the socio-demographic and medical/clinical characteristics of 
participants at baseline. 
 
Table 5.7. Baseline socio-demographic characteristics of the pilot test (n=10) 
Characteristics Participants
(n=10)
 M (SD)
Age (years)  62.6 (9.10)
  
 N (%)
Gender  
Male 
Female 
1 (10%)
9 (90%) 
Ethnicity 
Caucasian 
African 
Asian 
Aboriginal/Torres Strait Islanders 
Others 
 
8 (80%) 
0 
1 (10%) 
0  
1 (10%)
Education 
Completed primary schooling 
7-12 years 
Completed high school 
Completed tertiary education 
 
1 (10%) 
2 (20%) 
3 (30%) 
4 (40%)
Living Arrangement 
Live with partner 
Live with other family member or 
friend 
Alone 
 
5(50%) 
2 (20%) 
3 (30%) 
Income (per annum) 
<20,000 
20,001-30,000 
30,001-40,000 
40.001-50,000 
50,001-60,000 
>60,000 
 
4 (40%) 
4 (40%) 
0 
1 (10%) 
0 
1 (10%)
Marital status 
Married 
Divorce 
Widowed 
Single 
 
4 (50%) 
3 (30%) 
2 (10%) 
1 (10%)
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Table 5.8. Medical or clinical characteristics of the pilot test (n=10) 
Characteristics Participants 
(n=10) 
 
Baseline setting 
Inpatient  
Outpatient 
Tine 2 setting 
Inpatient 
Outpatient 
N (%) 
 
5 (50%) 
5 (50%) 
 
1 (10%) 
9 (90%) 
Primary tumour site 
Lung 
Breast 
Colorectal 
Prostate 
 
6 (60%) 
4 (40%) 
0 
0 
Current anti-cancer therapy 
Chemotherapy 
Radiotherapy only 
Chemotherapy and radiotherapy 
Targeted therapy only 
Not current anti-cancer therapy 
 
0  
3 (10%) 
1 (10%) 
1 (10%) 
5 (10%) 
  
 M (SD) Possible 
range
Australian Karnofsky Performance Scale 74 (18.38) 0-100
Fatigue NAS 5.6 (1.71) 0-10
  
 Median 
(Range) 
 
Charlson Comorbidity Index:  0 (0-6) N/A 
Note: NAS= Numeric Analogue Scale 
 
5.3.2  Face validity of the SMSFS-A 
For the purpose of this study, face validity was assessed by measuring the time 
to complete the assessment tool, and what other self-management behaviours the 
patients undertook for fatigue, but were not yet included in the tool. Subsequently, 
patients were asked whether the questions were easy to understand and answer. All 
participants answered that all items were easy to understand and answer. 
The average time to complete the survey at baseline was 11 minutes (7.5 
minutes for time 2). Ten participants completed baseline surveys, and nine 
participants completed time 2 surveys. One participant did not complete the time 2 
survey as she was too fatigued and was not able to concentrate. This participant did 
manage to answer two questions that asked “Overall, over the past 7 days, how 
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would you rate your effectiveness in relieving your fatigue?” and “Overall, over the 
past 7 days, how would you rate your confidence in managing your fatigue?”. No 
further adjustments of the items were made at this time according to the comments 
given by patients. 
 
5.3.3  Reproducibility of the SMSFS-A 
Reproducibility was examined using the Bland and Altman analysis with the 
pilot sample (n=10)293. The two main outcomes of the SMSFS-A (the self-perceived 
overall effectiveness levels and the overall confidence levels for fatigue self-
management) were selected for the reproducibility analysis, one week apart. The 
Bland-Altman plots are presented in Figures 5.2 and 5.3 respectively and show 
agreement between initial and following pilot tests outcomes over a 1-week interval. 
Results showed that agreement of approximately 95% between the initial and follow 
up test was achieved. 
 
Figure 5.2. Bland-Altman Plots (n=10) to establish the agreement between test-retest for the self-
perceived overall effectiveness levels for fatigue self-management. The mean difference (solid line) 
and the limit of agreement (broken lines) are indicated. 
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Figure 5.3. Bland-Altman Plots (n=10) to establish the agreement between test-retest for the self-
perceived overall confidence levels for fatigue self-management. The mean difference (solid line) and 
the limit of agreement (broken lines) are indicated. 
 
5.4 SUMMARY 
The process of constructing the items for the SMSFS-A, and the validity for 
this scale were presented in this chapter. A preliminary scale including twenty-two 
items from interview findings and a literature review was developed. These items 
represented the self-management strategies that patients with advanced cancer used 
for fatigue. Subsequently, two rounds of expert panel reviews, involving four expert 
panellists, were conducted. All comments from the expert panellists were considered 
for modification of the tool. The final version of the SMSFS-A, comprising of 17 
items, indicated good agreement for relevance (CVI=1, agreement=100%) for all 
items. The results of the pilot test indicated that the questions asked in the SMSFS-A 
were easy to understand and answer. Two main outcomes (the level of overall 
effectiveness and the level of overall confidence) were selected for the 
reproducibility analysis. Preliminary results also indicated that results were 
reproducible over a one week time frame. 
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Chapter 6: Results of the Main Study: 
Longitudinal Survey 
6.1 INTRODUCTION 
This chapter presents the results of the longitudinal survey. Sample 
characteristics are presented in Section 6.2. Findings are presented in sections 6.3 to 
6.9. Sections 6.3, 6.4 and 6.5 present the results for the descriptive analyses. Sections 
6.6 and 6.7 present the results of the bivariate analyses examining the relationships 
between a number of potential explanatory variables and self-management 
behaviours. Sections 6.8 and 6.9 present the main findings of the multivariable 
analyses investigating the predictors of the frequency and perceived effectiveness of 
self-management behaviours associated with fatigue in patients with advanced 
cancer. 
 
6.2 SAMPLE CHARACTERISTICS FOR THE LONGITUDINAL SURVEY 
6.2.1 Demographic and medical/clinical characteristics 
Tables 6.1 and 6.2 summarise the socio-demographic and medical/clinical 
characteristics of the participants at baseline. One hundred and fifty-two patients 
with advanced cancer (99 women and 53 men) from Cancer Care Services in the 
Royal Brisbane and Women’s Hospital participated in the main longitudinal survey. 
The higher proportion of women in the study is consistent with other similar studies 
due to the over-representation of breast cancer patients in this population of interest. 
This population is relatively young, with the mean age of 59.5 (SD= 8.86). The mean 
age of participants in this study is comparable to similar studies including patients 
with advanced cancer163, 360, although it is lower than the mean age of patients with 
cancer in the general population. At baseline, the majority of participants were 
outpatients (n=136, 88.9%). These participants had primary cancer diagnoses 
including breast, lung, colorectal and prostate cancers. All 152 participants had at 
least one distant metastasis, had finished first-line treatments for their cancer, and 
had, on average, few comorbidities. The educational levels of these participants 
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varied from having completed primary schooling to having completed tertiary 
education. The majority of participants had low educational levels, with 56.6 % not 
having completed high school.  
 
Table 6.1. Baseline socio-demographic characteristics of the survey participants  
Characteristics Participants 
(n=152) 
 M (SD) 
Age (years) 59.5 (8.86) 
  
 N (%) 
Gender 
Male 
Female 
 
53 (34.9) 
99 (65.1) 
Ethnicity 
Caucasian 
Asian 
Aboriginal/Torres Strait Islander 
Others 
 
146 (96.1) 
3 (2) 
1 (0.7)  
2 (1.3) 
Education 
< 7 years 
Completed primary schooling 
7-12 years 
Completed high school 
Completed tertiary education 
 
4 (2.6) 
10 (6.6) 
72 (47.4) 
34 (22.3) 
32 (21.1) 
Living Arrangement 
Live with partner 
Live with other family member or 
friend 
Alone
 
90 (59.2) 
37 (24.3) 
25 (16.4) 
Income (per annum) 
<20,000 
20,001-40,000 
>40,001 
 
106 (69.7) 
20 (13.2) 
26 (17.1) 
Marital status 
Married 
Divorced 
De facto 
Widowed 
Single 
Separated 
 
84 (55.3) 
27 (17.8) 
5 (3.3) 
9 (5.9) 
19 (12.5) 
8 (5.3) 
 
 124  Chapter 6: Results of the Main Study: Longitudinal Survey 
  
Table 6.2. Medical/clinical characteristics of the survey participants 
Characteristics Participants 
(n=152)
 N (%)
Primary tumour site 
Breast 
Lung 
Colorectal 
Prostate 
61 (40.1)
44 (28.9) 
32 (21.1) 
15 (9.9) 
Current anti-cancer therapy 
Chemotherapy only 
Radiotherapy only 
Other anti-cancer therapy 
Combined anti-cancer therapies 
No current anti-cancer therapy 
 
52 (34.2) 
30 (19.7) 
20 (13.2) 
23 (15.1) 
27 (17.8)
 M (SD) Possible range 
Australian Karnofsky Performance Scale 76.93 (12.68) 0-100 
Medical Outcome Study-Social Support Survey 84.02 (17.60) 0-100 
Fatigue NAS over the past 7 days 5.85(1.44) 0-10 
 Median (Range)  
Charlson Comorbidity Index  0 (0-4) N/A 
 
Participants in this study had relatively high functional status, but were 
moderately fatigued. The mean Australian Karnofsky Performance Status (AKPS) at 
baseline for this sample was 76.93 (SD=12.68). The mean fatigue level over the past 
seven days at baseline was 5.85 (SD=1.44). The majority of participants were low 
income earners with an annual income of <$20,000 (69.7%). Approximately two 
thirds of participants were partnered and were living with their partner. The mean 
Short Medical Outcomes Study Social Support Survey (MOS-SSS) score was 84.02 
(SD=17.60), on a scale of 0 to 100, suggesting a relatively high level of social 
support on average.  
 
6.2.2 Participants over the duration of the study 
One hundred and fifty two patients with advanced cancer participated in the 
study at baseline. Over the duration of the study, 21 patients were lost to follow-up 
(14 at time 2 and further 7 at time 3) (Figure 6.1). Table 6.3 presents the reasons for 
attrition. Three patients died over the duration of the study, and 18 participants did 
not complete the study due to being “too sick” (n=15) or “declined due to other 
reasons” (n=1) or were “unable to be contacted” (n=2). It is possible that the fatigue 
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severity scores could be underestimated in this study due to loss to follow-up, 
although the small attrition should not impact substantially on study findings.  
 
 
Figure 6.1. Participants over the duration of the study. 
Referred patients 
screened for the 
study (n=231) 
Completed the 
survey at time 2 (4 
weeks) (n=138) 
Completed the 
survey at time 3 
(8weeks) 
(n=131) 
Not eligible 
Fatigue severity <4: n=51 
Did not speak English: n=7 
Too unwell: n= 10 
Other reasons: n= 4 
 
Declined to consent: 
Declined to consent: n= 7
Completed survey 
at baseline (n= 152) 
Patients enrolled 
into the study 
(n=152) 
Loss to follow up 
Died: n=2 
Too sick: n=10 
Unable to be contacted: n=2 
Loss to follow up 
Died: n=1 
Too sick: n=5 
Declined to participate n=1 
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Table 6.3. Reasons for attrition for Stage 2 longitudinal survey 
Patient ID Baseline 4 weeks 8 weeks Reasons for attrition 
004 0 1 1 Died before Time 2 
011 0 0 1 Died before Time 3 
013 0 1 1 Too sick 
016 0 0 1 Too sick 
019 0 0 1 Too sick 
030 0 0 1 Declined (too busy) 
040 0 1 1 Too sick 
059 0 1 1 Too sick 
073 0 1 1 Too sick 
077 0 0 1 Too sick 
085 0 1 1 Too sick 
088 0 1 1 Unable to be contacted 
092 0 1 1 Too sick 
093 0 1 1 Too sick 
095 0 1 1 Too sick 
096 0 1 1 Unable to be contacted 
104 0 0 1 Too sick 
114 0 1 1 Too sick 
120 0 1 1 Too sick 
121 0 0 1 Too sick 
133 0 1 1 Died before Time 2 
Note. 0= not missing; 1 = missing 
 
Attrition due to death and being too sick is an unavoidable problem in a study 
of patients with advanced cancer. Therefore, understanding any possible systematic 
differences between patients who dropped out and those who remained in the study is 
important for the interpretation of results361.  
A post-hoc analysis was conducted to examine if there were any socio-
demographic or clinical differences between the group that dropped out and the 
group that did not. These variables included, age, gender, ethnicity, education, living 
arrangement, income level, marital status, functional status, all fatigue severity 
scores and other symptom profiles as assessed by ESAS and HADS. The group lost 
to follow up had lower functional status (t=2.36, p < .05, df=151), a higher level of 
“fatigue at the moment” (t=-.238, p < .05, df=151), and demonstrated a trend for 
having a higher level of “usual fatigue over the past 24 hours” (t=-2.09, p < .05, 
df=151) at baseline. There were no other differences between these two groups. 
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6.3 PATTERNS OF FATIGUE SEVERITY OVER A TWO MONTH 
PERIOD 
Question 1. What are the patterns of fatigue severity over a two month 
period? 
The BFI and fatigue distress NAS were used to measure fatigue severity and 
fatigue distress levels. Overall, all fatigue severity scores were approximately 
normally distributed. Mean scores, standard deviations and 95% confidence interval 
(CI) are reported for all fatigue severity scores over a two month period (Figure 6.2). 
As can be seen in Table 6.4 and Figure 6.2, the levels of fatigue severity were 
consistently moderate (4-6/10) from baseline to two months. According to the 
descriptive data, changes of fatigue severity over time were not considered to be 
clinically meaningful362, 363, with mean differences less than one throughout all time 
points. Therefore, no further testing was undertaken to test statistical differences 
between time points. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. The mean levels of fatigue over a two month period (higher scores representing greater 
severity)  
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Table 6.4. The mean scores, standard deviations and 95% confidence interval (CI) of fatigue over a two month period 
 Baseline T2 (4 weeks) T3 (8weeks)
Fatigue scores n M (SD) 95%CI n M (SD) 95%CI n M (SD) 95%CI 
Fatigue level over the past 7 
days a 
152 5.85 (1.44) [5.62,6.08] 138 5.79 (2.23) [5.41,6.17] 131 5.85 (2.21) [5.46,6.23] 
Distress level caused by fatigue 
over the past 7 days a
152 3.97 (3.28) [3.45,4.50] 138 4.37 (3.31) [3.81,4.93] 131 4.56 (3.30) [3.99,5.14] 
Fatigue level right now a 152 4.61 (2.30) [4.24,4.98] 138 4.80 (2.52) [4.37,5.22] 131 4.80 (2.67) [4.34,5.27] 
Usual fatigue level over the 
past 24 hours a
152 5.15 (3.25) [4.63,5.67] 138 5.27 (2.39) [4.87,5.67] 131 5.31 (2.17) [4.93,5.69] 
Worst fatigue level over the 
past 24 hours a
152 6.10 (2.50) [5.70,6.50] 138 6.28 (2.66) [5.83,6.73] 131 6.67 (2.26) [6.28,7.07] 
Total fatigue interference b 152 20.21 (15.48) [17.73,22.69] 138 24.11 (17.71) [21.12,27.10] 131 22.63 (16.92) [19.67,25.58] 
Note. CI= confidence interval. a Possible range
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6.4 PATTERNS OF BEHAVIOURS UNDERTAKEN BY PATIENTS TO 
MANAGE FATIGUE OVER A TWO MONTH PERIOD 
Question 2. What are the patterns of behaviours undertaken by patients to 
manage fatigue over a two month period? 
The SMSFS-A was used to assess the frequency of self-management 
behaviours associated with fatigue in this study. The proportion of patients who used 
the specified behaviours over a two month period (baseline, 4 weeks and 8 weeks) 
was determined. Table 6.5 presents the number of patients who used self-
management behaviours in the following categories: not used/occasionally/often/very 
often/all the time.  
At baseline, 4 weeks and 8 weeks, the three most commonly used behaviours 
were ‘doing relaxing things’, ‘drinking beverages with caffeine’, and ‘resting during 
the day without falling asleep’. Throughout all time points from baseline to 8 weeks, 
the three least commonly used behaviours were ‘doing stretching/flexibility 
exercises’, ‘doing strength resistance exercises’, and ‘using complementary or 
alternative therapies’.   
Although this study recruited 152 participants at baseline, approximately 10% 
of patients did not complete the SMSFS-A. Approximately 15% of the total of 138 
participants at time 2 and 10% of the total of 131 participants at time 3 did not 
complete the SMSFS-A. Analyses were conducted on a number of variables 
including age, AKPS, all fatigue severity scores, all symptom severity scores, and 
social support to examine if there were any differences between those who 
completed and those who did not complete the SMSFS-A. At baseline, patients who 
did not complete the SMSFS-A were older (t= 2.28, p <. 05) and had a lower AKPS 
(t=-2.18, p < .05). Similarly, patients who did not complete the SMSFS-A had lower 
AKPS at time 2 (t=11.74, p < .05) and time 3 (t=2.88, p <.05). There were no other 
differences (with all p values > .05) between other outcomes in those who completed 
and those who did not complete the SMSFS-A at any time point. 
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Table 6.5. Frequency of behaviours by patients to manage fatigue over a two month period 
Behaviours by patients to manage 
fatigue 
T1
 (n=134) 
n(%)
T2 
(n=118) 
n(%)
T3  
(n=118) 
n(%) 
  Not 
used 
Occasionall
y 
Ofte
n  
Ver
y 
ofte
n 
All 
the 
time 
Not 
used 
Occasionall
y  
Ofte
n  
Ver
y  
All 
the 
time 
Not 
used 
Occasionall
y 
Ofte
n  
Very 
Ofte
n 
All 
the 
time  
1 Take short sleeps during the day 20 
(14.9
) 
20 
(13.1) 
21 
(13.7
) 
13 
(8.5) 
60 
(39.2
) 
21 
(17.8
) 
17 
(14.4) 
18 
(15.3
) 
11 
(9.3) 
51 
(43.2
) 
20 
(16.9
) 
19 
(16.1) 
18 
(15.3
) 
11 
(9.3) 
50 
(42.4
) 
2 Rest during the day (without 
falling asleep) 
18 
(13.4
) 
18 
(13.4) 
17 
(12.7
) 
4 
(3) 
77 
(57.5
) 
21 
(17.8
) 
14 
(11.9) 
18 
(15.3
) 
5 
(4.2) 
60 
(50.8
) 
16 
(13.6
) 
12 
(10.2) 
15 
(12.7
) 
5 
(4.2) 
70 
(59.3
) 
3 Do aerobic exercise (e.g. 
walking/stair climbing/swimming) 
53 
(39.6
) 
18 
(13.4) 
13 
(9.7) 
7 
(5.2) 
43 
(32.1
) 
45 
(38.1
) 
12 
(10.2) 
14 
(11.9
) 
7 
(5.9) 
40 
(33.9
) 
51 
(43.2
) 
14 
(11.9) 
14 
(11.9
) 
7 
(5.9) 
32 
(27.1
) 
4 Do stretching/flexibility exercises 
(e.g. stretching/yoga/Pilates) 
103 
(76.9
) 
7  
(5.2) 
9  
(6.7) 
2 
(1.5) 
13 
(9.7) 
85 
(72) 
6 
(5.1) 
8 
(6.8) 
3 
(2.5) 
16 
(13.6
) 
84 
(71.2
) 
7 
(5.9) 
7 
(5.9) 
2 
(1.7) 
18 
(15.3
) 
5 Do strength/resistance exercises 
(e.g. weights/chest press/leg press) 
122 
(91.0
) 
2 
(1.5) 
3 
(2.2) 
3 
(2.2) 
4 
(3.0) 
103 
(87.3
) 
2 
(1.7) 
4 
(3.4) 
1 
(.8) 
8 
(6.8) 
104 
(88.1
) 
3 
(2.5) 
2 
(1.7) 
1 
(.8) 
8 
(6.8) 
6 Delegate tasks to others 55 
(41.0
) 
15 
(11.2) 
13 
(9.7) 
3 
(2.2) 
48 
(35.8
) 
48 
(40.7
) 
13 
(11.0) 
8 
(6.8) 
5 
(4.2) 
44 
(37.3
) 
48 
(40.7
) 
10 
(8.5) 
11 
(9.4) 
3 
(2.5) 
46 
(39.0
) 
7 Pace your activities throughout the 
day 
42 
(31.3
) 
7 
(5.2) 
9 
(6.7) 
4 
(3) 
72 
(53.7
) 
27 
(22.9
) 
0 
(0) 
7 
(5.9) 
3 
(2.5) 
81 
(68.6
) 
23 
(19.5
) 
3 
(2.5) 
3 
(2.5) 
2 
(1.7) 
87 
(73.7
) 
8 Do things to improve your sleep at 
night (e.g. reduce noise and light; 
avoid caffeine before bed) 
68 
(50.7
) 
8 
(6.0) 
6 
(4.5) 
8 
(6.0) 
44 
(32.8
) 
72 
(61.0
) 
3 
(2.5) 
9 
(7.6) 
5 
(4.2) 
29 
(24.6
) 
76 
(64.4
) 
5 
(4.2) 
6 
(5.1) 
1 
(.8) 
30 
(25.4
) 
9 Use complementary or alternative 
therapies (e.g. 
acupuncture/aromatherapy/massag
e/ reflexology) 
97 
(72.4
) 
8 
(6.0) 
3 
(2.2) 
1 
(.7) 
25 
(18.7
) 
89 
(75.4
) 
4 
(3.4) 
2 
(1.7) 
0 
(0) 
23 
(19.5
) 
82 
(69.5
) 
3 
(2.5) 
0 
(0) 
0 
(0) 
33 
(28.0
) 
1
0 
Do things that distract you from 
your fatigue (e.g. hobbies/ 
socialising) 
50 
(37.3
) 
14 
(10.4) 
12 
(9.0) 
6 
(4.5) 
52 
(38.8
) 
41 
(34.7
) 
7 
(5.9) 
11 
(9.3) 
7 
(5.9) 
52 
(44.1
) 
45 
(38.1
) 
3 
(2.5) 
10 
(8.5) 
7 
(5.9) 
53 
(44.9
) 
1
1 
Plan your activities to make the 
most of your energy levels through 
the day 
64 
(47.8
) 
5 
(3.7) 
6 
(4.5) 
3 
(2.2) 
56 
(41.8
) 
57 
(48.3
) 
2 
(1.7) 
4 
(3.4) 
3 
(2.5) 
52 
(44.1
) 
41 
(34.7
) 
3 
(2.5) 
2 
(1.7) 
7 
(5.9) 
65 
(55.1
) 
1 Do relaxing things (e.g. music and 11 6 15 4 98 13 5 8 8 84 11 4 8 1 94 
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2 reading) (8.2) (4.5) (11.2
) 
(3.0) (73.1
) 
(11) (4.2) (6.8) (6.8) (71.2
) 
(9.3) (3.4) (6.8) (.8) (79.7
) 
1
3 
Talk to someone about your fears 
and concerns about fatigue 
97 
(72.4
) 
23 
(17.2) 
8 
(6.0) 
1 
(.7) 
5 
(3.7) 
89 
(75.4
) 
12 
(10.2) 
8 
(6.8) 
1 
(.8) 
8 
(6.8) 
81 
(68.6
) 
15 
(12.7) 
8 
(6.8) 
3 
(2.5) 
11 
(9.3) 
1
4 
Eat a balanced diet 
 
24 
(17.9
) 
3 
(2.2) 
9 
(6.7) 
5 
(3.7) 
93 
(69.4
) 
29 
(24.6
) 
0 
(0) 
3 
(2.5) 
9 
(7.6) 
77 
(65.3
) 
27 
(22.9
) 
2 
(1.7) 
5 
(4.2) 
5 
(4.2) 
79 
(66.9
) 
1
5 
Drink beverages with caffeine 
(e.g. coffee/tea/Coke/®Red-Bull) 
11 
(8.2) 
5 
(3.7) 
3 
(2.2) 
3 
(2.2) 
112 
(83.6
) 
16 
(13.6
) 
4 
(3.4) 
2 
(1.7) 
2 
(1.7) 
94 
(79.7
) 
17 
(14.4
) 
1 
(.8) 
2 
(1.7) 
3 
(2.5) 
95 
(80.5
) 
 
1
6 
Drink nutritional supplements (e.g. 
high protein/vitamin drinks) 
95 
(70.9
) 
7 
(5.2) 
9 
(6.7) 
2 
(1.5) 
21 
(15.7
) 
81 
(68.6
) 
4 
(3.4) 
6 
(5.1) 
0 
(0) 
27 
(22.9
) 
80 
(67.8
) 
8 
(6.8) 
4 
(3.4) 
2 
(1.7) 
24 
(20.3
) 
Note. Occasionally (once/twice over the past 7 days), Often (3-4 times over the past 7 days), Very Often (5-6 times over the past 7 days), All the time (7 times 
or more over the past 7 days) 
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6.5 THE LEVELS OF PERCEIVED EFFECTIVENESS OF SELF-
MANAGEMENT BEHAVIOURS IN RELIEVING FATIGUE OVER A 
TWO MONTH PERIOD 
Question 3. What are the levels of perceived effectiveness of self-
management behaviours in relieving fatigue over a two month period?   
The SMSFS-A was used to assess the effectiveness of self-management 
behaviours associated with fatigue in this study. In Chapter Five, the 16 behaviours 
included in the SMSFS-A were grouped into five categories namely; activities, 
complementary or alternative therapies, cognitive, psychological and nutrition. The 
‘activities’ category included eight behaviours. The average perceived effectiveness 
scores were therefore calculated for all used behaviours at each time point (baseline, 
4 weeks and 8 weeks). For categories with less than three behaviours (i.e. 
complementary or alternative therapies, cognitive, psychological and nutrition), 
levels of perceived effectiveness are presented for each of the individual behaviours 
at each time point. The total effectiveness levels are the average effectiveness scores 
divided by the total number of behaviours used at each time point. 
 In the SMSFS-A, two scores were used to evaluate the perceived effectiveness 
levels for self-management behaviours for relieving fatigue. Similarly, two scores 
were used to evaluate the perceived self-efficacy levels. These included the total 
summary levels of perceived effectiveness and self-efficacy, and the global levels of 
perceived effectiveness and self-efficacy. The total summary scores were calculated 
using the sum of effectiveness/self-efficacy scores of all behaviours used divided by 
the number of behaviours used, whereas, the global score was the effectiveness level 
in general, ranging from 0 (not effective at all) to 10 (extremely effective). It was 
expected that both scores could provide different information. That is, the total 
summary score was used to capture the levels of effectiveness and self-efficacy 
corresponding to every behaviour used where the weight of each behaviour was 
equal. The global score refers to a global overall rating using a single item examining 
the effectiveness of the patient’s self-management for alleviating fatigue, where the 
weight of each behaviour might not be equal. The decision to use the summary score 
should be at the discretion of the instrument developer364, 365. In this study, 
descriptive analyses and inferential analyses were conducted using both scores to 
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ensure the completeness of results, and because it allowed for testing of a priori 
hypotheses. 
The levels of perceived effectiveness of self-management behaviours and the 
respective frequency and perceived confidence scores at each time point are 
summarised in Table 6.6 using descriptive statistics, mean scores, standard 
deviations and a 95% confidence interval (CI). The participants, on average, used 
approximately nine behaviours in total over the preceding seven days at all three time 
points. From the perspective of the participants, the five most effective behaviours 
for relieving fatigue were ‘pacing your activity’, ‘taking a short sleep during the 
day’, ‘planning your activities to make the most of your energy levels through the 
day’, ‘doing things that distract you from your fatigue’, and ‘doing things to improve 
your sleep at night’. Participants were generally very confident in undertaking all 
behaviours, with all the mean confidence scores >7/10 (high scores represent higher 
levels of confidence). 
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Table 6.6. ‘Number/percentage of people using, ‘frequency’, ‘levels of effectiveness’, and ‘levels of confidence’ associated with self-management behaviours in relieving 
fatigue over a two month period 
Types of behaviours T1 
 (n=134) 
T2  
(n=118) 
T3 
 (n=118) 
 Number 
of people 
using 
Frequency  Levels of 
effectiveness 
Levels of 
confidence 
Number 
of people 
using 
Frequency Levels of 
effectiveness 
Levels of 
confidence 
Number 
of people 
using 
Frequency Levels of 
effectiveness 
Levels of 
confidence 
 n(%) M (SD) M (SD) M (SD) n(%) M (SD) M (SD) M (SD) n(%) M (SD) M (SD) M (SD) 
Activities N/A 3.15 (.77) 5.38 (2.42) 7.52 (1.97) N/A 3.23 (.73) 5.51 (2.38) 7.85 (1.97) N/A 3.27 (.71) 5.27 (2.34) 7.74 (1.79) 
Complementary 37 (27.6) 3.16 (1.28) 4.13 (3.69) 8.11 (2.01) 29 (24.6) 3.45 
(1.21) 
3.24 (3.59) 7.69 (3.11) 30.5 (36) 3.75(.84) 3.17 (3.48) 8.81 (1.72) 
Cognitive             
Do things that distract you 
from your fatigue 
84 (62.7) 
 
3.14 (1.19) 5.87 (2.98) 7.87 (2.05) 77 (65.3) 
 
3.35 
(1.04) 
6.20 (2.96) 8.31 (1.88) 73 (61.9) 
 
3.51 (.88) 5.96 (3.08) 8.37 (1.87) 
Plan your activities to 
make the most of your 
energy levels through the 
day 
70 (52.2) 
 
3.57 (.93) 5.83 (3.13) 7.71 (2.15) 61 (51.7) 
 
3.72 (.73) 6.39 (3.03) 8.33 (1.71) 77 (65.3) 3.74 (.70) 5.81 (3.23) 8.27 (1.62) 
Psychological             
Do relaxing things 123 (91.8) 3.58 (.89) 4.72 (3.85) 8.13 (2.30) 100 (89.0) 3.63 (.82) 4.88 (3.67) 8.54 (2.18) 107 
(90.7) 
3.73 (.76) 4.68 (3.65) 8.72 (1.94) 
Talk to someone about 
your fears and concerns 
about fatigue 
37 (27.6) 1.68 (1.06) 2.41 (3.72) 8.00 (2.74) 29 (24.6) 
 
2.17 
(1.26) 
3.48 (4.02) 8.66 (2.21) 37 (31.4) 
 
2.27 (1.28) 2.57 (3.83) 9.27 (1.82) 
Nutrition             
Eat a balanced diet 110 (82.1) 3.71 (.73) 4.74 (3.81) 8.02 (2.39) 89 (75.4) 3.83 (.46) 4.73 (3.63) 8.35 (1.81) 91 (77.1) 3.77 (.65) 4.76 (3.75) 8.28 (2.20) 
Drink beverages with 
caffeine 
123 (91.8) 
 
3.80 (.67) 2.03 (3.16) 8.91 (2.61) 102 (86.4) 3.82 (.65) 2.18 (3.13) 9.15 (2.35) 101 
(85.6) 
 
3.90 (.44) 1.93 (2.97) 9.56 (1.21) 
Drink nutritional 
supplements 
39 (29.1) 2.95 (1.23) 4.26 (3.92) 8.41 (2.23) 37 (31.4) 3.35 
(1.11) 
4.16 (3.23) 9.00 (1.72) 38 (30.5) 3.11 (1.27) 3.55 (4.01) 9.37 (1.34) 
Total M (SD) M (SD) M (SD)
Total Summary frequency
a 
3.32 (.54) 3.40 (.49) 3.45 (.44) 
Total Summary 
effectiveness c 
4.74 (2.24) 4.93 (2.24) 4.57 (2.16) 
Global effectiveness c  6.00 (2.67) 5.95 (2.56) 5.86 (2.46) 
Total levels of confidence
c 
7.89 (1.58) 8.16 (1.61) 8.25 (1.35) 
Total number of 
behaviours usedd 
9.06 (2.50) 8.91 (2.36) 9.17 (2.44) 
a Possible range: 1-4; b Possible range: 0-8; c Possible range: 0-10, d Possible range: 0-16. 
Note. See Appendix 19 for self-management associated outcome results of the individual self-management behaviours within the ‘Activities’ category 
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With regards to drop out, a post-hoc analysis was undertaken to examine if 
there were any differences between those who dropped out and those who remained 
in the study in a number of outcomes associated with fatigue self-management. 
These outcomes included the total summary and global effectiveness scores, the total 
summary and global self-efficacy scores, and the total level of frequency of fatigue 
self-management at baseline. Using independent sample T-test, no differences were 
found between groups in these outcomes, except for total frequency of fatigue self-
management (t=-2.82, p < .01). That is, participants who dropped out at either time 2 
or time 3 were using self-management less frequently than those who remained in the 
study. 
 
6.6 THE RELATIONSHIPS BETWEEN THE PERCEIVED 
EFFECTIVENESS OF SELF-MANAGEMENT BEHAVIOURS AND 
SYMPTOM SEVERITY 
Question 4. What are the relationships between the perceived effectiveness 
of self-management behaviours and symptom severity at baseline? 
Pearson correlation coefficient tests were conducted to examine if there were 
any relationships between the levels of effectiveness of self-management behaviours 
and the symptom severity scores. Table 6.7 presents a matrix of correlations between 
the perceived effectiveness of self-management behaviours and the symptom severity 
scores. At baseline, the level of total perceived effectiveness of self-management 
behaviours was negatively correlated with fatigue level over the past 7 days, total 
fatigue interference and feeling of wellbeing. The level of global perceived 
effectiveness of self-management behaviours was negatively correlated with all 
symptom severity scores including fatigue level over the past 7 days, distress level 
caused by fatigue over the past 7 days, fatigue level right now, usual fatigue level 
over the past 24 hours, worst fatigue level over the past 24 hours, total fatigue 
interference and other symptoms as assessed by ESAS.  
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Table 6.7. Correlations between the perceived effectiveness of self-management behaviours and symptom severity scores at baseline (n=134)  
 Activities Complementary Cognitive Psychological Nutrition Total 
effectiveness 
Global 
effectiveness 
   Do 
things 
that 
distract 
you from 
your 
fatigue 
Plan your 
activities to 
make the most 
of your energy 
levels through 
the day 
Do 
relaxing 
things 
Talk to 
someone 
about your 
fears and 
concerns 
about 
fatigue  
Eat a 
balanced 
diet 
Drink 
beverages 
with 
caffeine 
Drink 
nutritional 
supplements 
  
 
Fatigue measures 
           
Fatigue level over the 
past 7 days  
-.15 -.03 .03 -.07 -.03 -.04 -.14 .01 -.12 -.18* -.36** 
Distress level caused 
by fatigue over the 
past 7 days  
-.20* -.01 .09 -.01 -.04 -.04 -.05 .15 -.13 -.16 -.35** 
Fatigue level right 
now 
-.05 -.03 .10 .11 -.16* -.01 .13 .12 .06 -.06 -.40** 
Usual fatigue level 
over the past 24 
hours  
-.17 -.08 .02 -.04 .07 .01 -.01 .11 -.01 -.10 -.26** 
Worst fatigue level 
over the past 24 
hours 
-.08 -.06 .14 .04 .16 .09 .05 .16 .01 -.09 -.40** 
Total fatigue 
interference 
-.24* -.03 .08 .04 .13 .05 -.07 .10 -.06 -.18* -.51** 
Other symptoms            
Pain -.05 -.06 .14 -.01 .22* .01 -.05 .01 -.03 -.02 -.21** 
Tiredness -.08 -.06 .08 .09 .13 -.01 .09 .09 .01 -.09 -.40** 
Nausea -.13 -.07 -.07 .06 .03 -.04 -.06 -.11 -.01 -.10 -.30** 
Depression -.18* -.07 .11 -.11 .12 .04 .01 .17* -.06 -.08 -.37** 
Anxiety -.05 .10 .18* .01 .07 .12 .02 .05 -.01 .01 -.24** 
Drowsiness -.12 .04 .11 .01 .09 -.10 .07 .09 -.02 -.10 -.34** 
Appetite -.08 -.10 -.02 -.07 -.11 -.09 -.22** -.03 .03 -.07 -.24** 
Feeling of wellbeing -.17 -.03 .03 -.10 -.03 -.07 -.16* -.00 -.09 -.18* -.44** 
Shortness of breath -.03 -.07 .06 -.08 -.02 -.06 -.18* -.13 -.04 -.13 -.23** 
Note. * p < .05, ** p < .001 
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6.7 THE RELATIONSHIPS BETWEEN THE SELECTED RISK AND 
PROTECTIVE FACTORS (ASSOCIATED WITH THE USE OF SELF-
MANAGEMENT BEHAVIOURS) AND THE PERCEIVED 
EFFECTIVENESS LEVELS OF SELF-MANAGEMENT BEHAVIOURS  
Question 5. What are the relationships between selected risk and 
protective factors associated with the use and the perceived effectiveness of 
(demographics, symptom severity, and levels of social support, depression, 
anxiety and self-efficacy) and  
 The frequency of self-management behaviours that patients undertake 
at baseline? 
 The number of self-management behaviours that patients undertake at 
baseline? 
 The perceived effectiveness of self-management behaviours at 
baseline? 
For the total number of behaviours used, frequency of behaviours used, total 
perceived levels of effectiveness of self-management behaviours, and global 
perceived levels of effectiveness of self-management behaviours, T-tests were 
conducted to examine the differences between groups (gender and ethnicity) (Table 
6.8). One way ANOVA tests were conducted to examine the differences between 
groups (education levels, primary cancer diagnosis, living arrangement, income 
levels, and marital status). Bivariate analyses were conducted using Pearson 
correlation coefficient tests to examine the relationships between the outcomes and 
age, performance status, comorbidity index, social support, depressive symptoms, 
anxiety symptoms, global levels of self-efficacy and total perceived levels of self-
efficacy (Table 6.9).    
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Table 6.8. The relationships between selected risk and protective factors associated with use of self-management behaviours (demographics, symptom severity, level of social 
support, level of depression, level of self-efficacy) and self-management behaviours associated with fatigue at baseline (n=134) 
Demographics Total number of behaviours 
used 
Frequency of behaviours used Total perceived levels of 
effectiveness of self-management 
behaviours 
Global perceived levels of 
effectiveness of self-management 
behaviours 
 M (SD) t df M (SD) t df M (SD) t df M (SD) t df 
Gender 
M 
F 
 
8.89(2.45) 
9.15(2.54) 
-.56 132  
3.45(.46) 
3.25(.57) 
2.01* 132  
4.93(2.15) 
4.64(2.30) 
.70 132  
6.26(2.60) 
5.86(2.70) 
.88 149 
Ethnicity 
Caucasian 
Other 
 
9.05(2.46) 
9.20(3.83) 
-.13 132  
3.34(.52) 
2.82(.84) 
1.38 132  
4.78 (2.23) 
2.61 (1.17) 
1.12 132  
6.07(2.61) 
4.33(3.67) 
1.57 149 
Education levels 
Did not complete high school 
Completed high school 
 
8.67(2.56) 
9.48(2.39) 
 
-1.9 132  
3.40(.49) 
3.23(.59) 
1.78 132  
4.27 (2.35) 
5.24 (2.02) 
-.258* 132  
5.97 (2.67) 
6.05 (2.69) 
-.17 149 
 M (SD) F df M (SD) F df M (SD) F df M (SD) F df 
Primary cancer diagnosis 
Breast 
Lung 
Colorectal 
Prostate 
 
9.02(2.67) 
9.63(2.49) 
9.37(2.34) 
9.92(2.28) 
.98 133  
3.23(.65) 
3.41(.38) 
3.30(.55) 
3.49(.35) 
1.26 133  
2.30(.31) 
2.35(.38) 
2.17(.42) 
1.35(.39) 
1.72 133  
6.01(2.82) 
5.95(2.65) 
5.91(2.59) 
6.33(2.44) 
.09 150 
Living arrangement 
Live alone 
Live with partner 
Live with a family member or 
friend 
 
8.22(2.83) 
9.34(2.51) 
8.97(2.14) 
1.84 133  
3.31(.55) 
3.28(.59) 
3.43(.40) 
.86 133  
4.84 (2.23) 
4.66 (2.28) 
4.85(2.23) 
.11 133  
5.80(2.47) 
6.02(2.77) 
6.11(2.59) 
.10 150 
Income levels 
<20,000 
20,001-40,000 
>40,001 
 
8.81(2.48) 
10.26(2.05) 
9.04(2.74) 
2.71 133  
3.37(.53) 
3.17(.55) 
3.25(.59) 
1.33 133  
4.58(2.32) 
4.93(2.21) 
5.16(1.98) 
.72 133  
6.08(2.57) 
5.85(2.60) 
5.83(3.14) 
.13 150 
Marital status 
Married 
Divorce 
De facto 
Widowed 
Single 
Separated 
 
9.41(2.42) 
8.32(2.46) 
10.00(2.35) 
8.14(2.04) 
8.27(3.22) 
9.88(1.81) 
1.55 133  
3.33(.54) 
3.21(.51) 
3.26(.81) 
3.40(.54) 
3.26(.62) 
3.59(.36) 
.69 133  
4.81(2.25) 
3.94(2.00) 
4.07(1.90) 
5.75(1.80) 
4.91(2.56) 
5.76(2.45) 
1.39 133  
6.11(2.78) 
5.04(2.47) 
5.20(2.39) 
7.11(2.52) 
6.26(2.60) 
6.75(2.19) 
1.32 150 
Current therapies: 
Chemotherapy only 
Radiotherapy only 
Other anti-cancer therapy 
Combined anti-cancer therapies 
No current anti-cancer therapy 
 
9.28(2.82) 
8.48(2.44) 
8.94(2.16) 
9.23(2.16) 
9.32(2.56) 
.55 133  
3.27(.47) 
3.48(.42) 
3.31(.82) 
3.29(.52) 
3.25(.58) 
.82 133  
5.01(2.30) 
4.34(2.24) 
4.56(2.35) 
4.84(2.14) 
4.73(2.24) 
.43 133  
5.94(2.80) 
5.55(2.70) 
6.70(2.70) 
5.96(2.72) 
6.15(2.33) 
.58 150 
Note. * p < .05 
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Table 6.9. The relationships between the selected risk and protective factors associated with use of self-management behaviours (demographics, symptom severity, level of 
social support, level of depression, levels of self-efficacy) and the perceived effectiveness of self-management behaviours at baseline (n=134) 
 Total 
number of 
behaviours 
used  
Frequency 
of 
behaviours 
used  
Levels of perceived effectiveness of self-management behaviours 
 
 Activities Complementary Cognitive Psychological Nutrition Total Global 
   Do things 
that 
distract 
you from 
your 
fatigue 
Plan your 
activities to 
make the 
most of your 
energy levels 
through the 
day 
Do 
relaxing 
things 
Talk to 
someone 
about 
your 
fears and 
concerns 
about 
fatigue  
Eat a 
balanced 
diet 
Drink 
beverages 
with 
caffeine 
Drink 
nutritional 
supplements 
  
Age -.02 .31** -.04 -.21** -.21** -.11 -.16 -.04 -.11 -.04 -.03 -.12 .09 
Performance 
status (AKPS) 
.10 .21* -.03 -.09 -.16 .10 .11 -.01 .14 -.34 -.05 .02 .05 
Comorbidity 
index 
-.16 .07 -.14 -.08 -.11 -.13 -.01 -.04 -.04 .08 -.01 -.09 -.11 
Social support 
(MOS-SSS) 
.22* -.01 -.06 .04 .01 .09 .08 .13 .20* -.05 .09 -.09 .10 
Depressive 
symptoms 
(HAD-D) 
-.16 .06 -.20* -.15 -.02 -.05 -.16 -.09 -.14 -.07 -.05 -.20* -
.37** 
Anxiety 
symptoms 
(HAD-A) 
.12 -.26** -.10 .04 .11 .01 -.06 .16* .03 .14 .02 -.01 -
.32** 
Global 
perceived 
levels of self-
efficacy 
.11 .06 .41** .10 .16 .12 .07 .14 .10 .02 .11 .35** .88** 
Total 
perceived 
levels of self-
efficacy 
-.06 .33** .39** -.02 .02 .01 .04 .09 .17 -.06 .10 .29** .41** 
Note. *p < .05, **p < .01. 
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Participants who completed high school had a higher total perceived level of 
effectiveness of self-management behaviours. Older participants conducted self-
management behaviours more frequently, compared to younger participants. Older 
participants also had lower levels of perceived effectiveness for the ‘using 
complementary and alternative therapies’ and ‘doing things that distract you from 
your fatigue’ items. Patients with higher performance status used the self-
management behaviours more frequently. 
Participants with a higher level of social support used a higher number of 
behaviours for relieving fatigue, and had a higher level of perceived effectiveness of 
‘eating a balanced diet’. Participants with more depressive symptoms had lower 
levels of perceived effectiveness: activities, total and global. Participants with a 
higher level of anxiety used the self-management behaviours less frequently, had a 
higher level of perceived effectiveness of ‘talking to someone about your fears and 
concerns about fatigue’, and had a lower level of ‘global perceived effectiveness of 
self-management behaviour’. 
Participants with a higher total perceived level of self-efficacy used the self-
management behaviours more frequently. Participants with higher total and global 
perceived self-efficacy levels had higher levels of perceived effectiveness of the 
‘activities’ behaviours. They also had higher levels of total and global perceived 
effectiveness of self-management behaviours. 
 
6.8 THE PREDICTIVE FACTORS ASSOCIATED WITH THE 
FREQUENCY OF SELF-MANAGEMENT BEHAVIOURS PATIENTS 
USED OVER A TWO MONTH PERIOD  
Question 6. Can the total levels of frequency of self-management 
behaviours patients undertake over a two month period be predicted by the risk 
and protective factors associated with self-management behaviours 
(demographics, clinical characteristics and levels of social support, depression, 
anxiety and self-efficacy)?  
On the basis of the theoretical model proposed in Chapter Four, all of the 
potential predictive factors that are associated with the outcome at a P value of < 
0.25 (age, education, performance status, depression, anxiety, drowsy, anxiety 
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profile, total fatigue management self-efficacy) were entered into the GEE model. 
The final model is presented in Table 6.10. The frequency of self-management 
behaviours over a two month period was predicted by these included variables. Age, 
performance status, and total level of fatigue management self-efficacy were the 
significant independent predictors in this model.  
 
Table 6.10. The final model of predictors of the total frequency of using self-management behaviours 
associated with fatigue from baseline to time 3 in patients with advanced cancer (Generalised 
Estimating Equation) (n=141) 
Note. LL=Low Level; HL= High Level  
 
6.9 THE PREDICTIVE FACTORS ASSOCIATED WITH PERCEIVED 
EFFECTIVENESS OF SELF-MANAGEMENT BEHAVIOURS USED 
OVER A TWO MONTH PERIOD  
Question 7. Can the levels of perceived effectiveness of self-management 
behaviours over a two month period be predicted by the risk and protective 
factors associated with self-management behaviours (demographics, clinical 
characteristics and levels of symptom severity, social support, depression, and 
self-efficacy)? 
Both the total and global perceived effectiveness of self-management 
behaviours were used as outcome variables for this research question. On the basis of 
Predictor Variables B 95% CI P-value 
   LL HL  
Constant  2.43 1.70 3.16 <.001 
Age  .01 .01 .02 .001 
Education Did not 
complete high 
school 
Completed 
high school
.07
 
 
-.05 .20 .25 
Performance status 
(AKPS) 
 -.01 -.01 -.002 <.01 
Symptom severity 
(ESAS) 
Depression
Anxiety 
Drowsy 
.01
-.01 
.01
-.02
-.03 
-.01
.03
-.02 
.03
.54 
.59 
.24 
Anxiety (HADS-A) -.004 -.02 .02 .65 
      
Total fatigue 
management self-
efficacy level  
 .08 .04 .13 <.001 
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the theoretical model proposed in Chapter Four, all of the potential predictive factors 
that are associated with the outcomes at a P value of < 0.25 were entered into the 
GEE models. The final models are presented in Tables 6.11 and 6.12.  
The total perceived effectiveness levels of self-management behaviours over a 
two month period were predicted by these included variables. The education level, 
total level of fatigue management self-efficacy and total global fatigue management 
self-efficacy were significant independent predictors in this model. The global 
perceived effectiveness levels of self-management behaviours over a two month 
period were predicted by these included variables. Ethnicity, depressive symptoms 
and the global fatigue management self-efficacy were the significant independent 
predictors in this model. 
 
Table 6.11. The final model of predictors of the total perceived effectiveness levels of self-
management behaviours associated with fatigue from baseline to time 3 in patients with advanced 
cancer (Generalised Estimating Equations) (n=141) 
Note. LL=Low Level; HL= High Level  
Predictor Variables B 95% CI P-value 
   LL HL  
Constant  3.47 .95 6.00 .01 
Age  -.03 -.06 .01 .12 
      
Education level Did not complete high 
school 
Completed high school 
-.71 -1.30 -.13 .02 
Primary cancer site Breast 
Lung 
Colorectal 
Prostate 
-.07
-.20 
.31 
-.10
-1.2 
-.60 
.87
.78 
1.23 
.56 
      
Symptom severity Wellbeing 
Shortness of breath 
-.03
-.06
-.13
-.16
.08
.03
.62 
.21 
      
Depression 
(HADS-D) 
 -.03 -.12 .06 .45 
Total fatigue 
management self-
efficacy level  
Global fatigue 
management self-
efficacy level 
 .29
 
 
.21 
.12
 
 
.11 
.46
 
 
.31 
.001 
 
 
<.001 
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Table 6.12. The final model of predictors of the global perceived effectiveness levels of self-
management behaviours for fatigue from Baseline to Time 3 in patients with advanced cancer 
(Generalised Estimating Equations) (n=138) 
Note. LL=Low Level; HL= High Level  
 
6.10 SUMMARY 
In summary, the major findings of the study included the wide use of a number 
of self-management behaviours associated with fatigue in patients with advanced 
cancer. The participants undertook these behaviours at different levels of frequency 
and were generally confident in undertaking these behaviours. However, there were 
discrepancies between the levels of frequency, confidence, and effectiveness. Results 
from the inferential analyses indicated that a number of variables could predict the 
frequency and effectiveness levels of self-management behaviours associated with 
fatigue in patients with advanced cancer. 
Predictor Variables B 95% CI P-value
   LL HL  
Constant  .87 -.62 2.36 .02 
 
Ethnicity Caucasian
Other 
1.24 .21 2.26 .02 
Social support 
(MOS-SSS) 
 
 -.01
 
-.02 .00 .20 
Symptom severity  
Pain 
Nausea 
Depression 
Anxiety 
Drowsy 
Appetite 
Wellbeing 
Shortness of breath 
 
.04 
-.07 
-.03 
.06 
-.05 
.01 
-.05 
.01 
 
-.02 
-.16 
-.11 
-.02 
-.11 
-.06 
-.18 
-.05 
 
.01 
.10 
.03 
.05 
.14 
.00 
.08 
.07 
 
 
.17 
.17 
.46 
.12 
.05 
.76 
.41 
.77 
Anxiety (HADS-
A) 
 .02 -.03 .07 .39 
Depression 
(HADS-D) 
 -.05 -.10 .00 .04 
Total fatigue 
management self-
efficacy level  
Global fatigue 
management self-
efficacy level 
 .01
 
 
.71 
-.15
 
 
.62 
.17
 
 
.81 
.86 
 
 
<.001 
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Chapter 7:  Discussion and Conclusion 
7.1 INTRODUCTION 
This chapter discusses the major findings of this study. The main purpose of 
this study was to test the explanatory model for self-management behaviours 
associated with fatigue in patients with advanced cancer. Section 7.2 discusses the 
fatigue severity in patients with advanced cancer over a period of two months. 
Section 7.3 reviews the findings on the frequency and perceived effectiveness of self-
management behaviours associated fatigue in patients with advanced cancer, 
followed in Section 7.4 by a discussion with reference to the literature to explain 
predictors of self-management behaviours. The implications arising from this study 
are presented in Section 7.5. The limitations of and recommendations arising from 
this study are presented in Section 7.6. Section 7.7 articulates the conclusions of the 
study. 
 
7.2 FATIGUE SEVERITY IN PATIENTS WITH ADVANCED CANCER 
OVER A TWO MONTH PERIOD 
The purpose of this study was to explore self-management behaviours 
associated with fatigue in patients with advanced cancer. The population of interest 
in this study was those with breast, lung, colorectal and prostate cancer, characterised 
by at least one distant metastasis and requiring medical treatments or follow-up 
appointments at an Australian tertiary cancer care centre. Over 80% of participants 
were receiving anti-cancer therapy (chemotherapy, radiotherapy, other anti-cancer 
therapy, or combined anti-cancer therapies) at baseline. Participants in this study 
experienced moderate to severe levels of fatigue over the two month period. The 
mean fatigue severity scores (over the past 7 days, right now, usual over the past 24 
hours, worst over the past 24 hours) at various time-intervals, ranged from 4.61 to 
6.67 (with a possible range of 0-10) from baseline to time 3. These severity scores 
were comparable to a number of studies on patients with advanced cancer295, 366, 367. 
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While the inclusion criterion limiting the major primary cancer sites to breast, 
lung, colorectal, and prostate might limit the generalisability of these findings, a 
number of studies have reported that the severity of fatigue does not vary largely 
across patients with advanced cancer with different primary tumour sites37, 71, 368, 369. 
A large cross sectional study comprising 796 patients with advanced cancer 
compared fatigue severity across 12 primary cancer groups (lung, breast, colorectal, 
prostate, hematologic, pancreas, head and neck, kidney, gynaecologic, oesophagus, 
bladder and melanoma) and found no difference between these groups37. Similarly, 
Stone and colleagues also reported that fatigue severity was not related to diagnosis, 
presence or site of metastases in patients with advanced cancer71. Although fatigue 
severity might not vary substantially across advanced cancer patients with different 
tumour types, the stage of a person’s disease is likely to influence severity and this 
may vary across tumour types. For example, patients with prostate cancer and at least 
one distant metastasis generally live longer than those with breast cancer, followed 
by colorectal and lung cancers3. Of these tumour groups, patients with lung cancer 
have the lowest five-year relative survival rate, at four per cent3. This study did not 
collect detailed information about the stage of the person’s advanced disease and as 
such it is difficult to speculate what impact disease stage may have had on fatigue 
severity. It was reasonable to postulate, however, that the participants in this study 
were not at end of life. That is, the majority of these patients had high performance 
status and were receiving anti-cancer treatment at baseline, with inclusion criterion 
specifying that patients must have a prognosis over three months at the judgement of 
the referring clinician. Moreover, very few patients were lost to follow up due to 
death, suggesting that recruitment may have favoured patients at earlier stages of 
advanced disease. It is important, therefore, that the findings of this study be 
understood in this context. 
While the findings of this study cannot be generalised to all advanced cancer 
patients especially those at end of life, the results do indicate that the problem of 
fatigue is not a single acute event for this population. The findings do, therefore, 
provide important data about fatigue experiences for those at the earlier stages of 
advanced cancer. Specifically, patients in this study commenced with moderate to 
severe levels of fatigue at baseline, and the severity levels maintained at time 2 (four 
weeks) and time 3 (eight weeks). Importantly, patients who dropped out of the study 
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at either time 2 or time 3 (n=21) were more fatigued at baseline compared with those 
who did not (n=131). This is consistent with a number of studies54, 61, 62, 370 that 
suggest that patients with advanced cancer experience fatigue as a chronic persistent 
symptom, with a progressively worsening pattern of severity over the trajectory. 
While not able to be determined by this study, these studies suggest this symptom is 
likely to worsen at end of life54, 61, 62, 370. Given the attrition from this study was for 
patients who had higher levels of fatigue at baseline, it is important to note that 
fatigue severity in this population at time 2 and time 3 could be underestimated in 
this study.  
There are a number of plausible explanations for the experience of moderate to 
high levels of fatigue experienced by the patients in this study. Firstly, although 
causes of cancer-related fatigue are multi-factorial, key aetiologic factors associated 
with fatigue in this population are likely to be anti-cancer treatment, disease 
progression, concurrent psychological symptoms, cachexia, fever, infection or 
metabolic disorder and medications with side effects causing sedation50, 54, 95, 96, 120, 
371. Recent studies have reported that such factors are associated with an increase in 
the circulation of pro-inflammatory cytokines372, 373, and this in turn leads to a 
number of biologic mechanisms causing fatigue170, 371, 374. These mechanisms may be 
peripheral mechanisms leading to energy depletion or central mechanisms that lead 
to dysregulation of the hypothalamic-pituitary-adrenal axis or serotonin 
metabolism50. While these recent studies provide some interesting data to help our 
understanding of the mechanisms of cancer-related fatigue, the interactions of 
aetiologic factors and the resultant biologic changes are not clearly understood. 
Further investigations to more fully understand the biological mechanisms 
contributing to fatigue is required. 
In addition to symptom severity, the extent to which patients were distressed or 
affected by fatigue was elicited in this study. In this sample, the mean distress levels 
caused by fatigue were 3.97 to 4.56 (with a possible range of 0-10), notably lower 
than mean fatigue severity levels discussed above. These findings thus suggest the 
concept of distress is likely to be different, although related to fatigue intensity30, 31. 
It is important therefore that clinicians assess the multiple dimensions of fatigue375. 
Regarding fatigue interference, the mean fatigue interference scores in the preceding 
24 hours were over 20 (with a possible range of 0-60), indicating that general 
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activity, mood, walking ability, normal work, relations with other people, and 
enjoyment of life were interfered somewhat by fatigue. The extent of fatigue 
interference reported in this study is consistent with findings in patients with 
advanced lung cancer94. Slight fluctuations in fatigue interference were reported in 
this study over the three time points. In the past, a number of longitudinal studies 
concerning fatigue in patients with advanced cancer have been conducted54, 60, 162, 366. 
However, the present study is unique in that it assessed multiple dimensions of 
fatigue including the levels of distress and interference caused by fatigue. 
The findings of this study regarding levels of fatigue distress and interference 
underscore the significant effects that fatigue has on the physical, psychological, 
social and spiritual aspects of patients’ lives86. Specifically, the interference scale of 
the BFI used in this study elicited the extent fatigue interfered with the patient’s 
walking ability, and a number of important aspects such as general activity, mood, 
relations with other people and enjoyment of life. Our findings of moderate 
interference scores suggest that fatigue itself can hinder patients’ use of fatigue self-
management behaviours such as walking or activity enhancement183. These findings 
illustrate the conceptual complexity and reciprocity of the impacts of fatigue and the 
ability to undertake fatigue self-management behaviours that have the potential to 
alleviate fatigue. Patients express the effects in terms of the burden they impose on 
others, their inability to participate in family and other social activities, and cognitive 
impairments such as memory loss and loss of ability to concentrate43, 86-89. Their 
experience of struggling to live with this debilitating symptom is linked for many 
patients with the process of adjusting to living with a progressive illness and 
ultimately death86, 89. 
 
7.3 SELF-MANAGEMENT BEHAVIOURS ASSOCIATED WITH 
FATIGUE IN PATIENTS WITH ADVANCED CANCER 
Participants in this study employed a range of behaviours to manage their 
fatigue. On average, patients used approximately nine behaviours consistently over a 
two-month period, with a range from zero to 16 as measured by the SMSFS-A. The 
number of behaviours used in this study is higher than those reported by two 
previous studies that measured this outcome (one Australian study23 and one Chinese 
study19).  Participants in these previous studies reported using only five fatigue self-
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management behaviours on average at a single time point. This difference between 
studies could be due to the different populations studied or the different research 
instruments used. Specifically, the other two studies were undertaken on patients 
with cancer of all stages undergoing chemotherapy19, 23. It may also be that different 
self-management support resources was available to patients across these studies126. 
Self-management behaviours can also be influenced by the cultural preferences of 
patients and health professionals19, 126, 161, 164, 183. Culture provides a dynamic 
framework of values and beliefs that influences the patient and family’s approach to 
care243. For example, behaviours such as “praying to God” and “listening to religious 
or political preaching” were identified as a self-management strategy for managing 
fatigue in Nepalese patients with cancer183. Another example is the use of traditional 
Chinese medicine among Chinese patients19. These medicines included fomes 
japonica Dendrobium, ginseng, spirulina, Naobai Jin (containing melatonin and 
oligose), soft-shelled turtles and loach19. These behaviours were not reported by the 
participants in the current study, nor in two other studies involving patients with 
cancer in the western countries127, 168. 
Not only did the participants in this study use a wide range of behaviours, they 
used these behaviours frequently. On average patients used each of the self-
management behaviours more than five times over the preceding seven days. These 
findings indicate that patients with advanced disease do take a proactive role and 
engage in a number of self-management behaviours for managing fatigue, which 
contradicts results of two previous qualitative studies reporting “nothing can be 
done” to manage fatigue from the perspective of health professionals and patients 
with advanced cancer87, 88. These qualitative studies had small sample sizes and 
included patients with advanced cancer who could have been closer to end of life and 
therefore had less ability to self-manage fatigue. This study thus provides new 
empirical evidence highlighting that patients at earlier stages of advanced disease can 
actively engage in a number of self-management behaviours.  
While this study did not follow patients to end of life, speculation that patients 
who are closer to end of life may engage in less or no self-management behaviours is 
not without support. The post-hoc analysis in this study reported that patients who 
dropped out at either time 2 or time 3 used self-management behaviours less 
frequently. Given that the majority (86%) of attrition in this study was attributed to 
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“being too sick” or death, it is reasonable to postulate that patients who were sicker 
or closer to death engaged in fatigue self-management behaviours less frequently. 
The findings of this study, while providing important data regarding the experience 
of patients at early stage advanced disease, should not therefore be generalised to 
patients at end of life. 
The five most commonly used fatigue self-management behaviours by the 
highest percentage of participants were ‘taking short sleeps during the day’, ‘resting 
during the day without falling asleep’ ‘doing relaxing things’, ‘eating a balanced 
diet’, ‘drinking beverages with caffeine’. Of those participants using these 
behaviours, the majority used them over seven times a week. It is difficult to 
compare these findings with previous studies19, 20, 127, 183, 184, as previous studies 
categorised and reported the behaviours differently to the current study, and were 
conducted with different cancer populations. Nonetheless, these findings provide 
useful information for health professionals to consider in optimising their self-
management support. Findings on use or frequency of use of fatigue self-
management are clinically relevant. While all of the commonly and frequently used 
behaviours are supported by evidence-based guidelines25, these findings reflect 
patient preferences, and can serve as baseline information for health professionals to 
consider and intervene accordingly.  
In terms of effectiveness, participants in this study reported that self-
management behaviours used were moderately effective in relieving their fatigue. 
This finding was reflected in the totally and global mean effectiveness scores, being 
approximately 5 and 6 (with a possible range of 0-10) respectively, over the three 
time points. The five behaviours rated by participants to be the most effective 
regarding participants’ levels of perceived effectiveness were ‘taking short sleeps 
during the day’, ‘pacing their activities through the day’, ‘doing things to improve 
their sleep at night’, ‘doing things that distract them from their fatigue’, and 
‘planning their activities to make the most of their energy levels through the day’. 
Table 7.1 compares the fatigue self-management behaviours findings with respect to 
supporting evidence and the NCCN guideline recommendations. Each category of 
the fatigue self-management behaviours used by patients with advanced cancer is 
discussed in relation to the current literature and the NCCN evidence-based clinical 
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guideline in the following section. The following section discusses the key findings 
of this study, in light of the NCCN guidelines and the current evidence base. 
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Table 7.1 A summary of fatigue self-management behaviours results respective to the supporting evidence and NCCN guideline recommendations 
 Supported by 
Direct/indirect level I 
or Level II evidence 
Recommended by NCCN guideline 
for patients with advanced 
cancer/at the end of life 
Percentages of 
participants used this 
study over the two month 
period 
Effectiveness mean 
scores over the two 
month period 
Activity 
Take short sleeps during the day  
Rest during the day 
X 
X 
√ 
√ 
82.2-85.1% a 
82.2-86.6%a 
6.10-6.35b 
5.52-5.88 
Do aerobic exercise 
Do stretching exercise 
Do strength exercises 
√ 
√ 
√ 
√  (Activity Enhancement) 
√  (Activity Enhancement) 
√  (Activity Enhancement) 
56.8-61.9% 
23.1-28.8% 
9-12.7% 
3.59-4.52 
3.27-3.79 
2.2-3.8 
Delegate tasks to others √ √ 59-59.3% 3.99-5.48 
Pace your activities √ √ 68.37-80.5% 5.57-6.55 b 
Do things to improve your sleep at night √ X 35.6-49.3% 5.73-6.17 b 
Complementary or alternative therapies 
Use complementary or alternative therapies √ X 24.6-30.5% 3.17-4.13 
Cognitive 
Do things that distract you from your fatigue √ √ 61.9-65.3% 5.87-6.20 b 
Plan your activities to make the most of your 
energy 
√ √ 51.7-65.3% 5.81-6.39 b 
Psychological 
Do Relaxing things √ X 89-91.8% a 4.68-4.88 
Talk to someone about your fears and 
concerns about fatigue 
X X 24.6-31.4% 2.41-3.48 
Nutrition 
Eat a balanced diet X X 75.4-82.1% a 4.73-4.76 
Drink beverages with caffeine X X 85.6-91.8% a 1.93-2.18 
Drink nutritional supplements X X 29.1-31.4% 3.55-4.26 
Note. a: The top five most popularly used self-management behaviours; b: The top five most effective self-management behaviours perceived by patients; √: 
supported/recommended; X: Not supported/not recommended. 
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Sleep and rest behaviours 
Sleep and rest behaviours were frequently used by participants of this study. 
This finding is consistent with previous findings in studies that included patients at 
early stages of cancer undergoing anti-cancer therapy19, 20, 127, 128, 183. Throughout all 
time points, approximately 80% of participants were “taking short sleeps during the 
day (fall asleep for less than 3 hours)” and “resting during the day without falling 
asleep”. Approximately 40% of participants were also “doing things to improve their 
sleep at night”. More specifically, at least half of the participants were “taking short 
sleeps during the day” at least seven times over the preceding seven days, throughout 
all time points. Participants reported this behaviour to be one of the most effective 
behaviours for relieving fatigue. This finding is of interest in that, evidence in 
relation to sleep hygiene programs suggests that avoiding long or late afternoon naps 
and limiting total time in bed can reduce sleep disturbance at night, and in turn 
improve fatigue376. The NCCN guideline further recommends that patients with 
advanced cancer or at end of life should be “allowed to take day-time naps as long as 
they do not disturb night-time sleep”25. Such recommendations relating to sleep and 
rest as a strategy to relieve fatigue may therefore lack clarity for patients and health 
care professionals. Nevertheless, the findings of this study suggest that taking short 
sleeps for less than three hours per day was perceived to be effective for relieving 
their fatigue. It is thus reasonable for health professionals to inform patients that 
short sleeps for less than three hours may be beneficial. To further advance 
knowledge in this area, future research is warranted to confirm the most optimal day 
time sleep and rest patterns for individuals without disturbing night time sleep. Given 
this behaviour was used frequently by a high percentage of patients in this 
population, it should be openly discussed with patients. 
In this study, “doing things to improve sleep at night” was also one of the top 
five most effective fatigue self-management behaviours. The literature shows that up 
to 70% of patients with advanced cancer experience significant disturbances in sleep 
patterns that could cause or exacerbate fatigue136-138. Current interventions in this 
area are designed to optimise sleep quality, and can in turn improve fatigue377. These 
interventions use stimulus control, sleep restriction and sleep hygiene25, which 
require patients to engage in a range of self-management activities. For example, 
these activities could include going to bed when sleepy, getting out of bed after 20 
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minutes if unable to fall asleep, going to bed at approximately the same time each 
night, maintaining a regular rising time each day and establishing an environment 
that is conducive to sleep (e.g. dark, quiet and comfortable). However, while the 
NCCN guideline recommends sleep therapies for patients undergoing active 
treatment and patients post anti-cancer treatment, they provide no commentary on 
whether these strategies are useful for those with advanced disease or at end of life. 
This may be due to the lack of direct evidence demonstrating the benefits of sleep 
hygiene programs for those with advanced disease25. The present study did not 
measure sleep disturbance as a potential concurrent symptom of fatigue, as this was 
not an item included in the ESAS tool.  
Although “doing things to improve sleep at night” was reported to be one of 
the most effective behaviours, less than half of the participants used this behaviour at 
any time point. Given that sleep disturbance is a common symptom in patients with 
advanced cancer136-138, health professionals should consider providing effective 
stimulus control, sleep restriction and sleep hygiene skill training to patients with 
sleep disturbance. To provide definitive guidance for patients with advanced cancer, 
future research is required to examine whether sleep hygiene self-management 
programs can improve fatigue outcomes in advanced cancer populations.  
 
Exercise behaviours 
Approximately 30% of participants did “aerobic exercise” over seven times a 
week, less than 20% did “stretching and flexibility exercises” at least seven times a 
week, and less than 10% of participants did “strength or resistance exercises” at least 
seven times a week. These findings are congruent with previous findings suggesting 
that exercise is used by some, but is not the most common fatigue management 
behaviour used by patients with cancer19, 183. There are many possible explanations 
for this. Although the patients in this study had a relatively high level of functional 
status and low level of comorbidity, there may have been some factors that hindered 
patients from exercising. Specifically, approximately half (50.3%) of the 152 patients 
in this study had bone metastasis, and were possibly experiencing bone pain378. Other 
potential barriers to exercise reported in the literature include fatigue itself, other 
physical problems such as dyspnoea and muscle weaknesses, problems related to 
cancer diagnosis or treatment such as thrombocytopenia, anaemia, fever/active 
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infection, post-surgical side effects, environmental factors, or the lack of time, a 
partner, professional guidance or perceived benefits25, 186. On the other hand, 
previous research suggests that some patients with cancer, even at the stage of 
advanced disease, are willing and able to exercise134, 139, 348, 349. Other studies suggest 
that exercise programs are feasible in patients with advanced cancer116, 121, 375, 376, and 
that patients with a life expectancy of less than 12 months could still be willing and 
able to attend a physical exercise program with desirable effects379. In 2007, a study 
of 128 patients with advanced cancer reported that up to 89% of participants planned 
to either increase or maintain their physical activity level and 47% were interested in 
receiving professional support for physical activity186. These findings indicate that 
this population requires appropriate self-management support in relation to exercise 
or activity enhancement from their health professionals.  
Given the low usage of exercise behaviours by patients in this study, the need 
for further self-management support in this area is justified. Specifically, future 
research should consider tailored self-management interventions that enhance the 
patient’s exercise self-efficacy and reduce perceived barriers to engaging in exercise. 
This recommendation is consistent with the NCCN guideline that clinicians should 
take a personal approach to match activity enhancement with the patient’s personal 
capacity and circumstances. A tailored approach is suggested with careful 
consideration and planning including the type of exercise (effectiveness/patient 
preference), the dose of intervention, perceived barriers and other potential disease-
related constraints that are common for patients with advanced cancer.  
The results of this study suggest that patients use aerobic and stretching 
exercises more frequently than strength and resistance exercises, and that they 
perceive them to be more effective. Given there is level II evidence121 suggesting that 
low intensity seated stretching and flexibility exercises can be beneficial for relieving 
fatigue and is feasible for this population, health professionals should consider 
teaching patients to use stretching and flexibility exercises as tolerated. The dose of 
intervention should be carefully considered for this population175. This finding is of 
particular relevance, given that there is evidence suggesting that low intensity 
exercise programs could be more appropriate and yield more desirable outcomes in 
this population120-122. The findings of an RCT involving 163 patients with advanced 
cancer indicated that intense exercise programs were less feasible for patients with a 
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life expectancy of less than six months122. Health professionals should also consider 
a number of other potential constraints that are common in patients with advanced 
disease such as bone metastases, thrombocytopenia, anaemia, fever/active infection 
increased risk of falls/stability25. Such considerations can further ensure an 
individualised approach in their fatigue self-management support to patients.  
 
Energy conversation and distraction behaviours 
In this study, the three energy conservation behaviours assessed included 
“delegating tasks to others” and “pacing their activities throughout the day” and 
“planning their activities to make the most of their energy levels through the day”. 
All three behaviours were used by the majority of participants throughout all time 
points. These three behaviours were some of the most effective behaviours for 
relieving fatigue perceived by patients. In particular, “delegating tasks to other” and 
“planning activities to make the most of their energy levels through the day” were 
rated with mean effectiveness scores above 6 at some point (with a possible range of 
0-10). These three behaviours were patients’ deliberate and planned management of 
their personal energy resources to prevent their depletion140. The literature suggests 
that the objective of these behaviours is to balance rest and activity during times of 
high fatigue so that valued activities and goals could be maintained140. While there is 
already evidence suggesting the effectiveness of the energy conservation behaviours 
for reducing fatigue in patients undergoing active anti-cancer treatment140, the 
findings of this present study provide new evidence that patients with advanced 
cancer do use these behaviours and perceive them to be effective, indicating the need 
to consider these behaviours as a core component of future fatigue self-management 
interventions for this population. 
For both planning and pacing activities, it is possible that patients undertake 
these behaviours independently without professional advice and support. However, 
with task delegation, an external agency has to be involved. There could be many 
reasons that participants were able to delegate tasks to others. The majority of 
participants in this study had a high level of social support and were living with at 
least one person (a partner, family member or friend). Several studies have reported 
that patients with advanced cancer who were married or lived with someone and had 
a higher education level experienced less sleep/wake disturbance, but these studies 
 156  Chapter 7: Discussion and Conclusion 
  
did not further measure the impact on fatigue240, 261, 262. No research to date has 
investigated the role of social support, family and caregivers in supporting patients to 
use energy conservation behaviours in this population. Considering that behaviours 
such as task delegation do require the involvement of the family or the patient’s 
support network, health professionals should assess the patient’s social support level 
and intervene by facilitating access to community services for those who do not have 
a social support network. To further understand how social support can impact 
individual fatigue self-management in this population, secondary analysis of 
available data could be undertaken to give qualitative insights into the self-
management support available to patients.  
“Doing things that distract them from their fatigue” was one of the most 
effective behaviours reported by participants in this study. The mean effectiveness 
scores were approximately 6 (with a possible range of 0-10) over all time points, 
indicating this behaviour was moderately to highly effective for relieving fatigue. 
This finding is consistent with similar studies of Chinese19 and British20 patients with 
cancer undergoing anti-cancer therapies. Both studies reported that this behaviour 
was well-used by patients and partly relieved fatigue. However, distraction behaviour 
was used by less than 65% of patients over time and was not as commonly used as 
other relatively less effective behaviours. The rationale for use of distraction 
strategies is primarily to reduce attentional fatigue, a form of cognitive fatigue 
manifested in a decreased ability to focus attention351, 352, as well as to take the 
patient’s mind off the fatigue19, 380. Distraction strategies require patients to practise 
diverting their attention away from fatigue380. The NCCN guideline25 suggests that 
distraction strategies such as games, music, reading and socialising “may be useful” 
in patients with advanced cancer. The uncertainty surrounding the benefits of using 
these recommendations concerning cognitive behaviours is due to the lack of 
understanding of the underlying mechanisms25 and the use of observational designs 
in evaluative studies20, 353. That said, in optimising the use and effectiveness of this 
behaviour, health professionals can collaborate with patients in goal setting and 
planning to access strategies that are feasible and suitable for them. For example, the 
patient can set goals to socialise or play games during times that they feel less 
fatigued. 
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Psychological behaviours 
Doing relaxing things was a moderately effective behaviour used by a high 
percentage (approximately 90%) of people for relieving fatigue in the present study. 
Although this behaviour is not perceived to be as effective as the cognitive 
behaviours by patients, it did provide some degree of relief for patients. The current 
NCCN guidelines do not use the term ‘doing relaxing things’25. Instead, it 
recommends patients use distraction such as games, music, reading and socialising. 
During the interview, some patients were confused about the difference between 
doing relaxing things and doing things that distract themselves, as there might have 
been conceptual overlaps. For example, watching TV could fit into both concepts. A 
modification of the SMSFS-A to enable a distinction between the two behaviours 
may be warranted. 
Interestingly, although the importance of facilitating discussion or expression 
of problems associated with fatigue in this population are supported by the findings 
of two qualitative studies by Krishnasamy87 and Potter86, patients in this study did 
not ‘talk to someone about their fears and concerns about fatigue’ very often and 
rated this behaviour as not very effective for relieving fatigue, with effectiveness 
scores being the lowest among all other behaviours. This could be because patients 
are mindful of the burden and effects on family and caregivers86-88. The importance 
of involving family/caregivers is clearly recognised in the care process and self-
management support in cancer care381, family play an important role in the gathering 
and sharing of information, decision-making and giving patients the necessary 
emotional/practical support381. While the behaviours were not reported to be 
effective by patients in this study, promoting open discussions of fears and concerns 
about fatigue could aid patients to express the impact of fatigue on an emotional 
level as the patients and caregivers/family members struggle to live with it43. Future 
research should examine efforts that aim to better prepare the caregivers/family 
members to respond with appropriate self-management support or initiate discussion 
with patients experiencing fatigue.  
 
Complementary and alternative therapies 
Despite the increasing use of complementary and alternative therapies among 
patients with cancer over the past two decades382-384, the results of this study indicate 
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that only a small percentage (27.6%) of patients used complementary and alternative 
therapies for relieving fatigue. Complementary and alternative therapies for relieving 
cancer-related fatigue can include, but are not limited to acupuncture, aromatherapy, 
adenosine triphosphate infusions, healing touch, hypnosis, lectin-standardised 
mistletoe extract, levocarnitine, massage, mindfulness-based stress reduction, 
polarity therapy, support group and yoga385. Complementary and alternative 
therapies were rated with relatively low levels of effectiveness for relieving fatigue, 
with mean effectiveness scores ranging from 3.17 to 4.13 (with a possible range of 0-
10). The low usage of 27.6% could be due to the lack of evidence suggesting the 
efficacy of these complementary and alternative therapies385, and the lack of 
recommendations for use by their cancer care health professionals126. This study is 
limited in that it did not investigate the perceived effects of each single specific 
therapy. Evidence from one recent non-blinded RCT suggests acupuncture is 
effective for improving fatigue in patients with earlier stages of breast cancer151, with 
clinically and statistically significant differences in a number of multidimensional 
fatigue outcomes. While there is limited research that can provide direct evidence 
demonstrating definitive benefits of other complementary and alternative therapies 
for this population, it is advisable that health professionals understand the evidence 
base in this area, so they can provide evidence-based information to patients to aid in 
their decision making17. 
 
Nutritional behaviours 
Another area lacking sufficient empirical evidence relates to the role of 
nutritional and dietary interventions for relieving cancer-related fatigue. To date, 
there is scant evidence suggesting that nutritional interventions/strategies can 
alleviate fatigue in this population25. This study reports that 82.1% of participants 
were eating a balanced diet and 29.1% of participants were drinking nutritional 
supplements, with reasonable levels of effectiveness (mostly >4 with a possible 
range of 0-10 over all time points). Patients with advanced cancer can often 
experience weight loss and loss of appetite386, with at least 45% finding it a 
problem188. Many patients with advanced cancer live with changing eating habits and 
do not necessarily expect health professionals to manage their loss of appetite182, 387. 
A UK mixed methods exploratory study reported that 30 patients with advanced 
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cancer self-initiated over 140 different actions to change eating habits182. Although 
these patients might not have changed their dietary/eating habits specifically for 
managing their fatigue, the findings from previous research do suggest that self-
management with regards to diet can be optimised from the patient’s perspective, 
suggesting a role for self-management support in this area.   
Although there have been speculation that poor nutritional intake, coupled with 
cachexia and anorexia may activate a number of biologic mechanisms and in turn 
induce fatigue388, nutritional counselling is typically only provided to a very small 
proportion of patients with cancer experiencing fatigue126. A recent American study 
by Escalante and colleagues reported that as little as 10% of 260 patients who 
attended a cancer-related fatigue clinic were provided with nutritional counselling126. 
Without specific data, it is difficult to know how many of the participants in this 
current study actually received nutritional counselling from health professionals. Due 
to lack of evidence, nutritional counselling is not currently recommended in clinical 
guidelines for managing cancer-related fatigue in this population25. It is 
recommended, however, that a dietitian assesses dietary intake/patterns and 
determines whether nutritional status is linked to fatigue and then intervene as 
appropriate389. Given the findings of this study, future research is suggested to 
prospectively examine the effects of nutritional counselling interventions on fatigue 
in this population. 
The findings of this study also suggest that there are some discrepancies 
between frequency and effectiveness of nutritional fatigue self-management 
behaviours. That is, participants use behaviours that they do not even perceive to be 
effective for relieving fatigue. Drinking beverages with caffeine was the most 
popular behaviour used throughout the three time points, however, the mean levels of 
effectiveness for relieving fatigue were only approximately 2 (with a possible range 
of 0-10). This wide range in scores suggests that some patients found this behaviour 
useful while others used this behaviour possibly out of habit, rather than using it for 
relieving fatigue. For patients with sleep disturbance and fatigue, most sleep hygiene 
programs typically recommend patients limit caffeine intake or avoid caffeine after 
noon25. These suggestions are based on the belief that caffeine can disrupt sleep and 
cause arousal from sleep390. The hypothesised action is the adenosine pathway 
caused by caffeine’s antagonism391, 392. However, the differential sensitivity to 
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caffeine could explain individual differences in caffeine-related sleep disturbances. 
Recent evidence suggests that caffeine-related sleep disturbance is closely associated 
with several genes in the general population393. These findings indicate that 
individuals respond to caffeine differently, and that advising all patients to reduce 
caffeine intake might not necessarily be appropriate. The results of this study 
suggests that “drinking beverages with caffeine in it” is a popular fatigue self-
management behaviour used by 91% of participants. Although patients do not find it 
effective for alleviating fatigue, its use may be due to the comfort they find from 
caffeine intake. Further prospective research could examine the effects of caffeine (if 
any) on fatigue and sleep disturbance in this population.  
 
7.4 FACTORS ASSOCIATED WITH FATIGUE SELF-MANAGEMENT 
BEHAVIOURS IN PATIENTS WITH ADVANCED CANCER 
The conceptual framework for the study proposed that fatigue self-
management behaviours could be explained by factors related to the individual, their 
condition and their environment. In particular, the frequency and the perceived 
effectiveness level of self-management behaviours associated with fatigue were 
considered in this study to reflect some of the most important aspects of self-
management in this population. This section discusses the factors associated with 
these two outcomes. 
According to the results of the multivariable analyses, levels of self-efficacy 
were consistently reported to be an independent positive predictor of the frequency 
of self-management behaviours used and the perceived effectiveness of self-
management behaviours. This finding was similar to findings reported by Lou (2011) 
concerning Chinese patients with cancer undergoing chemotherapy19. Lou’s cross-
sectional study19 was the first to report the relationship between self-efficacy 
associated with fatigue self-management behaviours and perceived relief in patients 
with cancer undergoing chemotherapy. Hence, the results of this study provide 
empirical evidence supporting the important role of self-efficacy in fatigue self-
management of patients with advanced cancer. To our knowledge, the present study 
is the first longitudinal study examining the predictors of fatigue self-management 
behaviours in this population. While cross-sectional research provides some clues 
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regarding the relationship between variables, only longitudinal studies can provide an 
empirical basis allowing for the prediction of fatigue self-management outcomes187. 
The relationship between self-efficacy, frequency and perceived effectiveness 
of fatigue self-management behaviours can be examined using key constructs from 
Bandura’s self-efficacy theory35, 200, 208, 210. Specifically, those with higher levels of 
self-efficacy could perceive fatigue as modifiable and thus invest more effort in self-
management behaviours to alleviate fatigue. Those individuals (with higher levels of 
self-efficacy) could also be more persistent when confronting difficulties, obstacles 
or adverse outcomes in the process of achieving goals35. A recently published study 
by Hoffman and colleagues reported some preliminary results that indicate potential 
benefits of a home-based exercise intervention for fatigue self-management in post-
surgical non-small cell lung cancer (NSCLC) patients248. Although the sample size 
was small (n=7), the results of this feasibility study suggest that nursing interventions 
may have a positive impact on perceived self-efficacy for fatigue self-management 
and in turn alleviate fatigue severity. There is an increasing body of literature and 
resources available which suggest the potential role of self-efficacy enhancement in 
self-management support17. It is therefore important for health professionals to 
understand their role in self-efficacy enhancement.   
Apart from levels of self-efficacy, age was another individual factor that could 
positively predict the frequency of self-management behaviours. Although older 
individuals used fatigue self-management behaviours more frequently, they were not 
as effective as their younger counterparts in their fatigue self-management. With 
cancer being recognised as a disease of old age394, the identification of specific 
challenges encountered by older people suggests that further attention is needed 
when providing self-management support to this group. Grey et al hypothesised that 
older people may require more assistance than they had previously to perform self-
management effectively164. A recent qualitative study reported that older people do 
have specific challenges and barriers to self-manage their long term chronic disease. 
These issues could be related to the lack of willingness to seek support, the ease of 
obtaining support and services, the usefulness of advice and support, and the greater 
awareness of local support providers395. It is important that future studies examine 
self-management challenges encountered by older patients with advanced cancer.  
 162  Chapter 7: Discussion and Conclusion 
  
Functional status was a significant negative predictor for the frequency of self-
management behaviours. Although it is reasonable to expect that individuals with 
higher functional status would use fatigue self-management behaviours more 
frequently, the findings of this study did not support this assumption. This finding is 
congruent with previous findings reported in Lou’s study19. Considering that this 
group had relatively high functional status (with mean AKPS over 75, with a 
possible range of 0-100), one possible explanation is that participants with higher 
functional status were possibly working or actively engaged in other normal duties, 
and thus had less time to engage in self-management behaviours. However, this 
study did not collect data on employment status. Further research should investigate 
the effects of employment status on outcomes associated with fatigue self-
management behaviours. It is hypothesised by Grey’s and Hoffman’s theoretical 
frameworks that patients with higher functional status could have better ability to 
self-manage their symptoms164, 247. The findings of this study suggest that there may 
be other mediating factors between functional status and self-management outcomes. 
For example, it is possible that patients with higher functional status are still more 
engaged in working or other work such as caring for their family members, and 
therefore neglect their fatigue self-management. 
Education level (completed high school vs. not completed), depressive 
symptoms (HADS-D) and ethnicity were the other three factors that independently 
predicted perceived effectiveness of self-management behaviours. With regard to the 
influence of education level, individuals who completed high school were more 
effective in self-managing their fatigue, compared to those who did not. This finding 
is congruent with a number of studies244-246 of patients with chronic disease. 
Specifically, two studies of patients with various types of chronic disease further 
reported that patients with a higher education level not only had better self-efficacy 
outcomes, but also lower levels of fatigue244, 246. It is possible that people with higher 
education have higher confidence, and higher health literacy to make use of self-
management support. This finding suggests that patients with lower education status 
require additional fatigue self-management support from their health professionals or 
family/caregivers.   
Lower levels of depressive symptoms is predictive of higher levels of fatigue 
self-management effectiveness in this study. This finding is consistent with those 
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reported by self-management studies of other chronic illness250-254, 257. Depressed 
individuals may not be motivated to carry out self-management activities 
effectively195. The co-occurrence of depression and fatigue has been reported in 
numerous studies concerning patients with advanced cancer63, 99, 296, 396. The results 
of the present study suggest a potential role of self-management outcomes serving as 
mediators between depression and fatigue in patients with advanced cancer. Future 
interventions for fatigue self-management should therefore concurrently address 
depressive symptoms in this population. 
The direction of the causal relationship between depression and fatigue remains 
controversial397. Possible theories include that cancer and treatment related fatigue 
may result in patients becoming depressed, fatigue may develop in patients with 
cancer as a consequence of their being depressed, and no causal relationship exists, 
indicating that the third factor is the direct cause of both fatigue and depression. 
Although there has been evidence supporting some of these claims, the relationship 
between depression and fatigue is not an exact science397. The results of this study 
support the second possibility, that fatigue is a consequence of patients being 
depressed. It is important to note that the measurements used (ESAS and HADS-
Depression) can only be used to assess depressive symptoms, rather than the 
diagnosis of depression. According to the literature, the type of sub-clinical 
depression assessed in this study is more common than clinical depression32, reported 
by 60% of patients with advanced cancer398. The results of this study provide 
preliminary evidence proposing a possible causal pathway between depression and 
fatigue via a modifying factor of fatigue self-management effectiveness.   
Although ethnicity was a significant predictor in the multivariable analysis in 
this study, the small sample size of individuals who were non-Caucasians (n=6, 
3.9%) did not allow a robust evaluation for this question of interest. Gender, marital 
status, comorbidities, income levels, living arrangement, primary tumour site, and 
current therapy were hypothesised to be potential protective and risk factors for 
explaining self-management behaviours. These variables were first proposed by Grey 
et al’s SMSF, based on health behavioural theories and research conducted in chronic 
illness management, not specific to cancer-related symptoms. The multivariable 
analysis of this study did not establish any relationship between self-management 
behaviours and other predictors. Future studies investigating fatigue self-
 164  Chapter 7: Discussion and Conclusion 
  
management or other cancer-related symptom self-management are suggested to 
confirm if these socio-demographic and clinical factors are in any way associated 
with self-management behaviours.   
 
7.5 IMPLICATIONS  
The purpose of this study was to contribute to the understanding of fatigue self-
management in patients with advanced cancer. The theoretical and practical 
implications of the study’s results are explored in the following sections. 
 
7.5.1 Theoretical implications 
When this study was originally conceptualised, there was no established cancer 
symptom self-management model in the published literature. Over the past two 
decades, a number of symptom management models have been proposed in nursing 
(i.e. Theory of Symptom Management, the Theory of Unpleasant Symptoms, the 
Symptoms Experience Model and the Symptoms Experience in Time Model)230. 
However, none of these symptom management models alone can provide sufficient 
conceptual understanding of the part that patients play in self-management. 
Therefore, it is important that these models are used in conjunction with self-
management models230. For this study, a conceptual framework based on Grey et al’s 
Self and Family Management Framework was proposed. The framework drew from 
some of the key health behavioural models and proposed a range of potential risk and 
protective factors that can influence individuals’ and families’ abilities to manage 
chronic illness and its symptoms. Grey et al acknowledged that the included factors 
were proposed for consideration, but not all would be associated with effective self-
management.  
In 2009, Hoffman and colleagues proposed a new hypothesised model of 
perceived self-efficacy and optimal physical functional status247. This theory 
hypothesised that physiological and contextual characteristics, including perceived 
self-efficacy, are contributing factors to the ability to carry out fatigue self-
management. Hoffman’s hypothesised model assumes that individuals undertake 
fatigue self-management behaviours ultimately to achieve higher functional status. 
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Although there may be a reciprocal relationship between effectiveness of fatigue 
self-management behaviours and functional status, the conceptual model in this 
present study, based on the Grey’s Self and Family Management Framework, 
hypothesised that functional status is one of the risk factors that can explain fatigue 
self-management behaviours, rather than the contrary. Another difference between 
the two models is that the Self and Family Management Framework considered self-
management as taking place in the context of the family, whereas Hoffman’s model 
does not emphasise the involvement of the family but has considered a range of 
“contextual” factors including family functioning. While some of these concepts may 
differ slightly between the two models, they are broadly similar at an operational 
level.  
The findings of this study confirm that perceived self-efficacy pertaining to 
fatigue self-management behaviours is a significant predictor influencing the 
perceived effectiveness of fatigue self-management overtime. Findings of this study 
provide empirical support for Grey’s (2006) and Hoffman’s (2009) propositions that 
self-efficacy is a significant factor explaining fatigue self-management and related 
outcomes in patients with advanced cancer. Specifically, self-efficacy is an important 
component to consider in clinical practice and future research that explores and 
promotes symptom self-management in patients with advanced cancer, as the results 
of this study demonstrate that higher levels of self-efficacy are associated with 
greater use and increased benefits of fatigue self-management behaviours. 
Existing self-management models164, 247, 274 suggest a number of socio-
demographic factors that should also be considered. This study confirms that 
educational level, functional status and depressive symptoms are significant factors 
influencing fatigue self-management. In particular, this study suggests that there may 
be a potential mediating role of fatigue self-management outcomes in the relationship 
between fatigue and depression. Further research is needed to test such hypotheses. 
These results may further inform the development of interventions in this area. 
On the other hand, a number of factors that were hypothesised in the Self and 
Family Management Framework as being associated with use of self-management 
behaviours were not significant. These included a number of socio-demographic 
factors, primary tumour sites, and current therapy. Not only were these factors not 
associated with the fatigue self-management outcomes, they have also not been 
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associated with fatigue severity levels in patients with advanced cancer37, 71, 362, 363. 
This study is the first to apply the Self and Family Management Framework in the 
context of symptom self-management in patients with advanced cancer. Although the 
current Self and Family Management Framework provides a comprehensive range of 
factors for consideration, not all are relevant in the specific context of this study. It is 
expected that a more simplified model could further enhance its usefulness for 
clinical research and practice purposes.   
It is important, however, not to overlook the uniqueness of the Self and Family 
Management Framework, and its emphasis on the family and their role in achieving 
better health outcomes164. The importance of family functioning and social support 
are well recognised in other populations with chronic illnesses and cancer16, 164, 175, 
224, although not identified in the current study. In order to understand these results, it 
is prudent to examine the perspective of the family or caregivers of this population 
on fatigue self-management behaviours.  
 
7.5.2 Practical implications 
Firstly, health professionals should routinely assess patients with advanced 
cancer and provide appropriate treatment or self-management support to alleviate 
fatigue. Despite the varying levels of distress and interference caused by fatigue in 
this population, it is a debilitating symptom that negatively affects quality of life. It 
should not be regarded as a less important symptom compared to pain or other 
symptoms. A number of assessment tools for cancer-related fatigue are available302, 
399. A simple assessment or screening tool such as the ESAS, which is a valid and 
reliable tool for use in this population308, can be used on patients with advanced 
cancer396. This and a number of other studies308 have demonstrated its feasibility in 
this population. When a more detailed assessment of fatigue is indicated, a fatigue 
specific inventory should be used. This study demonstrates that the BFI can be used 
to elicit the extent of fatigue severity and interference over the past seven days rather 
than a single time point. This study demonstrated some differences in severity 
between “fatigue right now”, “worse fatigue over the past 24 hours” and “fatigue 
over the past 7 days”. Such differences would not have been detected using an 
instrument that simplistically assesses fatigue “right now” at a single time point. The 
use of BFI in this population was also supported by Krishnasamy43. This tool is 
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recommended for its simplicity and reproducibility, and is therefore appropriate for 
patients with advanced cancer60, 112, 303. The BFI also allows the categorisation of 
fatigue severity as levels 1-3 fatigue (indicating mild), levels 4-6 fatigue (indicating 
moderate), and levels 7-10 fatigue (indicating severe). These categories may allow 
prioritisation of resources for clinical interventions including self-management 
support. 
Secondly, health professionals should be informed that patients with advanced 
cancer who are not at end of life can and do engage in a number of self-management 
behaviours. Self-management interventions and support should not be limited to 
those in early stages of disease or those receiving active treatment. Such a suggestion 
is consistent with the World Health Organization’s recommendation that patients 
should “live as actively as possible even in the terminal phase of their disease”400. 
Therefore, engagement in self-management should be encouraged as tolerated in 
patients with advanced cancer. There is a wide range of variation as to the choices of 
self-management behaviours used by patients with advanced cancer. It is important 
that health professionals consider the potential risk factors and preferences of the 
individual patient in the planning of their self-management support. Using 
‘delegating tasks to others’ as an example, the family/social support to patients 
should be assessed when recommending this particular self-management strategy. 
Health professionals should consider addressing some of the modifiable potential 
risk factors (e.g. depression/social support) to aid fatigue self-management in 
patients in this population. Some patients may not have any family 
members/caregivers to delegate tasks to but they may be able to delegate tasks to 
paid workers as funded by the government or not-for-profit organisations. On the 
other hand, some patients may have people to delegate to, but choose not to delegate 
tasks as they do not want to feel like being a burden to them87, 89. In Australia, 
patients with advanced cancer might be eligible for additional community support 
depending on prognosis and the resources available in their localities, however 
patients and families are not always aware of these resources270. Agencies providing 
such support should be resourced and prepared to promote self-management as much 
as possible, and to provide higher level support as patients transit to end of life (last 
weeks and days or life). It is therefore important for health professionals to 
understand the environmental factors, with consideration of the needs specific to the 
 168  Chapter 7: Discussion and Conclusion 
  
patient as an individual. The results of this study point to the complexity of self-
management support, warranting an individualised approach. 
Thirdly, for those commonly used self-management behaviours that are 
consistent with current evidence-based guidelines, such as doing relaxing things, and 
resting during the day without falling asleep25, resources should be directed to 
support use of these behaviours. Health professionals can be involved in endorsing 
these behaviours, and ensuring that patients have the right techniques and skills to 
undertake these behaviours effectively. 
Fourthly, for behaviours (e.g. appropriate level and type of exercise) that are 
evidence-based and not commonly used by patients, extra intervention might be 
necessary in the provision of self-management support. Health professionals (e.g. 
physiotherapists and trained nurses) can partner with patients/families and caregivers 
to identify reasons for not using these behaviours or barriers to using these 
behaviours. Health professionals and patients can work collaboratively to address 
these barriers. For example, promotion of appropriate stretching exercises with 
sufficient instructions could be incorporated into patients’ self-management plans as 
tolerated. Barriers such as lack of motivation, time, partner or professional guidance 
have been identified in this population and could be further addressed in 
collaboration between health professionals, the patient and family/caregivers. This 
collaborative process is a complex one, and should involve a comprehensive clinical 
assessment of the patient. Health professionals need to consider clinical factors that 
are common to patients with advanced cancer, such as bone metastases and pain, 
thrombocytopenia, anaemia, fever/active infection and assess safety issues such as 
risk of falls/stability25. 
Fifthly, for behaviours that are not effective or not evidence-based (e.g. 
drinking beverages with caffeine), patients should be provided with evidence-based 
information demonstrating the lack of evidence for their role in managing fatigue and 
in some cases, the potential to cause adverse effects. The qualitative findings of this 
study revealed that patients could have perceptions about certain fatigue management 
strategies that are not consistent with scientific evidence. For example, one patient 
suggested that haloperidol is an antidepressant that lifts her mood and consequently 
alleviated fatigue. It is important that health professionals do not approach patients 
with a judgmental attitude401. However, health professionals should share evidence-
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based information with patients to ensure that patients are making informed choices 
about their self-management approaches17. To use another example, health 
professionals should inform patients that drinking beverages with caffeine is not an 
effective strategy for relieving fatigue and could potentially interfere with sleep at 
night. However, patients should not be advised to not use such self-management 
techniques unless there is sufficient evidence suggesting the adverse effects of such 
behaviours. There is emerging evidence suggesting that the potential effects of 
caffeine can be attributed to the adenosine pathway caused by caffeine’s antagonism, 
and that individuals can respond to caffeine differently391-393. Further, this study 
demonstrated that patients may wish to continue to drink beverages with caffeine in 
spite of the lack of benefit in alleviating fatigue.  
Sixthly, it is desirable that patients experiencing fatigue can receive input from 
the multidisciplinary team as part of their fatigue self-management plan17. As 
highlighted in the discussion above, some behaviours require health professionals to 
equip patients with certain skills and guidance (e.g. exercise strategies/nutritional 
counselling etc.). The cancer nurse could serve as an overall coordinator that assesses 
fatigue and the patient’s needs/preferences, and initiate fatigue self-management care 
plans and support. Other relevant health professionals and family/caregivers can 
collaborate in providing the patient with self-management support. 
Last but not least, fatigue self-management interventions should consider self-
efficacy enhancement and depressive symptom management as key components. 
Patients with higher self-efficacy and lower depressive symptoms are more likely to 
perform fatigue self-management more frequently and more effectively. If a patient 
is depressed, they may be receiving antidepressant treatment402. However, 
antidepressants are unlikely to be effective for improving sub-clinical depressive 
symptoms in this population402. Level one evidence suggests that psychotherapy is 
effective for managing depression in patients with advanced cancer403. If a person has 
subclinical depression, as measured at baseline using the Hospital Anxiety and 
Depression Scale (HADS)320, clinicians can draw on some techniques applied in a 
psychosocial intervention program404 such as reducing negative or self-defeating 
cognitions403.  
Moreover, interventions that aim to enhance self-efficacy can be designed 
using the self-efficacy model200, 210 including the sources of information. 
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Specifically, cancer nurses can facilitate self-efficacy enhancement using the self-
efficacy model200, 210: direct mastery experiences, performance accomplishment, 
vicarious experiences observing nurse modelling skills, verbal persuasion: a nurse 
can influence a patient’s self-belief in their capabilities to achieve goals. Bandura 
suggests that when an authority figure expresses their belief in a person’s capacity to 
achieve a task, increased self-efficacy can result200, 210. The nurse can interpret 
inferences from physiological and psychological states indicative of the patient’s 
personal strengths and vulnerabilities to reach a patient’s goals. Fear or anxiety can 
affect patient attitudes and their ability to solve problems, as well as undermine 
coping activities. In such cases, the nurse can inform the patient of relaxation 
techniques as appropriate208. As self-efficacy with engaging in effective behaviours 
increases, it could potentially lead to more desirable self-management and fatigue 
severity outcomes in this population. 
 
7.6 LIMITATIONS OF THE STUDY 
The population of interest in this study (patients with advanced cancer) is a 
heterogeneous one. This study design did not include a single reference time point (at 
a particular time point such as referral to specialist palliative care service or at 
diagnosis of metastatic disease), and participants were not followed until death. The 
participants had cancers at different sites and stages, with different metastatic sites, 
courses and prognoses, with the clinical profile of the sample suggesting they were 
likely to be at an earlier stage of their advanced disease trajectory. This limits the 
generalisability of the findings to all patients with advanced cancer105. It is important 
to acknowledge that while this study is exploratory in nature, it can provide direction 
for future research. This study did measure functional status which is a well-used 
predictor for prognosis in patients with advanced cancer238. However, functional 
status tools such as the Karnofsky Performance Scales and the Australian Karnofsky 
Performance Scale are only sensitive for predicting survival when scores are low. It 
is a poor prognostic factor when scores are high238, 239, and as such it is difficult to 
ascertain the exact stage of the patient’s disease trajectory in this study. On the basis 
of findings from this study, it is recommended that future research can be undertaken 
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to follow patients towards end of life, to gain understanding of the meaning of 
fatigue and fatigue self-management as patients progress in their disease. 
Although Grey’s Self and Family Management Framework emphases family 
functioning and social support, this study did not investigate the perspectives of 
family and caregivers. This exploratory study focused first on gaining an 
understanding of the perspectives of the patient with respect to the effectiveness and 
frequency of fatigue self-management behaviours. This study also explored the level 
of social support available to patients. The findings of this study did not find any 
relationship between living arrangements, social support and marital status, and 
outcomes associated with fatigue self-management behaviours. Future research is 
needed to understand the role of the family/caregivers in fatigue self-management 
support from the perspectives of the family/caregivers. Since the family 
members/caregivers are presumed to have a role in providing patients with self-
management support, it is important for future research to investigate the family’s 
role in self-management support. 
The SMSFS-A was used to measure fatigue self-efficacy in this study. It is 
suggested that this tool was a useful exploratory tool, rather than a definitive measure 
of fatigue self-efficacy. Each of the behaviours included in the SMSFS-A were 
discrete behaviours. Construct validity testings and confirmatory factor analysis were 
not undertaken as these types of analyses require all items to be answered by the 
sample. Nevertheless, a number of robust procedures have been used to ensure the 
content validity and reliability of the SMSFS-A. The development involved an 
extensive literature review, content validity using an expert review panel, and face 
validity using a pilot test with ten participants. The content validity of this tool was 
further confirmed, as the results of the longitudinal study did not yield new 
behaviours that were not captured by the current SMSFS-A during the patient 
surveys. Since the conception of this study, another fatigue self-efficacy tool titled 
“the Perceived Self-efficacy for Fatigue Self-Management Instrument” has been 
developed by Hoffman247, 248. This tool was developed for patients with chronic 
illness and was only tested on patients with lung cancer undergoing chemotherapy247, 
248. Further research of concurrent validity analyses involving the SMSFS-A and 
other well tested self-efficacy measures might be useful to further improve the 
SMSFS-A for patients with advanced cancer.  
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7.7 RECOMMENDATIONS FOR FUTURE RESEARCH 
Firstly, a qualitative study should be conducted to understand the perspectives 
and involvement of family/caregivers in fatigue self-management for patients with 
advanced cancer. The research questions could include: What are the 
family/caregivers doing to support patients to engage in fatigue self-management 
behaviours? In what way are they supporting the patients (e.g. emotional support, 
practical assistance, decision making, and communication with health professionals)? 
What (support, resources, skills, and awareness) do they require in order to provide 
effective self-management support to patients with advanced cancer?  
Secondly, a fatigue self-management intervention should be developed based 
on best available evidence and the findings of this study. The intervention should be 
designed using a symptom management intervention model (the Revised Symptom 
Management Conceptual Model175) in conjunction with a self-management 
theoretical model164, 247 with the aim of enhancing the patient’s self-efficacy, and the 
effectiveness of fatigue self-management to ultimately reduce fatigue severity and its 
impacts in this population. The intervention should use a tailored approach 
considering the relevant risk and protective factors associated with fatigue self-
management for this population. Further, the design of this self-management 
intervention should consider the involvement of the family/caregivers as well as a 
number of important findings concerning specific self-management practices as 
reported in this study. This intervention should be piloted and tested using a 
randomised controlled trial design. Measured outcomes should include behavioural 
outcomes, fatigue intensity, distress and interference caused by fatigue, and quality 
of life in this population.  
 
7.8 CONCLUSIONS 
This study advances the understanding of fatigue self-management in patients 
with advanced cancer. Phase one of this study adapted the Self-efficacy in Managing 
Symptoms Scale - Fatigue Subscale instrument, for use in patients with advanced 
cancer. The items and scaling were modified using multiple sources of information 
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including an extensive literature review, ten semi-structured interviews, repeated 
expert panel reviews and a pilot test.  
The main study advances knowledge of self-management behaviours for 
fatigue in patients with advanced cancer. These results extend earlier research by 
providing information beyond patients receiving active treatment, and providing 
empirical evidence that patients with advanced cancer use a range of self-
management behaviours and have received varied levels of relief from these 
behaviours. Such findings provide new information to guide development of 
potentially effective self-management programs for patients with advanced disease. 
The findings of this study highlighted that perceived self-efficacy, depressive 
symptoms, age, and functional status are important factors in the use and perceived 
usefulness of fatigue self-management behaviours. On the basis of these results, this 
study has provided recommendations for practice and future research. Self-
management is a response of patients to the symptom experience. As patients are 
actively engaged in self-management, they obtain relief from these behaviours as 
well as some sense of control. For patients with advanced cancer, this process is 
extremely complex, requiring health professionals to be competent in providing high 
quality, evidence-based self-management support to patients. With ever increasing 
literature pointing to the importance of self-management in managing chronic 
conditions, this study focussed on fatigue self-management in patients with advanced 
cancer. This study particularly focused on the perspectives of patients, highlighting a 
number of issues requiring further attention from health professionals in their clinical 
practice, as well as the potential for future research. As we aim to provide high 
quality individualised cancer care to our patients, health professionals must hear the 
perspectives of the patient and realise the importance of the role of self-management 
in their day-to-day clinical practice.  
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Appendices 
Appendix 1 
Timeline for the IF49 program 
Timeline for the IF49 program- Ray Chan 
Doctor of Philosophy (PhD) - Part Time 2008-2009/Full time 2010-2011/Part time 2012-2013 
 
 2008 2009 2010 2011 2012 2013 
Schedule of 
Activities Feb- 
Mar 
Apr-
Jun 
Jul 
– 
Sep 
Oct-
Dec 
Jan- 
Mar 
Apr- 
Jun 
Jul 
– 
Sep 
Oct- 
Dec 
Jan-
Mar 
Apr- 
Jun 
Jul 
– 
Sep 
Oct-
Dec 
Jan- 
Mar 
Apr- 
Jun 
Jul 
– 
Sep 
Oct- 
Dec 
Jan- 
Mar 
Apr- 
Jun 
Jul 
– 
Sep 
Oct- 
Dec 
Jan- 
Mar 
Apr- 
Jun 
Jul 
– 
Sep 
Oct- 
Dec 
Consultation 
and Planning                         
Enrolment 
                        
Coursework 
                        
Stage 2 
Proposal                         
Literature 
Review                         
Post grad 
forum 
Presentation 
                        
Confirmation 
Seminar                         
Ethics 
Approval                         
Annual 
Progress 
Reports 
                        
Stage1A- 
Interviews                         
Expert Panel 
Consultation                         
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Stage 1 B- Pilot 
test                         
Stage 2- Survey 
                        
Data Analysis 
                        
Writing up 
                        
Editing of 
Thesis                          
Final Seminar 
                        
Submission for 
examination                         
CNSA 
Conference                         
MASCC 
Conference                         
 
Part time enrolment  Full time enrolment  
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Appendix 3  
Self-management associated with fatigue in patients with advanced cancer 
Questionnaire for Stage 1A 
 
 
Self-management associated with 
fatigue in patients with advanced 
cancer- Stage 1A 
 
Questionnaire 
 
 
  Date: 
 
 
  Code No.: 
 
 
 
 
 
 
 
Baseline      
Time 2     
Time 3     
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Code:______________ 
 
Demographic/medical information sheet 
 
A. Information from medical records 
Age: 
__________ (in years) 
 
Gender:
M/ F 
Ethnicity: 
Australian 
UK 
European 
Other 
Setting:
Inpatient 
Outpatient 
 
 
Primary cancer diagnosis _________________________ 
 
Site(s) of metastasis: ______________________________ 
 
 
Previous treatment (within the last month) 
Chemotherapy  Please specify regimen and date last receiving treatment: 
_________________________ 
Radiotherapy  Please specify regimen and date last receiving treatment: 
_________________________ 
Other treatment (e.g. immunotherapy)  Please specify regimen and date last 
receiving treatment: _________________________ 
 
 
Current treatment 
Chemotherapy  Please specify regimen: ____________________ 
Radiotherapy  Please specify regimen: _____________________ 
Other treatment (e.g. immunotherapy/ hormonal therapy)   Please specify 
regimen: __________________________ 
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Code:______________ 
 
Charlson Comorbidity Index (CCI) 
 
Assigned weights for diseases Conditions
1 Myocardial infarct
Congestive heart failure 
Peripheral vascular disease 
Cerebrovascular disease 
Dementia 
Chronic pulmonary disease 
Connective tissue disease 
Ulcer disease 
Mild liver disease 
Diabetes
2 Hemiplegia
Moderate or severe renal disease 
Diabetes with end organ damage 
Leukaemia
3 Moderate or severe liver disease
6 AIDS
Total Score  
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic 
Comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 
40(5):373-383. 
 
 
B. Information from the patient 
Living Arrangement: 
Live with partner 
Live with other family member or a friend
Alone 
Income (per annum): 
<20,000 
20,000- 30,000 
30,000-40,000 
40,000- 50,000  
50,000- 60,000 
>60,000 
Marital status: 
Married 
Divorce 
De facto 
Widowed 
Single  
(will be summarised as married or other)
Education:
 
________________ (in years) 
 
 
 
 
Fatigue Numeric Analogue Scale 
 
To what degree would you rate the severity of your tiredness over the past 
week? 
 
1 2 3 4 5 6 7 8 9 10
No tiredness Worst possible 
tiredness
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Interview guide (Stage 1A) 
 
 
Questions: 
 
1. Many people with cancer feel tired. What makes you feel tired? /When 
do you find that you are most tired? Are there certain things that make 
it worse? 
 
 
 
2. When patients with cancer feel tired, they do certain things to reduce 
their tiredness. Could you tell me about what you personally do to 
reduce your tiredness? 
 
Think about the last time you felt really tired. What did you do? Why did you 
do those things? (Prompt – because you thought it would help?; because you 
did not know what to do? Because you couldn’t do anything?) 
 
 
 
Then prompt with more specifics depending on response: 
 
a/ When people are tired, some people do things such as take naps/sleep.  
Is this something that you do? Can you describe to me a time when you did 
this? Was it helpful? 
 
 
 
b/ When people are tired, some people do things such as participate in an 
exercise program. Is this something that you do? Can you describe to me a 
time when you did this? What type of exercise/activity did you engage in? 
Was it helpful? 
 
 
 
c/ When people are tired, some people do things such as pace themselves; 
plan their day. Is this something that you do? Can you describe to me a time 
when you did this? What types of things did you do to plan? Was it helpful? 
 
 
 
d/ When people are tired, some people do things such as watch TV, or do 
things to take their mind of it. Is this something that you do? Can you 
describe to me a time when you did this? What type of things did you do to 
take your mind of the tiredness? Was it helpful? 
 
 
e/ When people are tired, some people do things such as think positive 
thoughts, try relaxation, or do other things to cope/feel better. Is this 
  
Appendices 209 
 
something that you do? Can you describe to me a time when you did this? 
What types of things help you to cope with your tiredness emotionally? Was it 
helpful? 
 
 
 
f/ When people are tired, some people do things such as spend time with 
loved ones. Is this something that you do? Can you describe to me a time 
when you did this? What types of things can your family/friends to help when 
you are tired? Was it helpful? 
 
 
 
g/ When people are tired, some people do things such as delegate 
household tasks or other chores to other people. Is this something that 
you do? Can you describe to me a time when you did this? What types of 
things do you delegate to others? Was it helpful? 
 
 
 
h/ When people are tired, some people do things such as change the 
foods they eat. Is this something that you do? Can you describe to me a 
time when you did this? What types of foods do you eat to help you if you are 
tired? Was it helpful? 
 
 
 
i/ When people are tired, some people do things such as take medications 
or other complementary therapies program. Is this something that you 
do? Can you describe to me a time when you did this? What type of 
medication/complementary therapies do you use? Was it helpful? 
 
 
 
 
J****/ If you do a number of things to help you to reduce your tiredness, are 
there certain things that you prefer? What makes you decide to try 
different things? 
 
 
 
K**** (It may not be necessary if answered previously)/ Is there anything you 
would say helps to reduce your tiredness? Can you describe how/when 
you do those things? 
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Appendix 4  
 Self-efficacy in Managing Symptoms Scale- Fatigue Subscale (SMS-F)  
Fatigue 
The following lists some of the things people sometimes do to help manage this symptom 
For each action listed, please indicate: 
a/ how much relief you have received from this action 
b/ how difficult you find this action 
c/ how confident you feel about using this action
 Part A Part B Part C 
 Not 
used 
Used, but 
no relief 
Used, a 
little 
relief 
Used, 
some 
relief 
Used, 
completely 
relief 
Not 
difficult 
      Extremely 
difficult 
Not 
confident 
      Extremely 
confident 
Action: 0 1 2 3 4 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
Went to bed earlier than 
usual 
0 1 2 3 4 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
Got up later than usual 0 1 2 3 4 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
Took naps 0 1 2 3 4 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
Got more exercise 0 1 2 3 4 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
Got fresh air 0 1 2 3 4 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
Keep busy to get your 
mind off it 
0 1 2 3 4 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
Drank more beverages 
with caffeine 
0 1 2 3 4 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
Planned your day and 
activities to cope with 
fatigue 
0 1 2 3 4 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
Other( please write in) 0 1 2 3 4 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
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Appendix 5  
 Self-efficacy in managing symptoms scale- fatigue subscale for patients with advanced cancer (SMSFS-A)- Fatigue (Initial) 
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Appendix 6  
Self-management associated with fatigue in patients with advanced cancer 
Questionnaire for Stage 1b and stage 2 
 
 
Self-management associated with 
fatigue in patients with advanced 
cancer- Stage 2 
 
Questionnaire 
 
 
  Date: 
 
 
  Code No.: 
 
 
 
 
 
 
 
Baseline      
Time 2      
Time 3      
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Code:______________ 
 
Demographic/medical information sheet  
 
 
Information from medical records 
Age: 
__________ (in years) 
 
Gender:
M/ F 
Ethnicity: 
European 
African  
Asian 
Aboriginal/Torres Strait Islanders 
Other 
Setting (at baseline):
Inpatient 
Outpatient 
Setting (at time 2): 
Inpatient 
Outpatient 
Setting (at time 3): 
Inpatient 
Outpatient
 
Primary cancer diagnosis _________________________ 
 
Site(s) of metastasis:  
(1) _____________________________ 
(2) _____________________________ 
(3) _____________________________ 
 Eligibility is defined as people who have finished the first-line treatment after 
their first metastasis was diagnosed.  
 
 
Current treatment 
 Chemotherapy  
Please specify regimen: ________________________ 
 Radiotherapy 
Please specify regimen: __________________________ 
 Other treatment (e.g. immunotherapy/ biological therapy/ hormonal therapy)   
 Please specify regimen: __________________________ 
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Code:______________ 
 
Charlson Comorbidity Index (CCI) 
Assigned weights for diseases Conditions
1 Myocardial infarct
Congestive heart failure 
Peripheral vascular disease 
Cerebrovascular disease 
Dementia 
Chronic pulmonary disease 
Connective tissue disease 
Ulcer disease 
Mild liver disease 
Diabetes
2 Hemiplegia
Moderate or severe renal disease 
Diabetes with end organ damage 
Leukaemia
3 Moderate or severe liver disease 
6 AIDS
Total Score  
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic 
Comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 
40(5):373-383. 
 
 
Australian Karnofsky Performance Scale (AKPS) 
Definition %
 
Criteria 
Able to carry on normal 
activity and 
to work. No special care is 
needed. 
 
100 
 
Normal; no complaints; no evidence of 
disease 
90 
 
Able to carry on normal activity; minor signs 
of 
symptoms of disease 
80 Normal activity with effort; some signs or 
symptoms of disease 
Unable to work. Able to live 
at 
home, care for most 
personal 
needs. A varying amount of 
assistance is needed. 
 
70 Cares for self. Unable to carry on normal 
activity or to do active work 
60 Able to care for most needs, but requires 
occasional 
assistance. 
50 Considerable assistance and frequent medical 
care 
required. 
Unable to care for self. 
Requires equivalent of 
institutional or hospital care. 
Disease may be progressing 
rapidly. 
40 In bed more than 50% of the time. 
30 Almost completely bedfast. 
20 Totally bedfast and requiring extensive nursing 
care by 
professionals and/or family. 
10 Comatose or barely arousable. 
0 Dead
Triggers: A Karnofsky assessment of 60 or below may trigger a family conference to 
discuss functional status and disease progression 
Abernethy, A. P., Shelby-James, T., Fazekas, B. S., Woods, D., & Currow, D. C. (2005). 
The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for 
contemporary palliative care clinical practice [Electronic Version]. BioMed Central 
Palliative Care, 4, 1-12. 
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Code:______________ 
 
 
Information from the patient 
Living Arrangement:
Live with partner 
Live with other family member or a friend
Alone 
Income (per annum):
<20,000 
20,000- 30,000 
30,000-40,000 
40,000- 50,000  
50,000- 60,000 
>60,000
Marital status: 
Married 
Divorce 
De facto 
Widowed 
Single  
 
Education:
 
________________ (in years) 
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Code:______________ 
 
 
 
Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. 
The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue 
Inventory. Cancer. 1999 Mar 1;85(5):1186-96. 
http://www.npcrc.org/usr_doc/adhoc/painsymptom/Brief%20Fatigue%20Invent
ory.pdf 
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Code:______________ 
 
Fatigue Distress Numeric Analogue Scale 
 
 
 
To what degree has fatigue caused you distress over the past week? 
 
1 2 3 4 5 6 7 8 9 10 
No distress A great deal  
of distress 
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Code:______________ 
 
Edmonton Symptom Assessment Scale 
 
 
 
 
 
 
 
 
 
Bruera E, Kuehn N, Miller M, Selmser P, Macmillan K. The Edmonton Symptom Assessment 
System (ESAS): A simple method for the assessment of palliative care patients. Journal of 
Palliative Care. 1991;7:6-9. 
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Code:______________ 
 
Zigmond A, Snaith R. The Hospital Anxiety and Depression Scale. Acta Psychiatrica 
Scandinavica. 1983;67(6):361-70. (License has been purchased) 
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Code:______________ 
 
THE MEDICAL OUTCOMES STUDY SOCIAL SUPPORT SURVEY  
1. About how many close friends and close relatives do you have 
(people you 
feel at ease with and can talk to about what is on your mind)? 
Write in the number of close friends and close relatives: 
 
People sometimes look to others for companionship, assistance, or other types of support.  
How often is each of the following kinds of support available to you if you need it? 
 (Circle one number on each line) 
 None of 
the time 
A little of 
the time 
Some of 
the time 
Most of 
the time 
All of 
the time 
 
2. Someone to help you if you were 
confined to bed 
 
1 
 
2 
 
3 
 
4 
 
5 
 
3. Someone you can count on to 
listen to you when you  
 need to talk 
1 2 3 4 5 
 
4. Someone to give you good 
advice about a crisis 
1 2 3 4 5 
 
5. Someone to take you to the 
doctor if you needed it 
1 2 3 4 5 
 
6. Someone who shows you love 
and affection 
1 2 3 4 5 
 
7. Someone to have a good time 
with 
1 2 3 4 5 
 
8. Someone to give you 
information to help you  
 understand a situation 
1 2 3 4 5 
9. Someone to confide in or talk to 
about yourself or your  
 problems 
1 2 3 4 5 
10. Someone who hugs you 1 2 3 4 5 
 
11. Someone to get together with 
for relaxation 
1 2 3 4 5 
 
12. Someone to prepare your meals 
if you were unable to do it 
yourself 
1 2 3 4 5 
13. Someone whose advice you 
really want 
1 2 3 4 5 
 
14. Someone to do things with to 
help you get your mind  off 
things 
1 2 3 4 5 
15. Someone to help with daily 
chores if you were sick 
1 2 3 4 5 
 
16. Someone to share your most 
private worries and fears   with 
1 2 3 4 5 
17. Someone to turn to for 
suggestions about how to deal  
with a personal problem 
1 2 3 4 5 
18. Someone to do something 
enjoyable with 
1 2 3 4 5 
 
19. Someone who understands your 
problems 
1 2 3 4 5 
 
20. Someone to love and make you 
feel wanted 
1 2 3 4 5 
 
Sherbourne C, Stewart A. 1991 The MOS Social Support Survey. Social Science 
and Medicine, 32:705-14
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Appendix 7  
Approval from the Human Research Ethics Committees (Royal Brisbane and 
Women’s Hospital) 
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Appendix 8  
Approval from the University Human Research Ethics Committees 
(Queensland University of Technology)  
From: QUT Research Ethics Unit <ethicscontact@qut.edu.au> 
Date: Tue, 30 Nov 2010 10:02:27 +1000 
Subject: Ethics Application Approval -- 1000001178 
Dear Mr Ray Chan 
 
Project Title: 
Self-management associated with fatigue in patients with advanced cancer 
 
Approval Number:     1000001178 
Clearance Until:        1/06/2012 
Ethics Category:        Human 
 
 This email is to advise that your application has been reviewed by the 
Chair, University Human Research Ethics Committee and confirmed as meeting the 
requirements of the National Statement on Ethical Conduct in Human Research. We 
note ethics clearance has already been obtained from another institution. 
 Whilst the data collection of your project has received ethical 
clearance, the decision to commence and authority to commence may be dependent 
on factors beyond the remit of the ethics review process. For example, your research 
may need ethics clearance from other organisations or permissions from other 
organisations to access staff. Therefore the proposed data collection should not 
commence until you have satisfied these requirements. 
 If you require a formal approval certificate, please respond via reply 
email and one will be issued. 
 This project has been awarded ethical clearance until 1/06/2012 and a 
progress report must be submitted for an active ethical clearance at least once every 
twelve months. Researchers who fail to submit an appropriate progress report may 
have their ethical clearance revoked and/or the ethical clearances of other projects 
suspended. When your project has been completed please advise us by email at your 
earliest convenience. 
 For variations, please ensure that approval has been sought from the 
lead university before completing and submit the QUT online variation form:     
http://www.research.qut.edu.au/ethics/forms/hum/var/variation.jsp 
 
Please do not hesitate to contact the unit if you have any queries. 
 
Regards 
 
Janette Lamb on behalf of the Chair UHREC 
Research Ethics Unit   |   Office of Research 
Level 4   |   88 Musk Avenue   |   Kelvin Grove 
p: +61 7 3138 5123 
e: ethicscontact@qut.edu.au 
w: http://www.research.qut.edu.au/ethics/ 
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Appendix 9  
Patient information and consent forms (Stage 1- Part A) 
 
 
 
INFORMATION FOR PARTICIPANTS (Stage 1- Part A) 
 
Project Title:  Self-management associated with fatigue in patients with cancer 
Purpose of the research project 
This research is conducted as part of a higher degree program by a researcher who is 
a postgraduate student. Many patients with cancer experience fatigue for a number of 
reasons related to their cancer diagnosis and treatment. The experience of fatigue can 
be debilitating and can impair quality of life. Patients with cancer may use a range of 
strategies to manage their fatigue. This research project aims to gain an 
understanding of the strategies patients undertake to manage their fatigue. The results 
of this project could help identify the factors that affect patients’ fatigue management 
strategies, and to design support programs that might help patients with cancer to 
manage their fatigue. For the aims of this stage of the study, a total of 10 patients will 
be involved. 
 
Your involvement 
Your participation in this project will involve participating in an interview 
conducted by the researcher. During the interview, you will be asked questions 
about what you do to manage your fatigue and what helps you cope when you 
are fatigued. The interview will last for about 10-15 minutes and will be audio-
recorded. This interview will take place in the oncology clinic area, or at your 
bedside if you are an inpatient. Before the interview begins, the researcher will 
ensure privacy and ensure that you are comfortable with the venue. 
 
Benefits 
Participation in this study will result in no direct benefits for you. However, it is 
expected that this research project has the potential to help future patients with 
cancer to manage their fatigue. 
 
 
Risks 
Some patients may experience emotional distress when discussing their experiences of 
having cancer. The interviewer will observe you carefully for signs of emotional distress. 
The interviewer will stop the interview if needed and with your permission, advise your 
health care team if you require any support. 
 
Participation 
Participation in the project is voluntary and you may elect not to participate or to withdraw at 
any time without comment, penalty or loss of benefits. A decision not to participate, or to 
withdraw, will have no impact upon your present or future care in any way.  
 
Confidentiality of information 
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This study will involve access to your medical records to obtain information on demographic 
and medical details. Only the members of the research team will have access to information 
provided by participants. The audio file will be transferred to a CD. Subsequently, all 
interview data will be transcribed. We will replace your names with pseudonyms during the 
transcription. All information will be coded and kept in a locked filing cabinet within the 
Cancer Care Services, Royal Brisbane and Women’s Hospital for 7 years. After 7 years, all 
archived materials will be destroyed in a secure manner. No identifying names or 
information will be included in any transcripts, research reports or publications. 
 
Questions or concerns 
This study has been reviewed and approved by the Royal Brisbane & Women’s Hospital 
Human Research Ethics Committee. Should you wish to discuss the study in relation to your 
rights as a participant, or should you wish to make an independent complaint, you may 
contact the Coordinator or Chairperson, Human Research Ethics Committee, Royal Brisbane 
& Women’s Hospital, Herston, Qld, 4029 or telephone (07) 3636 5490, email: 
RBWH_Ethics@health.qld.gov.au. 
 
You may request feedback from the study by contacting the Chief Investigators, whose 
contact numbers are below. 
 
Thank you for considering participation in this study, your involvement is appreciated. 
 
Regards, 
Mr Raymond Chan 
 
CHIEF INVESTIGATORS 
Mr Raymond Chan 
Doctor of Philosophy Candidate, School of Nursing and Midwifery, Queensland University of 
Technology, Kelvin Grove 4059 
Nurse Researcher, Cancer Care Services, Royal Brisbane and Women’s Hospital 
Phone: 3636 5833/ 0419653831 
Email: Raymond_chan@health.qld.gov.au 
 
Professor Patsy Yates 
School of Nursing and Midwifery, Queensland University of Technology  
Phone:  3138 3835 
Email: p.yates@qut.edu.au 
 
Dr Alexandra McCarthy 
School of Nursing and Midwifery, Queensland University of Technology 
Phone: 3138 3850 
Email: al.mccarthy@qut.edu.au 
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CONSENT FORM 
 
Chief Investigator: 
Mr Raymond Chan 
Doctor of Philosophy Candidate 
School of Nursing and Midwifery, Queensland University of Technology, Kelvin Grove 
Phone  3636 5833/ 0419653831 
Email:  Raymond_chan@health.qld.gov.au 
 
 
 
 
 
Participant’s Name:  ________________________________________ 
 
I have 
Read and understood the information package; 
Had any questions or queries answered to my satisfaction; 
Been informed of the possible risks associated with the interview being conducted; 
Understood that the project is for the purpose of research and not for treatment; 
Been informed that the confidentiality of the information will be maintained and 
safeguarded; 
Given permission for access to my medical records, for the purpose of this research; 
Given permission for medical practitioners, other health professionals, hospitals or 
laboratories outside this hospital, to release information concerning my disease and treatment 
which is needed for this trial and understand that such information will remain confidential; 
Been assured that I am free to withdraw at any time without comment or penalty; and 
Agreed to participate in the project. 
 
 
Signatures: ................................................................................................... 
Participant Date 
................................................................................................... 
Witness (if applicable) Date 
 
 
 
 
 
 
 
 
Project Title:   
Self-management associated with fatigue in patients with cancer 
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Appendix 10  
Patient information and consent forms (Stage 1- Part B) 
 
 
 
INFORMATION FOR PARTICIPANTS (Stage 1- Part B) 
 
Project Title:  Self-management associated with fatigue in patients with 
cancer 
 
 
Purpose of the research project 
This research is conducted as part of a higher degree program by a 
researcher who is a postgraduate student. Many patients with cancer 
experience fatigue for a number of reasons related to their cancer diagnosis 
and treatment. The experience of fatigue can be debilitating and can impair 
quality of life. Patients with cancer may use a range of strategies to manage 
their fatigue. This research project aims to gain an understanding of the 
strategies patients undertake to manage their fatigue. The results of this 
project could help identify the factors that affect patients’ fatigue 
management strategies, and to design support programs that might help 
patients with cancer to manage their fatigue. For the aims of this stage of the 
study, a total of 10 patients will be involved.  
Your involvement 
Your participation in this project will involve participating in a survey 
conducted by the researcher. During the survey, you will be asked questions 
about “what you did to manage your fatigue over the past 7 days”, “how often 
you did them”, “how effective you think they were”, and “how confident you 
were in doing them”. It is expected that the interview will last for about 10-20 
minutes. This survey will take place in the oncology clinic, or at your bedside if 
you are an inpatient. Before the interview begins, the researcher will ensure 
privacy and ensure that you are comfortable with the venue. After 7 days, you 
will be contacted over the telephone to repeat this survey. The questions of this 
telephone survey will be the same as the first interview. In this telephone survey, 
you will also be asked some questions on whether the questions are clear and 
easy to answer. 
 
Benefits 
Participation in this study will result in no direct benefits for you. However, it is 
expected that this research project has the potential to help future patients with 
cancer to manage their fatigue. 
  
Risks 
Some patients may experience emotional distress when discussing their 
experiences of having cancer. If you do have any emotional distress during 
the survey, please notify the interviewer. The interviewer will stop the survey, 
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or reschedule the survey if needed and with your permission, advise your 
health care team if you require any support. 
 
 
Participation 
Participation in the project is voluntary and you may elect not to participate or 
to withdraw at any time without comment, penalty or loss of benefits. A 
decision not to participate, or to withdraw, will have no impact upon your 
present or future care in any way.  
 
Confidentiality of information 
This study will involve access to your medical records to obtain information 
on demographic and medical details. Only the members of the research team 
will have access to information provided by participants. All information will 
be coded and kept in a locked filing cabinet within the Cancer Care Services, 
Royal Brisbane and Women’s Hospital for 7 years. After 7 years, all archived 
materials will be destroyed in a secure manner. No identifying names or 
information will be included in any transcripts, research reports or 
publications. 
 
Questions or concerns 
This study has been reviewed and approved by the Royal Brisbane & 
Women’s Hospital Human Research Ethics Committee. Should you wish to 
discuss the study in relation to your rights as a participant, or should you wish 
to make an independent complaint, you may contact the Coordinator or 
Chairperson, Human Research Ethics Committee, Royal Brisbane & 
Women’s Hospital, Herston, Qld, 4029 or telephone (07) 3636 5490, email: 
RBWH_Ethics@health.qld.gov.au. You may request feedback from the study 
by contacting the Chief Investigators, whose contact numbers are below. 
 
Thank you for considering participation in this study, your involvement is 
appreciated. 
 
Regards, 
Mr Raymond Chan 
 
CHIEF INVESTIGATORS 
Mr Raymond Chan 
Doctor of Philosophy Candidate, School of Nursing and Midwifery, Queensland University of 
Technology, Kelvin Grove 4059  
Nurse Researcher, Cancer Care Services, Royal Brisbane and Women’s Hospital 
Phone: 3636 5833/ 0419653831 
Email: Raymond_chan@health.qld.gov.au 
 
Professor Patsy Yates 
School of Nursing and Midwifery, Queensland University of Technology  
Phone:  3138 3835 
Email: p.yates@qut.edu.au 
 
Dr Alexandra McCarthy 
School of Nursing and Midwifery, Queensland University of Technology 
Phone: 3138 3850 
Email: al.mccarthy@qut.edu.au 
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CONSENT FORM 
 
Chief Investigator: 
Mr Raymond Chan 
Doctor of Philosophy Candidate 
School of Nursing and Midwifery, Queensland University of Technology, Kelvin Grove 
Phone  3636 5833/ 0419653831 
Email:  Raymond_chan@health.qld.gov.au 
 
 
 
 
 
Participant’s Name:  ________________________________________ 
 
I have 
Read and understood the information package; 
Had any questions or queries answered to my satisfaction; 
Been informed of the possible risks associated with the interviews being conducted; 
Understood that the project is for the purpose of research and not for treatment; 
Been informed that the confidentiality of the information will be maintained and 
safeguarded; 
Given permission for access to my medical records, for the purpose of this research; 
Given permission for medical practitioners, other health professionals, hospitals or 
laboratories outside this hospital, to release information concerning my disease and treatment 
which is needed for this trial and understand that such information will remain confidential; 
Been assured that I am free to withdraw at any time without comment or penalty; and 
Agreed to participate in the project. 
 
Signatures: ................................................................................................... 
Participant Date 
................................................................................................... 
Witness (if applicable) Date 
 
 
 
 
 
 
 
 
 
 
Project Title:   
Self-management associated with fatigue in patients with cancer 
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Appendix 11  
Patient information and consent forms (Stage 2) 
 
 
 
INFORMATION FOR PARTICIPANTS (Stage 2) 
 
Project Title: Self-management associated with fatigue in patients with 
cancer 
 
 
Purpose of the research project 
This research is conducted as part of a higher degree program by a 
researcher who is a postgraduate student. Many patients with cancer 
experience fatigue for a number of reasons related to their cancer diagnosis 
and treatment. The experience of fatigue can be debilitating and can impair 
quality of life. Patients with cancer may use a range of strategies to manage 
their fatigue. This research project aims to gain an understanding of the 
strategies patients undertake to manage their fatigue and some of the factors 
that may influence the way they manage their fatigue. The results of this 
project could help identify the factors that affect patients’ fatigue 
management strategies, and to design support programs that might help 
patients with cancer to manage their fatigue. For the aims of this stage of the 
study, a total of 200 patients will be involved.  
 
Your involvement 
Your participation in this project will involve participating in a survey 
conducted by the researcher. During the survey interview, you will be asked 
questions about a) the strategies that you undertake to manage fatigue; b) a 
number of factors that could affect the frequency with which you perform these 
strategies; and c) the effectiveness of these strategies. It is expected that the 
interview will last for about 30 minutes. This survey will take place in the 
oncology clinic, or at your bedside if you are an inpatient. Before the interview 
begins, the researcher will ensure privacy and ensure that you are comfortable 
with the venue. You will be contacted over the telephone to repeat this survey 
after 4 weeks and 8 weeks. Each telephone interview is expected to take 
approximately 15-20 minutes. The timing of these telephone interviews can be 
flexible and conducted at a time convenient to you. 
 
Benefits 
Participation in this study will result in no direct benefits for you. However, it is 
expected that this research project has the potential to help future patients with 
cancer to manage their fatigue. 
 
Risks 
Some patients may experience emotional distress when discussing their 
experiences of having cancer. If you have any emotional distress during the survey, 
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please notify the interviewer. The interviewer will stop the survey, or reschedule the 
survey if needed and with your permission, advise your health care team if you 
require any support. 
 
 
Participation 
Participation in the project is voluntary and you may elect not to participate or to 
withdraw at any time without comment, penalty or loss of benefits. A decision not to 
participate, or to withdraw, will have no impact upon your present or future care in 
any way.  
 
Confidentiality of information 
This study will involve access to your medical records to obtain information on 
demographic and medical details. Only the members of the research team will have 
access to information provided by participants. All information will be coded and kept 
in a locked filing cabinet within the Cancer Care Services, Royal Brisbane and 
Women’s Hospital for 7 years. After 7 years, all archived materials will be destroyed 
in a secure manner. No identifying names or information will be included in any 
transcripts, research reports or publications. 
 
Questions or concerns 
This study has been reviewed and approved by the Royal Brisbane & Women’s 
Hospital Human Research Ethics Committee. Should you wish to discuss the study 
in relation to your rights as a participant, or should you wish to make an independent 
complaint, you may contact the Coordinator or Chairperson, Human Research 
Ethics Committee, Royal Brisbane & Women’s Hospital, Herston, Qld, 4029 or 
telephone (07) 3636 5490, email: RBWH_Ethics@health.qld.gov.au. You may 
request feedback from the study by contacting the Chief Investigators, whose 
contact numbers are below. 
 
Thank you for considering participation in this study, your involvement is 
appreciated. 
 
Regards, 
 
Mr Raymond Chan 
 
 
CHIEF INVESTIGATORS 
Mr Raymond Chan 
Doctor of Philosophy Candidate, School of Nursing and Midwifery, Queensland University of 
Technology, Kelvin Grove 4059  
Nurse Researcher, Cancer Care Services, Royal Brisbane and Women’s Hospital 
Phone: 3636 5833/ 0419653831 
Email: Raymond_chan@health.qld.gov.au 
 
Professor Patsy Yates 
School of Nursing and Midwifery, Queensland University of Technology  
Phone:  3138 3835 
Email: p.yates@qut.edu.au 
 
Dr Alexandra McCarthy 
School of Nursing and Midwifery, Queensland University of Technology 
Phone: 3138 3850 
Email: al.mccarthy@qut.edu.au 
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CONSENT FORM 
 
Chief Investigator: 
Mr Raymond Chan 
Doctor of Philosophy Candidate 
School of Nursing and Midwifery, Queensland University of Technology, Kelvin Grove 
Phone  3636 5833/ 0419653831 
Email:  Raymond_chan@health.qld.gov.au 
 
 
 
 
 
Participant’s Name:  ________________________________________ 
 
I have 
 Read and understood the information package 
 Had any questions or queries answered to my satisfaction 
 Been informed of the possible risks associated with the interviews being 
conducted 
 Understood that the project is for the purpose of research and not for 
treatment 
 Been informed that the confidentiality of the information will be maintained 
and safeguarded 
 Given permission for access to my medical records, for the purpose of this 
research 
 Given permission for medical practitioners, other health professionals, 
hospitals or laboratories outside this hospital, to release information 
concerning my disease and treatment which is needed for this trial and 
understand that such information will remain confidential 
 Been assured that I am free to withdraw at any time without comment or 
penalty; and 
 Agreed to participate in the project. 
 
Signatures: ................................................................................................... 
Participant Date 
................................................................................................... 
Witness (if applicable) Date 
 
Project Title:   
Self-management associated with fatigue in patients with cancer 
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Appendix 12  
Self-efficacy in Managing Symptoms scale- Fatigue subscale for Patients in 
Advanced Cancer” for Expert Panellists Review 
 
 
22th March 2011 
Dear ________________, 
 
 
Thank you for agreeing to be on this expert panel. The “Self-efficacy in Managing Symptoms scale- 
Fatigue subscale for Patients with Advanced Cancer” (SMSFS-A) has been developed to : 
1. examine the frequency of use of self-management behaviours associated with fatigue in 
patients with advanced cancer, 
2. assess the levels of effectiveness associated with these behaviours, and  
3. assess the levels of self-efficacy associated with these behaviours. 
 
The SMSFS-A is designed for interviewer-administration. Twenty-two behavioural tasks were 
identified from analysis of data from semi-structured interviews with ten patients, and themes 
identified from research, a review of literature and evidence-based guidelines.  
For each behaviour, patients are asked to rate the following dimensions: 
Frequency of use of the behaviours: 0= not used, 4= all the time  
Levels of effectiveness: 1= not relieved at all, 10= relieved completely  
Levels of self-efficacy: 1= not confident at all, 10= extremely confident  
 
In this package, you will find the initial version of the SMSFS-A (page 2-4), and an evaluation form 
with instructions (page 5-9). If an item does not have an 80% agreement among panellists, comments 
about the item will be reviewed for item revision. Those items that are revised will be sent to you after 
review.  
 
 
Could you please advise if it is possible for you to return all materials to me by e-mail within 14 days? 
I seek your permission to list your name in the acknowledgement section of my thesis; however any 
reporting of specific data will not identify you by name. Thank you in advance for your assistance in 
evaluating this instrument. If you have further questions, please do not hesitate to contact me via email 
(r6.chan@student.qut.edu.au) or by phone (614-19653831). 
 
 
Yours Sincerely, 
 
Raymond Chan 
PhD Candidate, School of Nursing and Midwifery, 
Queensland University of Technology 
E-mail: r6.chan@student.qut.edu.au 
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School of Nursing and Midwifery 
Queensland University of Technology 
 
Self-efficacy in Managing Symptoms scale-  
Fatigue subscale for Patients in Advanced Cancer 
(SMSFS-A) 
Instructions: 
There are two parts to this review. 
 
 
Part I 
The items listed in the instrument have been selected for inclusion in the SMSFS-
A. The items will be rated by patients based on the Likert type format: 
Frequency of use of the behaviours: 0= not used, 4= all the time  
Levels of effectiveness: 1= not relieved at all, 10= relieved completely  
Levels of self-efficacy: 1= not confident at all, 10= extremely confident  
 
Please review and rate the items and the selected responses listed below for their 
relevance and clarity in assessing the SMSFS-A, using the following scale: 
 
4= completely applicable 
3= applicable but needs minor alteration 
2= unable to assess application without item revision 
1= not applicable 
 
4= very clear 
3= clear 
2= unclear 
1= very unclear 
 
Please provide any recommendations for item revision in the space provided under 
each item. 
 
 
Part II 
There are two additional questions in this section for this review, please provide 
your recommendations after each question. 
 
Thank you. 
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Part I: Frequency of use of behaviours:  
Question: How often have you used this strategy over the past 7 days?
( 0- not used, 1- occasionally, 2- often, 3- very often, 4- all the time)
 
Item 
 
 
 
 
 
 
Relevance of item Clarity of item 
C
om
pletely 
applicable 
A
pplicable but 
needs m
inor 
alteration 
U
nable to assess 
application 
w
ithout item
 
N
ot applicable 
V
ery clear 
C
lear 
U
nclear 
V
ery unclear 
1. Naps 4 3 2 1 4 3 2 1 
Suggestions: 
2. Resting 4 3 2 1 4 3 2 1 
Suggestions: 
3. Aerobic exercise (e.g. 
walking, jogging) 
4 3 2 1 4 3 2 1 
Suggestions: 
4. Stretching/ flexibility exercise 
(e.g. stretching, yoga) 
4 3 2 1 4 3 2 1 
Suggestions: 
5. Strength/ resistance exercise 
(e.g. weights, chest press, leg 
press) 
4 3 2 1 4 3 2 1 
Suggestions: 
6. Delegating tasks 4 3 2 1 4 3 2 1 
Suggestions: 
7. Pacing yourself 4 3 2 1 4 3 2 1 
Suggestions: 
8. Taking prescribed 
medications that reduce 
fatigue 
4 3 2 1 4 3 2 1 
Suggestions: 
9. Taking non-prescribed 
medications that reduce 
fatigue 
4 3 2 1 4 3 2 1 
Suggestions: 
10. Reducing/ stopping 
medications that cause fatigue 
4 3 2 1 4 3 2 1 
Suggestions: 
11. Using complementary and 
alternative therapies (e.g. 
acupuncture, aromatherapy, 
massage, reflexology) 
4 3 2 1 4 3 2 1 
Suggestions: 
12. Doing relaxing things (e.g. 
music, watching tv, reading, 
hobbies, and socialising) 
4 3 2 1 4 3 2 1 
Suggestions: 
13. Doing things that distract 
yourself from fatigue 
4 3 2 1 4 3 2 1 
Suggestions: 
14. Planning your activities 4 3 2 1 4 3 2 1 
Suggestions: 
15. Eating meat or legumes 4 3 2 1 4 3 2 1 
Suggestions: 
16. Eating dairy products 4 3 2 1 4 3 2 1 
Suggestions: 
17. Eating vegies or fruit 4 3 2 1 4 3 2 1 
Suggestions: 
18. Eating carbohydrates (e.g. 
bread, cereal, pasta, rice) 
4 3 2 1 4 3 2 1 
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Part I: Levels of effectiveness:  
Question: How much did this strategy relieve your fatigue over the past 7 days?  
(1= not relieved at all, 10= relieved completely) 
 
Suggestions: 
19. Drinking more water or fluid 4 3 2 1 4 3 2 1 
Suggestions: 
20. Drinking  beverages with 
caffeine 
4 3 2 1 4 3 2 1 
Suggestions:   
21. Drinking energy drinks 4 3 2 1 4 3 2 1 
Suggestions:         
22. Taking nutritional 
supplements (e.g. drinking 
high protein/ vitamin drinks) 
4 3 2 1 4 3 2 1 
Suggestions: 
Item 
 
 
 
 
 
 
Relevance of item Clarity of item
C
om
pletely 
applicable 
A
pplicable but 
needs m
inor 
alteration
U
nable to assess 
application 
w
ithout item
 
N
ot applicable 
V
ery clear 
C
lear 
U
nclear 
V
ery unclear 
1. Naps 4 3 2 1 4 3 2 1 
Suggestions: 
2. Resting 4 3 2 1 4 3 2 1 
Suggestions: 
3. Aerobic exercise (e.g. 
walking, jogging) 
4 3 2 1 4 3 2 1 
Suggestions: 
4. Stretching/ flexibility exercise 
(e.g. stretching, yoga) 
4 3 2 1 4 3 2 1 
Suggestions: 
5. Strength/ resistance exercise 
(e.g. weights, chest press, leg 
press) 
4 3 2 1 4 3 2 1 
Suggestions: 
6. Delegating tasks 4 3 2 1 4 3 2 1 
Suggestions: 
7. Pacing yourself 4 3 2 1 4 3 2 1 
Suggestions: 
8. Taking prescribed 
medications that reduce 
fatigue 
4 3 2 1 4 3 2 1 
Suggestions: 
9. Taking non-prescribed 
medications that reduce 
fatigue 
4 3 2 1 4 3 2 1 
Suggestions: 
10. Reducing/ stopping 
medications that cause fatigue 
4 3 2 1 4 3 2 1 
Suggestions: 
11. Using complementary and 
alternative therapies (e.g. 
acupuncture, aromatherapy, 
massage, reflexology) 
4 3 2 1 4 3 2 1 
Suggestions: 
12. Doing relaxing things (e.g. 
music, watching tv, reading, 
hobbies, and socialising) 
4 3 2 1 4 3 2 1 
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Part I: Levels of self-efficacy  
Question: How confident do you feel about using this strategy? 
(1 = not confident at all, 10 = extremely confident)
 
Suggestions: 
13. Doing things that distract 
yourself from fatigue 
4 3 2 1 4 3 2 1 
Suggestions: 
14. Planning your activities 4 3 2 1 4 3 2 1 
Suggestions: 
15. Eating meat or legumes 4 3 2 1 4 3 2 1 
Suggestions: 
16. Eating dairy products 4 3 2 1 4 3 2 1 
Suggestions: 
17. Eating vegies or fruit 4 3 2 1 4 3 2 1 
Suggestions: 
18. Eating carbohydrates (e.g. 
bread, cereal, pasta, rice) 
4 3 2 1 4 3 2 1 
Suggestions: 
19. Drinking more water or fluid 4 3 2 1 4 3 2 1 
Suggestions: 
20. Drinking beverages with 
caffeine 
4 3 2 1 4 3 2 1 
Suggestions:   
21. Drinking energy drinks 4 3 2 1 4 3 2 1 
Suggestions:         
22. Taking nutritional 
supplements (e.g. drinking 
high protein/ vitamin drinks) 
4 3 2 1 4 3 2 1 
Suggestions: 
Item 
 
 
 
 
 
 
Relevance of item Clarity of item 
C
om
pletely 
applicable 
A
pplicable but 
needs m
inor 
alteration
U
nable to assess 
application 
w
ithout item
 
N
ot applicable 
V
ery clear 
C
lear 
U
nclear 
V
ery unclear 
1. Naps 4 3 2 1 4 3 2 1 
Suggestions: 
2. Resting 4 3 2 1 4 3 2 1 
Suggestions: 
3. Aerobic exercise (e.g. 
walking, jogging) 
4 3 2 1 4 3 2 1 
Suggestions: 
4. Stretching/ flexibility exercise 
(e.g. stretching, yoga) 
4 3 2 1 4 3 2 1 
Suggestions: 
5. Strength/ resistance exercise 
(e.g. weights, chest press, leg 
press) 
4 3 2 1 4 3 2 1 
Suggestions: 
6. Delegating tasks 4 3 2 1 4 3 2 1 
Suggestions: 
7. Pacing yourself 4 3 2 1 4 3 2 1 
Suggestions: 
8. Taking prescribed 
medications that reduce 
fatigue 
4 3 2 1 4 3 2 1 
Suggestions: 
9. Taking non-prescribed 4 3 2 1 4 3 2 1 
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Part I: Overall questions 
 
medications that reduce 
fatigue 
Suggestions: 
10. Reducing/ stopping 
medications that cause fatigue 
4 3 2 1 4 3 2 1 
Suggestions: 
11. Using complementary and 
alternative therapies (e.g. 
acupuncture, aromatherapy, 
massage, reflexology) 
4 3 2 1 4 3 2 1 
Suggestions: 
12. Doing relaxing things (e.g. 
music, watching tv, reading, 
hobbies, and socialising) 
4 3 2 1 4 3 2 1 
Suggestions: 
13. Doing things that distract 
yourself from fatigue 
4 3 2 1 4 3 2 1 
Suggestions: 
14. Planning your activities 4 3 2 1 4 3 2 1 
Suggestions: 
15. Eating meat or legumes 4 3 2 1 4 3 2 1 
Suggestions: 
16. Eating dairy products 4 3 2 1 4 3 2 1 
Suggestions: 
17. Eating vegies or fruit 4 3 2 1 4 3 2 1 
Suggestions: 
18. Eating carbohydrates (e.g. 
bread, cereal, pasta, rice) 
4 3 2 1 4 3 2 1 
Suggestions: 
19. Drinking more water or fluid 4 3 2 1 4 3 2 1 
Suggestions: 
20. Drinking beverages with 
caffeine 
4 3 2 1 4 3 2 1 
Suggestions:   
21. Drinking energy drinks 4 3 2 1 4 3 2 1 
Suggestions:         
22. Taking nutritional 
supplements (e.g. drinking 
high protein/ vitamin drinks) 
4 3 2 1 4 3 2 1 
Suggestions: 
Item 
 
 
 
 
 
 
Relevance of item Clarity of item
C
om
pletely 
applicable 
A
pplicable but 
needs m
inor 
alteration 
U
nable to assess 
application 
w
ithout item
 
i
i
N
ot applicable 
V
ery clear 
C
lear 
U
nclear 
V
ery unclear 
1. Over the past 7 days, how 
would you rate your 
effectiveness in relieving your 
fatigue?
4 3 2 1 4 3 2 1 
Suggestions: 
2. Over the past 7 days, how 
would you rate your 
confidence in managing your 
fatigue?
4 3 2 1 4 3 2 1 
Suggestions: 
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Part II- Evaluation of Scale Items of the SMSFS-A
 
1. Would you add any item? Please specific below. 
 
 
 
 
2. Do you think that any patients with cancer who is experiencing fatigue could 
answer these items? 
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Appendix 13  
Self-efficacy in Managing Symptoms scale- Fatigue subscale for Patients in 
Advanced Cancer” (SMSFS-A) for the second round of expert panel review 
documents 
 
20th May 2011 
 
Dear Expert Panellist, 
 
Thank you for your valuable review and comment on The “Self-efficacy in Managing 
Symptoms scale- Fatigue subscale for Patients with Advanced Cancer” (SMSFS-A). I have 
reviewed your comments and made appropriate modifications to the instrument. As a 
number of items have been modified on the basis of your feedback, I would like to invite you 
to provide comment on the revised instrument if you are able to at this time.  
Three major modifications have been made to the instrument on the basis of your feedback: 
1. Clarified definition of self-management behaviours:  
a. For the purpose of this study, self-management behaviours will be 
considered to be any behaviour ‘self-initiated’ by the patient to manage 
the symptom As such, the behaviours included in the instrument may 
not necessarily be evidence-based, but rather may include those actions 
that patients themselves may spontaneously implement 
b. For the purpose of this study, self-management behaviours will exclude 
actions associated with taking medication 
2. Improved clarity of items that related to more general behaviours, by providing 
exemplars.  
3. The rating scales have been modified to include a “0”.  
 
For the purpose of this second expert panel review, you will only be required to rate the 
clarity and relevance of the xx revised items once. It is expected to take 10 minutes if your 
time.  
 
Could you please advise if it is possible for you to return all materials to me by e-mail within 
10 days? I would like to thank you in advance for your assistance in evaluating this 
instrument once again. If you have further questions, please do not hesitate to contact me via 
email (email.rchan@gmail.com) or by phone (614-19653831). 
 
 
Yours Sincerely, 
 
Raymond Chan 
PhD Candidate, School of Nursing and Midwifery, 
Queensland University of Technology 
E-mail: email.rchan@gmail.com 
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School of Nursing and Midwifery 
Queensland University of Technology 
 
Self-efficacy in Managing Symptoms scale-  
Fatigue subscale for Patients in Advanced Cancer 
(SMSFS-A) 
Second Expert Panel Review 
 
Instructions: 
There are two parts to this review. 
 
Part I 
The items listed in the instrument have been selected for inclusion in the SMSFS-A. The 
items will be rated by patients based on the Likert type format: 
Frequency of use of the behaviours: 0= not used, 4= all the time  
Levels of effectiveness: 0= not relieved at all, 10= relieved completely  
Levels of self-efficacy: 0= not confident at all, 10= extremely confident  
 
 
Please review and rate the items and the selected responses listed below for their relevance 
and clarity in assessing the SMSFS-A, using the following scale: 
 
4= completely applicable 
3= applicable but needs minor alteration 
2= unable to assess application without item revision 
1= not applicable 
 
4= very clear 
3= clear 
2= unclear 
1= very unclear 
 
Please provide any recommendations for item revision in the space provided under each 
item. 
 
Part II 
There are two additional questions in this section for this review, please provide your 
recommendations after each question. 
 
 
*The full instrument is provided on page 5-7. 
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Thank you. 
Ray 
 
 
Item 
 
 
 
 
 
 
Relevance of item Clarity of item
C
om
pletely 
applicable 
A
pplicable but 
needs m
inor 
alteration
U
nable to assess 
application 
w
ithout item
 
N
ot applicable 
V
ery clear 
C
lear 
U
nclear 
V
ery unclear 
1. Take short sleeps during the 
day 
4 3 2 1 4 3 2 1 
Suggestions: 
 
2. Rest during the day (without 
falling asleep) 
4 3 2 1 4 3 2 1 
Suggestions: 
 
3. Do aerobic exercise (e.g. 
walking/ stair climbing/ 
swimming) 
4 3 2 1 4 3 2 1 
Suggestions: 
 
4. Do stretching/ flexibility 
exercises (e.g. stretching/ 
yoga/pilates) 
4 3 2 1 4 3 2 1 
Suggestions: 
 
5. Do strength/ resistance 
exercises (e.g. weights/ chest 
press/leg press) 
4 3 2 1 4 3 2 1 
Suggestions: 
 
6. Delegate tasks 4 3 2 1 4 3 2 1 
Suggestions: 
 
7. Pace your day to day activities 
over time 
4 3 2 1 4 3 2 1 
Suggestions: 
 
8. Do things to improve your sleep 
at night (e.g. reduce noise and 
light; avoid caffeine before bed) 
4 3 2 1 4 3 2 1 
Suggestions: 
 
9. Use complementary or 
alternative therapies (e.g. 
acupuncture/ 
aromatherapy/massage/ 
reflexology) 
4 3 2 1 4 3 2 1 
Suggestions: 
 
10. Do things that distract you from 
fatigue (e.g. hobbies/ 
socialising) 
4 3 2 1 4 3 2 1 
Suggestions: 
 
11. Plan your activities to make the 
most of your energy levels 
through the day 
4 3 2 1 4 3 2 1 
Suggestions: 
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Part 
II- 
Evalu
ation 
of 
Scale 
Items 
of the 
modif
ied-
SMS
FS-A 
 
3. 
 
12. Do relaxing things (e.g. listen to 
music and reading) 
4 3 2 1 4 3 2 1 
Suggestions: 
 
13. Talk to someone about your 
fears and concerns about 
fatigue 
4 3 2 1 4 3 2 1 
Suggestions: 
 
14. Eat a balanced diet (e.g. eat 
different food groups) 
4 3 2 1 4 3 2 1 
Suggestions: 
 
15. Drink more water or fluid than 
usual 
4 3 2 1 4 3 2 1 
Suggestions: 
 
16. Drink beverages with caffeine 
(e.g. coffee/tea/ coke/®Red-
Bull) 
4 3 2 1 4 3 2 1 
Suggestions:   
 
17. Drink nutritional supplements 
(e.g. high protein/ vitamin 
drinks) 
4 3 2 1 4 3 2 1 
Suggestions: 
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Appendix 14  
Agreement to participate on expert panel 
 
Hi Ray 
  
I will be pleased to do this.  
  
Regards 
  
Helen Skerman  
Ph:  +61 7 3138 6127 
Fax: +61 7 3138 6030 
Email: h.skerman@qut.edu.au 
 
Dear Helen,  
How are you? This is Ray here. I have mentioned to you briefly about 
inviting you to be on my expert panel. 
  
My dissertation focuses on “self-management behaviours associated with 
fatigue in patients with advanced cancer”. As part of my research 
study, I am developing a research instrument to understand: 
-          The frequency of self-management behaviours patients (with 
advanced cancer) undertake for fatigue 
-          The levels of perceived effectiveness associated with these 
behaviours 
-          The levels of self-efficacy associated with these behaviours 
  
I have developed the first draft of the instrument, as informed by a 
literature review and results of semi-structured interviews with 10 
patients with advanced cancer. I am currently seeking 5 experts to 
be part of my expert panel to assess the content validity of this 
instrument. 
  
If you agree to be part of the expert panel, please kindly let me know your 
agreement and your mailing address. I will then send you a formal 
invitation letter with the draft instrument for your comments. 
Participation should take no more than 20 minutes and your 
participation will be acknowledged in all reports. 
  
I am certain that your valuable advice and your assistance will be 
invaluable to my research. I look forward to hearing your 
favourable reply. 
  
Thank you, 
  
Kind Regards, 
Raymond Chan 
PhD Candidate 
School of Nursing and Midwifery 
Queensland University of Technology 
E-mail: r6.chan@student.qut.edu.au 
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Ray, 
  
Congratulations on the progress you are making on your doctoral research. I am 
pleased to serve as an expert in instrument development for your instrument.  
My mailing address is noted below, but I think sending via email will be faster 
for you to do as long as that will work for the validation process. 
  
Best regards, 
Lillie 
 *********************************************************** 
Lillie M. Shortridge-Baggett, EdD, RN, FAAN, FNAP 
Professor, Department of Graduate Studies 
Lienhard School of Nursing, Lienhard Hall 309 
College of Health Professions, Pace University 
 
 
Dear Lillie (If I may),  
How are you? My name is Raymond Chan. We have met last time when 
you visited Brisbane. I am one of the Nurse Researchers at the 
Royal Brisbane and Women's Hospital. 
I am currently undertaking my PhD studies under Professor Patsy Yates. 
My dissertation focuses on “self-management behaviours 
associated with fatigue in patients with advanced cancer”. As part 
of my research study, I am developing a research instrument to 
understand: 
-          The frequency of self-management behaviours patients (with 
advanced cancer) undertake for fatigue 
-          The levels of perceived effectiveness associated with these 
behaviours 
-          The levels of self-efficacy associated with these behaviours 
  
I have developed the first draft of the instrument, as informed by a 
literature review and results of semi-structured interviews with 10 
patients with advanced cancer. I am currently seeking 5 experts to 
be part of my expert panel to assess the content validity of this 
instrument. 
  
If you agree to be part of the expert panel, please kindly let me know your 
agreement and your mailing address. I will then send you a formal 
invitation letter with the draft instrument for your comments. 
Participation should take no more than 20 minutes and your 
participation will be acknowledged in all reports. 
  
I am certain that your valuable advice and your assistance will be 
invaluable to my research. I look forward to hearing your 
favourable reply. 
  
Thank you, 
 Kind Regards, 
Raymond Chan 
PhD Candidate 
School of Nursing and Midwifery Queensland University of Technology 
E-mail: r6.chan@student.qut.edu.au 
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Dear Raymond, 
  
I’d be delighted to help. 
  
BFP 
  
Barbara F. Piper, DNSc, RN, AOCN, FAAN 
Professor and Chair of Nursing Research 
Scottsdale Healthcare/University of Arizona 
10460 N. 92nd Street, Suite 206 
Scottsdale, AZ 85258 
Ph: 480-323-1243; Fax: 480-323-1739 
Cell: 480-414-3333; Email: bpiper@shc.org; bpiper@nursing.arizona.edu 
*Envision *Engage  *Innovate 
 
 
Dear Professor Piper, 
  
How are you? My name is Raymond Chan, I am currently undertaking my 
PhD studies under Professor Patsy Yates. My dissertation focuses 
on “self-management behaviours associated with fatigue in 
patients with advanced cancer”. As part of my research study, I am 
developing a research instrument to understand: 
-          The frequency of self-management behaviours patients (with 
advanced cancer) undertake for fatigue 
-          The levels of perceived effectiveness associated with these 
behaviours 
-          The levels of self-efficacy associated with these behaviours 
  
I have developed the first draft of the instrument, as informed by a 
literature review and results of semi-structured interviews with 10 
patients with advanced cancer. I am currently seeking 5 experts to 
be part of my expert panel to assess the content validity of this 
instrument. 
  
If you agree to be part of the expert panel, please kindly let me know your 
agreement and your mailing address. I will then send you a formal 
invitation letter with the draft instrument for your comments. 
Participation should take no more than 20 minutes and your 
participation will be acknowledged in all reports. 
  
I am certain that your valuable advice and your assistance will be 
invaluable to my research. I look forward to hearing your 
favourable reply. 
  
Thank you, 
  
Kind Regards, 
Raymond Chan 
PhD Candidate 
School of Nursing and Midwifery 
Queensland University of Technology 
E-mail: r6.chan@student.qut.edu.au 
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Dear Ray, i'd be delighted to help in any way. My address is Dept of Nursing and 
Supportive Care Research, Peter MacCallum Cancer Centre, St Andrew's 
Place, East Melbourne, Vic 3002 
Mei 
 
 
Dear Mei,  
How are you? This is Ray here, I am currently undertaking my PhD 
studies under Professor Patsy Yates. My dissertation focuses on 
“self-management behaviours associated with fatigue in patients 
with advanced cancer”. As part of my research study, I am 
developing a research instrument to understand: 
-          The frequency of self-management behaviours patients (with 
advanced cancer) undertake for fatigue 
-          The levels of perceived effectiveness associated with these 
behaviours 
-          The levels of self-efficacy associated with these behaviours 
  
I have developed the first draft of the instrument, as informed by a 
literature review and results of semi-structured interviews with 10 
patients with advanced cancer. I am currently seeking 5 experts 
to be part of my expert panel to assess the content validity of this 
instrument. 
  
If you agree to be part of the expert panel, please kindly let me know 
your agreement and your mailing address. I will then send you a 
formal invitation letter with the draft instrument for your 
comments. Participation should take no more than 20 minutes 
and your participation will be acknowledged in all reports. 
  
I am certain that your valuable advice and your assistance will be 
invaluable to my research. I look forward to hearing your 
favourable reply. 
  
Kind Regards, 
Raymond Chan 
PhD Candidate 
School of Nursing and Midwifery 
Queensland University of Technology 
E-mail: r6.chan@student.qut.edu.au 
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Appendix 15  
Self-efficacy in Managing Symptoms Scale- Fatigue Subscale for Patients with 
Advanced Cancer (SMSFS-A) 
 
 
 
School of Nursing and Midwifery 
Queensland University of Technology 
 
Self-efficacy in Managing Symptoms Scale-  
Fatigue Subscale for Patients with Advanced Cancer 
(SMSFS-A) 
 
 
 
For administration by health professionals/researchers 
only: 
(Please read the statement below to the participant before 
administering this survey) 
 
“The aim of this questionnaire is to understand what patients with cancer do to 
manage their tiredness.  
The questionnaire includes a list of things that patients with cancer may do.  
It does not mean that all behaviours are suitable for you.” 
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Appendix 16  
Self-efficacy in Managing Symptoms Scale- Fatigue Subscale for Patients with 
Advanced Cancer (SMSFS-A) 
 
 
 
School of Nursing and Midwifery 
Queensland University of Technology 
 
Self-efficacy in Managing Symptoms Scale-  
Fatigue Subscale for Patients with Advanced Cancer 
(SMSFS-A) 
 
 
 
For administration by health professionals/researchers 
only: 
(Please read the statement below to the participant before 
administering this survey) 
 
“The aim of this questionnaire is to understand what patients with cancer do to 
manage their tiredness.  
The questionnaire includes a list of things that patients with cancer may do.  
It does not mean that all behaviours are suitable for you.” 
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Appendix 17  
Interview Guide: Face Validity Assessment 
 
Interview Guide: Face Validity  Patient Code: __IIA_____________ 
 
Time taken to complete the interview (face to face): __________ min 
Time taken to complete the interview (via telephone): _____________ min 
 
Questions to be asked after the administration of the SMSFS-A 
A:  Other than the list of actions in the questionnaire, did you do any other things 
when you felt tiredness? 
 
 
 
B: Going through each item with the participant: 
1. Was it easy for you to understand the questions for this action? If not, why?  
Items Comments 
Take short sleeps during the day (fall asleep for less 
than 3 hours)  
Rest during the day (without falling asleep)  
Do aerobic exercise (e.g. walking/ stair climbing/ 
swimming)  
Do stretching/ flexibility exercises (e.g. stretching/ 
yoga/Pilates)  
Do strength/ resistance exercises (e.g. weights/ 
chest press/leg press)  
Delegate tasks to others  
Pace your activities throughout the day  
Do things to improve your sleep at night (e.g. 
reduce noise and light; avoid caffeine before bed)
 
Use complementary or alternative therapies (e.g. 
acupuncture/aromatherapy/massage/ reflexology) 
 
Do things that distract you from your fatigue (e.g. 
hobbies/ socialising) 
 
Plan your activities to make the most of your energy 
levels through the day 
 
Do relaxing things (e.g. music and reading)  
Talk to someone about your fears and concerns 
about fatigue 
 
Eat a balanced diet  
Drink beverages with caffeine (e.g. coffee/tea/ 
Coke/®Red-Bull) 
 
Drink nutritional supplements (e.g. high protein/ 
vitamin drinks) 
 
 
 
 
2. Was it easy for you to answer the questions for this action? If not, why? 
Items Comments 
Take short sleeps during the day (fall asleep for less 
than 3 hours)  
Rest during the day (without falling asleep)  
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Do aerobic exercise (e.g. walking/ stair climbing/ 
swimming)  
Do stretching/ flexibility exercises (e.g. stretching/ 
yoga/Pilates)  
Do strength/ resistance exercises (e.g. weights/ 
chest press/leg press)  
Delegate tasks to others  
Pace your activities throughout the day  
Do things to improve your sleep at night (e.g. 
reduce noise and light; avoid caffeine before bed)
 
Use complementary or alternative therapies (e.g. 
acupuncture/aromatherapy/massage/ reflexology) 
 
Do things that distract you from your fatigue (e.g. 
hobbies/ socialising) 
 
Plan your activities to make the most of your energy 
levels through the day 
 
Do relaxing things (e.g. music and reading)  
Talk to someone about your fears and concerns 
about fatigue 
 
Eat a balanced diet  
Drink beverages with caffeine (e.g. coffee/tea/ 
Coke/®Red-Bull) 
 
Drink nutritional supplements (e.g. high protein/ 
vitamin drinks) 
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Appendix 18  
Purchase of license to use the Hospital Anxiety and Depression Scale 
 
 
Tax Invoice / Receipt 
Thank you for your online purchase with ACER on: 
2010-08-14 15:16:46 
 
Invoice Details 
Payment reference number:622119 
Customer number:28747 
Invoice number:93871 
Provider reference:VUJR5D80157B 
Cardholder name: Raymond Chan 
Payment amount: AUD $362.81  
 
 
 
Merchant Details 
Name: Australian Council for Educational Research 
ACN:004 398 145 
ABN:19 004 398 145 
Contact: ACER Shop Sales <sales@acer.edu.au> 
Phone:+61 3 9277 5447 
 
 
 
Order Details 
Description Code Price per unit Quantity Total Price 
HADS Record Forms (100)100QCP$144.951$144.95 
HADS Complete Set (Manual and 100 Record 
Forms)990QCP$207.961$207.96 
Freight - Mail $9.90 
    Total:    AUD $362.81 
    (Includes GST of AUD $32.99) 
 
Version 4.3 - Copyright © 2004 - 2010 Australian Council for Educational 
Research 
 
-----------------Please consider the environment before you print ------------ 
 
 
 
 
 
 
 
 
 
 270  Appendices 
  
Appendix 19  
Authorisation to use the Brief Fatigue  
Inventory
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Appendix 20  
Fatigue self-management associated outcome: ‘Activities’   
Types of 
behaviours 
T1 (n=134) T2 (n=118) T3 (n=118) 
Activities Number/ 
Percentage 
of people 
using 
Frequencya Levels of 
effectivenessb 
Levels of 
confidenceb 
Number/ 
Percentage 
of people 
using 
Frequencya Levels of 
effectivenessb 
Levels of 
confidenceb 
Number / 
Percentage 
of people 
using 
Frequencya Levels of 
effectivenessb 
Levels of 
confidenceb 
 n(%) M (SD) M (SD) M (SD) n(%) M (SD) M (SD) M (SD) n(%) M (SD) M (SD) M (SD) 
Take short 
sleeps during 
the day (fall 
asleep for less 
than 3 hours) 
114 (85.1) 
 
2.99 (1.19) 6.33 (2.43) 7.47(2.58) 97 (82.2) 
 
2.99 (1.20) 6.35 (2.67) 7.61(2.70) 98 (83.1) 
 
2.94 (1.22) 6.10 (2.47) 7.43(2.80) 
Rest during 
the day 
(without 
falling asleep) 
116 (86.6) 
 
3.21 (1.18) 5.68 (3.02) 7.38(2.59) 97 (82.2) 
 
3.14 (1.17) 5.88 (2.81) 7.64(2.78) 102 (86.4) 
 
3.30 (1.11) 5.52 (2.89) 7.40(2.52) 
Do aerobic 
exercise (e.g. 
walking/ stair 
climbing/ 
swimming) 
81 (60.4) 2.93 (1.26) 4.52 (3.46) 7.45(2.66) 73 (61.9) 3.03 (1.19) 3.59 (3.47) 7.18(2.55) 67 (56.8) 2.85 (1.23) 3.60 (2.96) 6.88(2.55) 
Do stretching 
exercises 
31 (23.1) 
 
2.68 (1.45) 3.27 (3.74) 7.57(2.08 33 (28.0) 
 
2.88 (1.22) 3.27 (3.33) 7.29(2.65) 34 (28.8) 
 
2.91 (1.26) 3.79 (3.57) 7.53(2.27) 
Do strength 
exercises 
12 (9) 
 
2.75 (1.14) 3.83 (3.86) 7.83(2.33) 15 (12.7) 
 
3.00 (1.20) 2.2 (3.82) 7.93(2.74) 14 (11.9) 3.00 (1.30) 3.43 (3.74) 8.21(1.93) 
Delegate tasks 
to others 
79 (59) 
 
3.06 (1.24) 5.48 (3.74) 8.11(2.49) 70 (59.3) 
 
3.14 (1.22) 5.20 (3.68) 8.09(2.64) 70 (59.3) 
 
3.21 (1.17) 3.99 (4.13) 8.23(2.78) 
Pace your 
activities 
throughout the 
day 
92 (68.7) 
 
3.53 (.95) 5.57 (3.16) 7.41(2.41) 91 (77.1) 
 
3.81 (.56) 6.55 (2.97) 8.07(2.31) 95 (80.5) 
 
3.82 (.64) 6.51 (2.79) 8.03(1.94) 
Do things to 
improve your 
sleep at night 
(e.g. reduce 
noise and 
light; avoid 
caffeine before 
bed) 
66 (49.3) 3.33 (1.07) 5.73 (3.40) 7.59(2.56) 46 (39.0) 3.30 (1.01) 6.02 (3.07) 8.15(2.22) 42 (35.6) 3.33 (1.12) 6.17 (3.02) 7.50(2.14) 
a Possible range: 1-4, bPossible range: 0-10 
